advertisement

Oculus

List of abstracts related to

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
Ophthalmology 2020; 127: 1627-1641

Listed by Classification


11.16 Vehicles, delivery systems, pharmacokinetics, formulation (2528 abstracts found)


92812 Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles
Halder A
Current Eye Research 2021; 46: 1031-1037 (IGR: 22-1)


92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Ding Y
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)


92597 Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma
Sharma PK
Current Eye Research 2021; 0: 1-14 (IGR: 22-1)


91911 Advances in medical therapy for glaucoma
Ostler E
Current Opinions in Ophthalmology 2021; 32: 129-133 (IGR: 22-1)


92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Schnichels S
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)


92598 Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
Erb C
Clinical Ophthalmology 2021; 15: 931-938 (IGR: 22-1)


92071 New strategies for the management of ocular surface disease in glaucoma patients
Voicu L
Current Opinions in Ophthalmology 2021; 32: 134-140 (IGR: 22-1)


92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Güçlü H
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)


92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Bessone CDV
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)


92630 Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study
Abdelmonem R
Pharmaceutics 2021; 13: (IGR: 22-1)


92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Ansari E
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)


92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Harasymowycz P
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)


92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Tan C
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)


92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Kim JM
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)


92066 Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia
Sahlu M
BMC Ophthalmology 2021; 21: 155 (IGR: 22-1)


92043 Nanomedicines for the treatment of glaucoma: Current status and future perspectives
Zhai Z
Acta biomaterialia 2021; 125: 41-56 (IGR: 22-1)


92288 Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma
Allam A
International Journal of Pharmaceutics 2021; 598: 120380 (IGR: 22-1)


92630 Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study
Elhabal SF
Pharmaceutics 2021; 13: (IGR: 22-1)


91911 Advances in medical therapy for glaucoma
Rhee D
Current Opinions in Ophthalmology 2021; 32: 129-133 (IGR: 22-1)


92288 Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma
Elsabahy M
International Journal of Pharmaceutics 2021; 598: 120380 (IGR: 22-1)


92066 Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia
Giorgis AT
BMC Ophthalmology 2021; 21: 155 (IGR: 22-1)


92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Pavicic-Astalos J
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)


92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Jia F
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)


92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Chow SH
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)


92043 Nanomedicines for the treatment of glaucoma: Current status and future perspectives
Cheng Y
Acta biomaterialia 2021; 125: 41-56 (IGR: 22-1)


92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Hutnik C
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)


92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Kim TW
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)


92598 Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
Stalmans I
Clinical Ophthalmology 2021; 15: 931-938 (IGR: 22-1)


92071 New strategies for the management of ocular surface disease in glaucoma patients
Salim S
Current Opinions in Ophthalmology 2021; 32: 134-140 (IGR: 22-1)


92812 Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles
Khopade AJ
Current Eye Research 2021; 46: 1031-1037 (IGR: 22-1)


92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Akhlaghi SP
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)


92597 Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma
Chauhan MK
Current Eye Research 2021; 0: 1-14 (IGR: 22-1)


92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Çınar AK
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)


92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Hurst J
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)


92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Park SW
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)


92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Tártara LI
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)


92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Çınar AC
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)


92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Ayan F
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)


92043 Nanomedicines for the treatment of glaucoma: Current status and future perspectives
Hong J
Acta biomaterialia 2021; 125: 41-56 (IGR: 22-1)


92630 Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study
Abdelmalak NS
Pharmaceutics 2021; 13: (IGR: 22-1)


92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Rouland JF
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)


91911 Advances in medical therapy for glaucoma
Burney E
Current Opinions in Ophthalmology 2021; 32: 129-133 (IGR: 22-1)


92288 Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma
El Badry M
International Journal of Pharmaceutics 2021; 598: 120380 (IGR: 22-1)


92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
de Vries JW
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)


92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Zhang P
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)


92598 Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
Iliev M
Clinical Ophthalmology 2021; 15: 931-938 (IGR: 22-1)


92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Chen J
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)


92598 Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
Muñoz-Negrete FJ
Clinical Ophthalmology 2021; 15: 931-938 (IGR: 22-1)


92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Quinteros DA
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)


92288 Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma
Eleraky NE
International Journal of Pharmaceutics 2021; 598: 120380 (IGR: 22-1)


92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Park HL
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)


92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Sun X
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)


92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Ullah S
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)


92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Brun APL
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)


92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Akaray İ
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)


92630 Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study
El-Nabarawi MA
Pharmaceutics 2021; 13: (IGR: 22-1)


91911 Advances in medical therapy for glaucoma
Sozeri Y
Current Opinions in Ophthalmology 2021; 32: 129-133 (IGR: 22-1)


92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
King AJ
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)


92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Negrete FJM
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)


92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Loh W
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)


92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Economou MA
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)


92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Frößl K
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)


92630 Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study
Teaima MH
Pharmaceutics 2021; 13: (IGR: 22-1)


92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Şambel Aykutlu M
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)


92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Kinsella M
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)


92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Hwang YH
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)


92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Wu CM
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)


92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Qiao Y
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)


92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Duff AP
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)


92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Denis P
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)


92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Jeoung JW
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)


92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Chen X
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)


92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Gruszka A
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)


92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Allemandi DA
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)


92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Ng E
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)


92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Sakallıoğlu AK; Gürlü V
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)


92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Wang Y
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)


92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Kim CY
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)


92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Wang Y
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)


92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Baudouin C
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)


92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Löscher M
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)


92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Nita A;
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)


92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Song J
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)


92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Chen J
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)


92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Bartz-Schmidt KU
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)


92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Lei Y
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)


92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Wang JH
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)


92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Spitzer MS; Herrmann A
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)


92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Wong VHY; Zhao D; Nishimura T; Lee TH; Conn CE; Hsu HY; Bui BV; Liu GS; Shen HH
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)


91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Rahić O
Pharmaceutics 2020; 13: (IGR: 21-4)


91324 Effect of preservative-free and preserved prostaglandin analogues on the histology of cornea of adult male Guinea pigs following repeated exposure
Ali AF
Folia morphologica 2021; 0: (IGR: 21-4)


91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Sanchez FG
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)


91577 Patients' Experience of Using Eye Drop Guide Device to Aid Self-Administration of Glaucoma Medications
Sakiyalak D
Clinical Ophthalmology 2020; 14: 3781-3788 (IGR: 21-4)


91202 Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
So HR
Journal of clinical medicine 2020; 9: (IGR: 21-4)


91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Lorenzo-Soler L
Acta Ophthalmologica 2020; 0: (IGR: 21-4)


91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Kobia-Acquah E
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)


91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Ruangvaravate N
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)


91725 Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost
Halder A
Clinical Ophthalmology 2020; 14: 3057-3064 (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Rodrigo MJ
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


91648 Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study
Su CC
Graefe's Archive for Clinical and Experimental Ophthalmology 2021; 259: 1243-1251 (IGR: 21-4)


91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Kozdon K
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)


91695 Effects of Benzalkonium Chloride in Ophthalmic Eyedrop Medications on Corneal Epithelium
Seino S
Yakugaku Zasshi 2021; 141: 35-39 (IGR: 21-4)


91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Sanchez FG
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)


91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Figus M
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)


91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Rubião F
Current Drug Delivery 2020; 0: (IGR: 21-4)


90921 Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities
El Hoffy NM
European Journal of Pharmaceutical Sciences 2021; 158: 105648 (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Rodrigo MJ
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


90987 Understanding the Dual Dilemma of Dry Eye and Glaucoma: An International Review
Nijm LM
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; 9: 481-490 (IGR: 21-4)


91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Konstas AG
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)


91252 Soft Contact Lens with Embedded Microtubes for Sustained and Self-Adaptive Drug Delivery for Glaucoma Treatment
Ding X
ACS applied materials & interfaces 2020; 12: 45789-45795 (IGR: 21-4)


91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Halkiadakis I
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)


91342 THE EFFECT OF THERAPY ON THE OCULAR SURFACE IN PATIENTS WITH UNILATERAL PEDIATRIC GLAUCOMA Purpose: The aim of the study was to evaluate ocular surface and
Janderová M
?eska a Slovenska Oftalmologie 2021; 77: 28-34 (IGR: 21-4)


91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
Stalmans I
Clinical Ophthalmology 2020; 14: 3675-3680 (IGR: 21-4)


91413 Sustained-release drug delivery systems for the treatment of glaucoma
Kesav NP
International Journal of Ophthalmology 2021; 14: 148-159 (IGR: 21-4)


91725 Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost
Khopade AJ
Clinical Ophthalmology 2020; 14: 3057-3064 (IGR: 21-4)


91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Agnifili L
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)


91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Olafsdottir OB
Acta Ophthalmologica 2020; 0: (IGR: 21-4)


91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
Lemij H
Clinical Ophthalmology 2020; 14: 3675-3680 (IGR: 21-4)


91342 THE EFFECT OF THERAPY ON THE OCULAR SURFACE IN PATIENTS WITH UNILATERAL PEDIATRIC GLAUCOMA Purpose: The aim of the study was to evaluate ocular surface and
Filouš A
?eska a Slovenska Oftalmologie 2021; 77: 28-34 (IGR: 21-4)


91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Vernikou A
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)


91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Choojun K
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)


91773 Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits
Verma A
Drug Delivery 2020; 27: 888-899 (IGR: 21-4)


91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Gyekye GA
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)


91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Tucak A
Pharmaceutics 2020; 13: (IGR: 21-4)


91413 Sustained-release drug delivery systems for the treatment of glaucoma
Young CEC
International Journal of Ophthalmology 2021; 14: 148-159 (IGR: 21-4)


91648 Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study
Lee YC
Graefe's Archive for Clinical and Experimental Ophthalmology 2021; 259: 1243-1251 (IGR: 21-4)


91695 Effects of Benzalkonium Chloride in Ophthalmic Eyedrop Medications on Corneal Epithelium
Takada Y
Yakugaku Zasshi 2021; 141: 35-39 (IGR: 21-4)


91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Labbé A
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)


91202 Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
Park HYL
Journal of clinical medicine 2020; 9: (IGR: 21-4)


91324 Effect of preservative-free and preserved prostaglandin analogues on the histology of cornea of adult male Guinea pigs following repeated exposure
Salama RM
Folia morphologica 2021; 0: (IGR: 21-4)


91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Araújo ACF
Current Drug Delivery 2020; 0: (IGR: 21-4)


90921 Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities
Abdel Azim EA
European Journal of Pharmaceutical Sciences 2021; 158: 105648 (IGR: 21-4)


91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Mansberger SL
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Cardiel MJ
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


90987 Understanding the Dual Dilemma of Dry Eye and Glaucoma: An International Review
de Benito-Llopis L
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; 9: 481-490 (IGR: 21-4)


91577 Patients' Experience of Using Eye Drop Guide Device to Aid Self-Administration of Glaucoma Medications
Kobwanthanakun S
Clinical Ophthalmology 2020; 14: 3781-3788 (IGR: 21-4)


91252 Soft Contact Lens with Embedded Microtubes for Sustained and Self-Adaptive Drug Delivery for Glaucoma Treatment
Ben-Shlomo G
ACS applied materials & interfaces 2020; 12: 45789-45795 (IGR: 21-4)


91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Caridi B
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)


91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Kung Y
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)


91648 Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study
Lee PRC
Graefe's Archive for Clinical and Experimental Ophthalmology 2021; 259: 1243-1251 (IGR: 21-4)


91342 THE EFFECT OF THERAPY ON THE OCULAR SURFACE IN PATIENTS WITH UNILATERAL PEDIATRIC GLAUCOMA Purpose: The aim of the study was to evaluate ocular surface and
Hložánek M
?eska a Slovenska Oftalmologie 2021; 77: 28-34 (IGR: 21-4)


90921 Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities
Hathout RM
European Journal of Pharmaceutical Sciences 2021; 158: 105648 (IGR: 21-4)


91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Srikulsasitorn B
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)


90987 Understanding the Dual Dilemma of Dry Eye and Glaucoma: An International Review
Rossi GC
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; 9: 481-490 (IGR: 21-4)


91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Sancio JB
Current Drug Delivery 2020; 0: (IGR: 21-4)


91413 Sustained-release drug delivery systems for the treatment of glaucoma
Ertel MK
International Journal of Ophthalmology 2021; 14: 148-159 (IGR: 21-4)


91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Omerović N
Pharmaceutics 2020; 13: (IGR: 21-4)


91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Antwi-Adjei EK
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)


91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
Clarke J
Clinical Ophthalmology 2020; 14: 3675-3680 (IGR: 21-4)


91252 Soft Contact Lens with Embedded Microtubes for Sustained and Self-Adaptive Drug Delivery for Glaucoma Treatment
Que L
ACS applied materials & interfaces 2020; 12: 45789-45795 (IGR: 21-4)


91202 Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
Chung SH
Journal of clinical medicine 2020; 9: (IGR: 21-4)


91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Tzimis V
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)


91324 Effect of preservative-free and preserved prostaglandin analogues on the histology of cornea of adult male Guinea pigs following repeated exposure
Soliman MA
Folia morphologica 2021; 0: (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Fraile JM
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Duru I
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)


91773 Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits
Jain N
Drug Delivery 2020; 27: 888-899 (IGR: 21-4)


91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Lanzini M
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)


91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Garhöfer G
Acta Ophthalmologica 2020; 0: (IGR: 21-4)


91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Srikulsasitorn B
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)


91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Katsanos A
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)


91695 Effects of Benzalkonium Chloride in Ophthalmic Eyedrop Medications on Corneal Epithelium
Saika S
Yakugaku Zasshi 2021; 141: 35-39 (IGR: 21-4)


90921 Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities
Fouly MA
European Journal of Pharmaceutical Sciences 2021; 158: 105648 (IGR: 21-4)


91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Meier-Gibbons F
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Mendez-Martinez S
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Brescia L
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)


91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Ezra DG
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)


91202 Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
Kim HS
Journal of clinical medicine 2020; 9: (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Mendez-Martinez S
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


90987 Understanding the Dual Dilemma of Dry Eye and Glaucoma: An International Review
Vajaranant TS
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; 9: 481-490 (IGR: 21-4)


91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Gardiner SK
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)


91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Jansook P
Acta Ophthalmologica 2020; 0: (IGR: 21-4)


91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Koomson NY
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)


91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
Baudouin C
Clinical Ophthalmology 2020; 14: 3675-3680 (IGR: 21-4)


91342 THE EFFECT OF THERAPY ON THE OCULAR SURFACE IN PATIENTS WITH UNILATERAL PEDIATRIC GLAUCOMA Purpose: The aim of the study was to evaluate ocular surface and
Dotřelová D
?eska a Slovenska Oftalmologie 2021; 77: 28-34 (IGR: 21-4)


91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Nogueira BS
Current Drug Delivery 2020; 0: (IGR: 21-4)


91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Chokboonpiem J
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)


91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Sirbubalo M
Pharmaceutics 2020; 13: (IGR: 21-4)


91413 Sustained-release drug delivery systems for the treatment of glaucoma
Seibold LK
International Journal of Ophthalmology 2021; 14: 148-159 (IGR: 21-4)


91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Markopoulos I
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Martinez-Rincon T
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


91202 Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
Byun YS
Journal of clinical medicine 2020; 9: (IGR: 21-4)


91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Cobbina F
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)


91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Sartini F
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)


91413 Sustained-release drug delivery systems for the treatment of glaucoma
Kahook MY
International Journal of Ophthalmology 2021; 14: 148-159 (IGR: 21-4)


91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Burgoyne CF
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)


91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Phillips JB
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Martinez-Rincon T
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


90921 Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities
Elkheshen SA
European Journal of Pharmaceutical Sciences 2021; 158: 105648 (IGR: 21-4)


91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Sartini F
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)


91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Kristinsdottir IM
Acta Ophthalmologica 2020; 0: (IGR: 21-4)


91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Irkec M
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)


91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Sartini F
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)


91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Hindija L
Pharmaceutics 2020; 13: (IGR: 21-4)


91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Popeskou K
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)


90987 Understanding the Dual Dilemma of Dry Eye and Glaucoma: An International Review
Coroneo MT
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; 9: 481-490 (IGR: 21-4)


91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments

Clinical Ophthalmology 2020; 14: 3675-3680 (IGR: 21-4)


91342 THE EFFECT OF THERAPY ON THE OCULAR SURFACE IN PATIENTS WITH UNILATERAL PEDIATRIC GLAUCOMA Purpose: The aim of the study was to evaluate ocular surface and
Mahelková G
?eska a Slovenska Oftalmologie 2021; 77: 28-34 (IGR: 21-4)


91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Franca JR
Current Drug Delivery 2020; 0: (IGR: 21-4)


91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Asanatong D
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)


91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Konstadinidou V
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)


91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Cunningham ET
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)


91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Mastropasqua L
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)


91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Tan A
Acta Ophthalmologica 2020; 0: (IGR: 21-4)


91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Nogueira JC
Current Drug Delivery 2020; 0: (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Subias M
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Boboridis KG
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)


91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Bailly M
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)


91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Trakanwitthayarak S
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Subias M
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Donkor R
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)


91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Hadžiabdić J
Pharmaceutics 2020; 13: (IGR: 21-4)


91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Holló G
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)


91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Vranić E
Pharmaceutics 2020; 13: (IGR: 21-4)


91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Ferreira AJ
Current Drug Delivery 2020; 0: (IGR: 21-4)


91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Rees JP
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Polo V
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Loftsson T
Acta Ophthalmologica 2020; 0: (IGR: 21-4)


91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Posarelli C
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)


91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Akowuah PK
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Ruberte J
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Faraco AAG
Current Drug Delivery 2020; 0: (IGR: 21-4)


91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Stefansson E
Acta Ophthalmologica 2020; 0: (IGR: 21-4)


91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
García-Feijoo J
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)


91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Jones EP
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)


91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Foureaux G
Current Drug Delivery 2020; 0: (IGR: 21-4)


91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Kinast RM
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)


91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Dutton GN
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Ramirez T; Vispe E
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Baudouin C
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)


91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Cronemberger S
Current Drug Delivery 2020; 0: (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Luna C
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Mayoral JA; Garcia-Martin E
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)


90627 Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma
Nguyen DD
Acta biomaterialia 2020; 111: 302-315 (IGR: 21-3)


90672 Effect of aging on heat transfer, fluid flow and drug transport in anterior human eye: A computational study
Bhandari A
Journal of Controlled Release 2020; 328: 286-303 (IGR: 21-3)


89989 Intractable Ocular Diseases and Treatment Progress
Zhang X
AAPS PharmSciTech 2020; 21: 236 (IGR: 21-3)


90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Mietzner R
Pharmaceutics 2020; 12: (IGR: 21-3)


90541 Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties
Ismail A
International Journal of Pharmaceutics 2020; 583: 119402 (IGR: 21-3)


90627 Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma
Nguyen DD
Acta biomaterialia 2020; 111: 302-315 (IGR: 21-3)


90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Stack T
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)


90655 Numerical modeling of therapeutic lens drug delivery in the anterior human eye for the treatment of primary open-angle glaucoma
Bhandari A
Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine 2020; 234: 942-954 (IGR: 21-3)


89986 Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
Kwon S
International Journal of Nanomedicine 2020; 15: 5745-5765 (IGR: 21-3)


90502 The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial
Kasetsuwan N
Clinical Ophthalmology 2020; 14: 2891-2902 (IGR: 21-3)


90570 Nanoscale Drug Delivery Systems for Glaucoma: Experimental and In Silico Advances
Sharma S
Current Topics in Medicinal Chemistry 2021; 21: 115-125 (IGR: 21-3)


89876 Bimatoprost Implant: First Approval
Shirley M
Drugs and Aging 2020; 37: 457-462 (IGR: 21-3)


90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
Mohammed I
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)


90252 Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography
Gozawa M
BMC Ophthalmology 2020; 20: 244 (IGR: 21-3)


90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Taka E
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)


90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Cesar ALA
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)


90473 Effect of Long-Term Topical Antiglaucoma Medication Use on the Ocular Surface
Awe OO
Nigerian medical journal : journal of the Nigeria Medical Association 2020; 61: 184-188 (IGR: 21-3)


90507 The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study
Guo Y
BMC Ophthalmology 2020; 20: 277 (IGR: 21-3)


90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Schnichels S
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)


90021 Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma
Kompella UB
Progress in Retinal and Eye Research 2020; 0: 100901 (IGR: 21-3)


90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Han X
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)


90630 Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapy
Cuggino JC
Materials science & engineering. C, Materials for biological applications 2021; 118: 111383 (IGR: 21-3)


90661 Polypeptide and glycosaminoglycan polysaccharide as stabilizing polymers in nanocrystals for a safe ocular hypotensive effect
Donia M
International Journal of Biological Macromolecules 2020; 162: 1699-1710 (IGR: 21-3)


90252 Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography
Takamura Y
BMC Ophthalmology 2020; 20: 244 (IGR: 21-3)


90541 Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties
Nasr M
International Journal of Pharmaceutics 2020; 583: 119402 (IGR: 21-3)


90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Vincent M
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)


90655 Numerical modeling of therapeutic lens drug delivery in the anterior human eye for the treatment of primary open-angle glaucoma
Bansal A
Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine 2020; 234: 942-954 (IGR: 21-3)


90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Zhao Y
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)


90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Karavasili C
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)


90570 Nanoscale Drug Delivery Systems for Glaucoma: Experimental and In Silico Advances
Bhatia V
Current Topics in Medicinal Chemistry 2021; 21: 115-125 (IGR: 21-3)


89986 Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
Kim SH
International Journal of Nanomedicine 2020; 15: 5745-5765 (IGR: 21-3)


90473 Effect of Long-Term Topical Antiglaucoma Medication Use on the Ocular Surface
Onakpoya OH
Nigerian medical journal : journal of the Nigeria Medical Association 2020; 61: 184-188 (IGR: 21-3)


90661 Polypeptide and glycosaminoglycan polysaccharide as stabilizing polymers in nanocrystals for a safe ocular hypotensive effect
Osman R
International Journal of Biological Macromolecules 2020; 162: 1699-1710 (IGR: 21-3)


90630 Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapy
Tártara LI
Materials science & engineering. C, Materials for biological applications 2021; 118: 111383 (IGR: 21-3)


90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Hurst J
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)


90021 Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma
Hartman RR
Progress in Retinal and Eye Research 2020; 0: 100901 (IGR: 21-3)


89989 Intractable Ocular Diseases and Treatment Progress
Li S
AAPS PharmSciTech 2020; 21: 236 (IGR: 21-3)


90627 Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma
Luo LJ
Acta biomaterialia 2020; 111: 302-315 (IGR: 21-3)


90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Navarro LC
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)


90672 Effect of aging on heat transfer, fluid flow and drug transport in anterior human eye: A computational study
Bansal A
Journal of Controlled Release 2020; 328: 286-303 (IGR: 21-3)


90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
Kulkarni B
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)


90502 The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial
Suwajanakorn D
Clinical Ophthalmology 2020; 14: 2891-2902 (IGR: 21-3)


90507 The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study
Ha JY
BMC Ophthalmology 2020; 20: 277 (IGR: 21-3)


90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Kade C
Pharmaceutics 2020; 12: (IGR: 21-3)


90661 Polypeptide and glycosaminoglycan polysaccharide as stabilizing polymers in nanocrystals for a safe ocular hypotensive effect
Awad GAS
International Journal of Biological Macromolecules 2020; 162: 1699-1710 (IGR: 21-3)


90021 Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma
Patil MA
Progress in Retinal and Eye Research 2020; 0: 100901 (IGR: 21-3)


90672 Effect of aging on heat transfer, fluid flow and drug transport in anterior human eye: A computational study
Sinha N
Journal of Controlled Release 2020; 328: 286-303 (IGR: 21-3)


90252 Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography
Iwasaki K
BMC Ophthalmology 2020; 20: 244 (IGR: 21-3)


89989 Intractable Ocular Diseases and Treatment Progress
Tang Y
AAPS PharmSciTech 2020; 21: 236 (IGR: 21-3)


90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
Faraj LA
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)


90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Froemel F
Pharmaceutics 2020; 12: (IGR: 21-3)


90655 Numerical modeling of therapeutic lens drug delivery in the anterior human eye for the treatment of primary open-angle glaucoma
Sinha N
Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine 2020; 234: 942-954 (IGR: 21-3)


90672 Effect of aging on heat transfer, fluid flow and drug transport in anterior human eye: A computational study
Sinha N
Journal of Controlled Release 2020; 328: 286-303 (IGR: 21-3)


90502 The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial
Tantipat C
Clinical Ophthalmology 2020; 14: 2891-2902 (IGR: 21-3)


90507 The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study
Piao HL
BMC Ophthalmology 2020; 20: 277 (IGR: 21-3)


90630 Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapy
Gugliotta LM
Materials science & engineering. C, Materials for biological applications 2021; 118: 111383 (IGR: 21-3)


90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Liu H
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)


89986 Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
Khang D
International Journal of Nanomedicine 2020; 15: 5745-5765 (IGR: 21-3)


90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Bouropoulos N
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)


90541 Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties
Sammour O
International Journal of Pharmaceutics 2020; 583: 119402 (IGR: 21-3)


90655 Numerical modeling of therapeutic lens drug delivery in the anterior human eye for the treatment of primary open-angle glaucoma
Sinha N
Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine 2020; 234: 942-954 (IGR: 21-3)


90627 Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma
Lai JY
Acta biomaterialia 2020; 111: 302-315 (IGR: 21-3)


90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Vahabikashi A
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)


90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
de Vries JW
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)


90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Castilho RO
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)


90473 Effect of Long-Term Topical Antiglaucoma Medication Use on the Ocular Surface
Adeoye AO
Nigerian medical journal : journal of the Nigeria Medical Association 2020; 61: 184-188 (IGR: 21-3)


90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Goulart GAC
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)


90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
Abbas A
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)


90502 The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial
Reinprayoon U
Clinical Ophthalmology 2020; 14: 2891-2902 (IGR: 21-3)


90507 The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study
Sung MS
BMC Ophthalmology 2020; 20: 277 (IGR: 21-3)


90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Li H
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)


90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Ullah S
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)


90661 Polypeptide and glycosaminoglycan polysaccharide as stabilizing polymers in nanocrystals for a safe ocular hypotensive effect
Mortada N
International Journal of Biological Macromolecules 2020; 162: 1699-1710 (IGR: 21-3)


90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Pauly D
Pharmaceutics 2020; 12: (IGR: 21-3)


90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Li G
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)


90630 Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapy
Palma SD
Materials science & engineering. C, Materials for biological applications 2021; 118: 111383 (IGR: 21-3)


89989 Intractable Ocular Diseases and Treatment Progress
Guo Y
AAPS PharmSciTech 2020; 21: 236 (IGR: 21-3)


90252 Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography
Arimura S
BMC Ophthalmology 2020; 20: 244 (IGR: 21-3)


90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Moschakis T
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)


89986 Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
Lee JY
International Journal of Nanomedicine 2020; 15: 5745-5765 (IGR: 21-3)


90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Stamer WD
Pharmaceutics 2020; 12: (IGR: 21-3)


89989 Intractable Ocular Diseases and Treatment Progress
Gao S
AAPS PharmSciTech 2020; 21: 236 (IGR: 21-3)


90252 Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography
Inatani M
BMC Ophthalmology 2020; 20: 244 (IGR: 21-3)


90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Perkumas KM
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)


90630 Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapy
Alvarez Igarzabal CI
Materials science & engineering. C, Materials for biological applications 2021; 118: 111383 (IGR: 21-3)


90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Foureaux G
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)


90507 The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study
Park SW
BMC Ophthalmology 2020; 20: 277 (IGR: 21-3)


90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Liu S
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)


90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Gruszka A
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)


90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
Dua HS
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)


90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Andreadis DDD
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)


90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Kwak M
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)


90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Ohlmann A
Pharmaceutics 2020; 12: (IGR: 21-3)


90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Zacharis CKK
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)


90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Stamer WD
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)


90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Ferreira AJ
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)


90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
King AJ
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)


90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Rupenthal ID
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)


90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Johnson M
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)


90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Yang F
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)


90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Wegener J
Pharmaceutics 2020; 12: (IGR: 21-3)


90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Fatouros DGG
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)


90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Cronemberger S
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)


90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Löscher M; Dammeier S
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)


90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Gomes Faraco AA
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)


90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Fuchshofer R
Pharmaceutics 2020; 12: (IGR: 21-3)


90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Scott E
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)


90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Lv Z; Chen Y
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)


90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Bartz-Schmidt KU
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)


90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Breunig M
Pharmaceutics 2020; 12: (IGR: 21-3)


90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Spitzer MS
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)


90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Zang L
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)


90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Herrmann A
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)


90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Li W; Ping Q; Tao Q; Hou D
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)


86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Liu S
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)


86682 Factors Predetermining Increased Aqueous Humour Flare in Long-Term Glaucoma Treatment
Pakuliene G
Journal of Ophthalmology 2020; 2020: 7345687 (IGR: 21-2)


86433 Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy
Luo LJ
Biomaterials 2020; 243: 119961 (IGR: 21-2)


86715 Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops
Inoue D
Cutaneous and Ocular Toxicology 2020; 39: 158-164 (IGR: 21-2)


86650 Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma
Liao YT
Journal of materials chemistry. B 2017; 5: 7008-7013 (IGR: 21-2)


86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Erichev VP
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)


86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Hedengran A
British Journal of Ophthalmology 2020; 104: 1512-1518 (IGR: 21-2)


86724 Progress on ocular siRNA gene-silencing therapy and drug delivery systems
Jiang J
Fundamental and Clinical Pharmacology 2021; 35: 4-24 (IGR: 21-2)


86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Dorofeev DA
Vestnik Oftalmologii 2019; 135: 52-59 (IGR: 21-2)


86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
López ES
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)


86753 Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases
Durgun ME
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 323-341 (IGR: 21-2)


86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Esteban-Pérez S
Pharmaceutics 2020; 12: (IGR: 21-2)


86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Chamard C
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)


86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Agnifili L
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)


86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Roy Chowdhury U
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)


86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Li T
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)


86685 Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma
Fathalla D
Drug Development and Industrial Pharmacy 2020; 46: 806-813 (IGR: 21-2)


86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
El-Feky YA
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)


86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Sun J
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)


86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Mostafa DA
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)


86724 Progress on ocular siRNA gene-silencing therapy and drug delivery systems
Zhang X
Fundamental and Clinical Pharmacology 2021; 35: 4-24 (IGR: 21-2)


86650 Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma
Lee CH
Journal of materials chemistry. B 2017; 5: 7008-7013 (IGR: 21-2)


86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Petrov SY
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)


86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Brescia L
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)


86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Kudgus RA
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)


86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
Machado ALL
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)


86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Petrov SY
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)


86753 Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases
Güngör S
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 323-341 (IGR: 21-2)


86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Larrieu S
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)


86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Liu X
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)


86715 Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops
Mohamed YH
Cutaneous and Ocular Toxicology 2020; 39: 158-164 (IGR: 21-2)


86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Han X
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)


86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Petrov SY
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)


86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Wang Y
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)


86685 Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma
Fouad EA
Drug Development and Industrial Pharmacy 2020; 46: 806-813 (IGR: 21-2)


86433 Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy
Nguyen DD
Biomaterials 2020; 243: 119961 (IGR: 21-2)


86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Steensberg AT
British Journal of Ophthalmology 2020; 104: 1512-1518 (IGR: 21-2)


86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Tur EV
Vestnik Oftalmologii 2019; 135: 52-59 (IGR: 21-2)


86682 Factors Predetermining Increased Aqueous Humour Flare in Long-Term Glaucoma Treatment
Kuzmiene L
Journal of Ophthalmology 2020; 2020: 7345687 (IGR: 21-2)


86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Petrov SY
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)


86433 Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy
Nguyen DD
Biomaterials 2020; 243: 119961 (IGR: 21-2)


86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Andrés-Guerrero V
Pharmaceutics 2020; 12: (IGR: 21-2)


86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Volzhanin AV
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)


86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Al-Sawahli MM
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)


86724 Progress on ocular siRNA gene-silencing therapy and drug delivery systems
Tang Y
Fundamental and Clinical Pharmacology 2021; 35: 4-24 (IGR: 21-2)


86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Virgili G
British Journal of Ophthalmology 2020; 104: 1512-1518 (IGR: 21-2)


86685 Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma
Soliman GM
Drug Development and Industrial Pharmacy 2020; 46: 806-813 (IGR: 21-2)


86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
López-Cano JJ
Pharmaceutics 2020; 12: (IGR: 21-2)


86682 Factors Predetermining Increased Aqueous Humour Flare in Long-Term Glaucoma Treatment
Januleviciene I
Journal of Ophthalmology 2020; 2020: 7345687 (IGR: 21-2)


86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Chen J
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)


86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Volzhanin AV
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)


86433 Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy
Lai JY
Biomaterials 2020; 243: 119961 (IGR: 21-2)


86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Liu H
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)


86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Baudouin C
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)


86650 Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma
Chen ST
Journal of materials chemistry. B 2017; 5: 7008-7013 (IGR: 21-2)


86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Vizgalova LO
Vestnik Oftalmologii 2019; 135: 52-59 (IGR: 21-2)


86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Rinkoski TA
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)


86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
Vidal LB
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)


86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Lei Y
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)


86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Volzhanin AV
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)


86715 Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops
Uematsu M
Cutaneous and Ocular Toxicology 2020; 39: 158-164 (IGR: 21-2)


86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Scatena B
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)


86753 Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases
Özsoy Y
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 323-341 (IGR: 21-2)


86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Volzhanin AV
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)


86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Gao X
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)


86715 Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops
Kitaoka T
Cutaneous and Ocular Toxicology 2020; 39: 158-164 (IGR: 21-2)


86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Molina-Martínez I
Pharmaceutics 2020; 12: (IGR: 21-2)


86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Holman BH
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)


86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Tang M
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)


86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Oddone F
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)


86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
El-Telbany RFA
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)


86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Azuara-Blanco A
British Journal of Ophthalmology 2020; 104: 1512-1518 (IGR: 21-2)


86724 Progress on ocular siRNA gene-silencing therapy and drug delivery systems
Li S
Fundamental and Clinical Pharmacology 2021; 35: 4-24 (IGR: 21-2)


86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Bron A
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)


86650 Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma
Lai JY
Journal of materials chemistry. B 2017; 5: 7008-7013 (IGR: 21-2)


86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
González-Pizarro R
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)


86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Ghazaryan SA
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)


86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Zhao Y
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)


86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Tryapitsin ID
Vestnik Oftalmologii 2019; 135: 52-59 (IGR: 21-2)


86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Dai Z
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)


86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Li H
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)


86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Ciganov AZ
Vestnik Oftalmologii 2019; 135: 52-59 (IGR: 21-2)


86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Villain M
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)


86724 Progress on ocular siRNA gene-silencing therapy and drug delivery systems
Chen J
Fundamental and Clinical Pharmacology 2021; 35: 4-24 (IGR: 21-2)


86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Bahler CK
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)


86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Figus M
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)


86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Herrero-Vanrell R
Pharmaceutics 2020; 12: (IGR: 21-2)


86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Pan S
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)


86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Zakaria S
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)


86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Kolko M
British Journal of Ophthalmology 2020; 104: 1512-1518 (IGR: 21-2)


86650 Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma
Wu KC
Journal of materials chemistry. B 2017; 5: 7008-7013 (IGR: 21-2)


86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
Silva AD
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)


86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Fayez AM
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)


86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
Souto EB
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)


86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Yang X
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)


86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Bravo-Osuna I
Pharmaceutics 2020; 12: (IGR: 21-2)


86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Su Y
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)


86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Perna F
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)


86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
D Rupenthal I
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)


86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Hann CR
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)


86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Daien V
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)


86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Doronzo E
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)


86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Lv Z
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)


86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Zhou X
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)


86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Yu X
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)


86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Ahmed KA
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)


86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Reid JM
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)


86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Alolayan EM
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)


86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Dosa PI
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)


86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
D'Ugo E
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)


86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Chen Y
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)


86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Yu L; Sun X
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)


86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Mastropasqua L
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)


86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
El-Telbany DFA
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)


86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Fautsch MP
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)


86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Yang F; Ping Q
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)


86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Ding J
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)


86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Pan Y; Hou D
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)


84893 Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment
Jeong H
Molecular pharmaceutics 2020; 17: 656-665 (IGR: 21-1)


84963 Brinzolamide Dimethyl Sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation
Bhalerao H
AAPS PharmSciTech 2020; 21: 69 (IGR: 21-1)


84572 Dendritic Effects of Injectable Biodegradable Thermogels on Pharmacotherapy of Inflammatory Glaucoma-Associated Degradation of Extracellular Matrix
Nguyen DD
Advanced healthcare materials 2019; 8: e1900702 (IGR: 21-1)


84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Guarnieri A
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)


85206 Promising therapeutic drug delivery systems for glaucoma: a comprehensive review
Singh RB
Therapeutic advances in ophthalmology 2020; 12: 2515841420905740 (IGR: 21-1)


84144 Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study
Emad Eldeeb A
Drug Delivery 2019; 26: 509-521 (IGR: 21-1)


85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Quiroz-Mercado H
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)


84655 Benzoic acid derivative-modified chitosan-g-poly(N-isopropylacrylamide): Methoxylation effects and pharmacological treatments of Glaucoma-related neurodegeneration
Luo LJ
Journal of Controlled Release 2020; 317: 246-258 (IGR: 21-1)


85115 Albumin Levels in Tear Film Modulate the Bioavailability of Medically-Relevant Topical Drugs
Sebbag L
Frontiers in pharmacology 2019; 10: 1560 (IGR: 21-1)


84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Zhang F
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)


85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Sato K
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)


84572 Dendritic Effects of Injectable Biodegradable Thermogels on Pharmacotherapy of Inflammatory Glaucoma-Associated Degradation of Extracellular Matrix
Nguyen DD
Advanced healthcare materials 2019; 8: e1900702 (IGR: 21-1)


84579 Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study
Dubey V
International Journal of Biological Macromolecules 2020; 152: 1224-1232 (IGR: 21-1)


85206 Promising therapeutic drug delivery systems for glaucoma: a comprehensive review
Singh RB
Therapeutic advances in ophthalmology 2020; 12: 2515841420905740 (IGR: 21-1)


84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Yoon CH
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)


84927 Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma
Yan F
AAPS PharmSciTech 2020; 21: 63 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Yagi-Yaguchi Y
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Craven ER
Drugs 2020; 80: 167-179 (IGR: 21-1)


85089 Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Mylla Boso AL
Clinical Ophthalmology 2020; 14: 103-111 (IGR: 21-1)


85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Rogov AG
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)


84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Lee HJ
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)


84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Carnero E
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)


85089 Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Gasperi E
Clinical Ophthalmology 2020; 14: 103-111 (IGR: 21-1)


84572 Dendritic Effects of Injectable Biodegradable Thermogels on Pharmacotherapy of Inflammatory Glaucoma-Associated Degradation of Extracellular Matrix
Luo LJ
Advanced healthcare materials 2019; 8: e1900702 (IGR: 21-1)


85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Nakagawa Y
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)


84579 Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study
Mohan P
International Journal of Biological Macromolecules 2020; 152: 1224-1232 (IGR: 21-1)


85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Goleva TN
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)


84655 Benzoic acid derivative-modified chitosan-g-poly(N-isopropylacrylamide): Methoxylation effects and pharmacological treatments of Glaucoma-related neurodegeneration
Nguyen DD
Journal of Controlled Release 2020; 317: 246-258 (IGR: 21-1)


85115 Albumin Levels in Tear Film Modulate the Bioavailability of Medically-Relevant Topical Drugs
Moody LM
Frontiers in pharmacology 2019; 10: 1560 (IGR: 21-1)


84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Liu K
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)


84927 Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma
Liu Y
AAPS PharmSciTech 2020; 21: 63 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Kojima T
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


84963 Brinzolamide Dimethyl Sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation
Koteshwara KB
AAPS PharmSciTech 2020; 21: 69 (IGR: 21-1)


85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Ivri E
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)


84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Walters T
Drugs 2020; 80: 167-179 (IGR: 21-1)


85206 Promising therapeutic drug delivery systems for glaucoma: a comprehensive review
Ichhpujani P
Therapeutic advances in ophthalmology 2020; 12: 2515841420905740 (IGR: 21-1)


84893 Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment
Park S
Molecular pharmaceutics 2020; 17: 656-665 (IGR: 21-1)


84144 Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study
Salah S
Drug Delivery 2019; 26: 509-521 (IGR: 21-1)


84655 Benzoic acid derivative-modified chitosan-g-poly(N-isopropylacrylamide): Methoxylation effects and pharmacological treatments of Glaucoma-related neurodegeneration
Nguyen DD
Journal of Controlled Release 2020; 317: 246-258 (IGR: 21-1)


84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Carnero E
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)


85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Omodaka K
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)


84579 Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study
Dangi JS
International Journal of Biological Macromolecules 2020; 152: 1224-1232 (IGR: 21-1)


84893 Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment
Park K
Molecular pharmaceutics 2020; 17: 656-665 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Higa K
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Park HY
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)


84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Pan Z
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)


85206 Promising therapeutic drug delivery systems for glaucoma: a comprehensive review
Thakur S
Therapeutic advances in ophthalmology 2020; 12: 2515841420905740 (IGR: 21-1)


84963 Brinzolamide Dimethyl Sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation
Chandran S
AAPS PharmSciTech 2020; 21: 69 (IGR: 21-1)


85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Gonzalez-Salinas R
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)


84144 Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study
Ghorab M
Drug Delivery 2019; 26: 509-521 (IGR: 21-1)


84927 Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma
Han S
AAPS PharmSciTech 2020; 21: 63 (IGR: 21-1)


84655 Benzoic acid derivative-modified chitosan-g-poly(N-isopropylacrylamide): Methoxylation effects and pharmacological treatments of Glaucoma-related neurodegeneration
Lai JY
Journal of Controlled Release 2020; 317: 246-258 (IGR: 21-1)


84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Bleau AM
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)


85089 Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Fernandes L
Clinical Ophthalmology 2020; 14: 103-111 (IGR: 21-1)


84572 Dendritic Effects of Injectable Biodegradable Thermogels on Pharmacotherapy of Inflammatory Glaucoma-Associated Degradation of Extracellular Matrix
Lai JY
Advanced healthcare materials 2019; 8: e1900702 (IGR: 21-1)


85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Sukhanova EI
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)


84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Christie WC
Drugs 2020; 80: 167-179 (IGR: 21-1)


84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Bleau AM
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)


85115 Albumin Levels in Tear Film Modulate the Bioavailability of Medically-Relevant Topical Drugs
Mochel JP
Frontiers in pharmacology 2019; 10: 1560 (IGR: 21-1)


85089 Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Costa VP
Clinical Ophthalmology 2020; 14: 103-111 (IGR: 21-1)


84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Day DG
Drugs 2020; 80: 167-179 (IGR: 21-1)


85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Asada H
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)


84579 Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study
Kesavan K
International Journal of Biological Macromolecules 2020; 152: 1224-1232 (IGR: 21-1)


85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Kourtis IC
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)


85206 Promising therapeutic drug delivery systems for glaucoma: a comprehensive review
Jindal S
Therapeutic advances in ophthalmology 2020; 12: 2515841420905740 (IGR: 21-1)


84893 Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment
Kim M
Molecular pharmaceutics 2020; 17: 656-665 (IGR: 21-1)


84927 Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma
Zhao Q
AAPS PharmSciTech 2020; 21: 63 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Dogru M
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
López de Aguileta Castaño N
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)


84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Kim H
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)


84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Cao M
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)


85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Epremyan KK
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)


84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Zhou D
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)


85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Fujii S
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)


84927 Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma
Liu N
AAPS PharmSciTech 2020; 21: 63 (IGR: 21-1)


84893 Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment
Hong J
Molecular pharmaceutics 2020; 17: 656-665 (IGR: 21-1)


84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Llorente Ortega M
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)


85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Trendeleva TA
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)


84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Kim MK
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Ibrahim OM
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Lewis RA
Drugs 2020; 80: 167-179 (IGR: 21-1)


85089 Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Alves M
Clinical Ophthalmology 2020; 14: 103-111 (IGR: 21-1)


85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Gilbert J; Pérez-Vázquez JF
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)


85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Ovchenkova AP
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)


84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Moreno-Montañés J
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Shimizu T
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Jeoung JW
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)


84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Goodkin ML
Drugs 2020; 80: 167-179 (IGR: 21-1)


84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Liu H
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)


85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Masaki K
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)


85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Blumenkranz M
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)


85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Aliverdieva DA
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)


84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Chen M
Drugs 2020; 80: 167-179 (IGR: 21-1)


84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Huang Y
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Tsubota K
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Nakazawa T
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)


84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Oh JY
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Shimazaki J
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Zvyagilskaya RA
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)


84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Duan X
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)


84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Wangsadipura V
Drugs 2020; 80: 167-179 (IGR: 21-1)


85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Jiménez-Román J
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)


84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Robinson MR
Drugs 2020; 80: 167-179 (IGR: 21-1)


85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Marcellino G
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)


84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Bejanian M;
Drugs 2020; 80: 167-179 (IGR: 21-1)


82613 Preservative-free preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages
Duru Z
Cutaneous and Ocular Toxicology 2020; 39: 21-24 (IGR: 20-4)


82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Murugesan V
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)


82758 Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
Kumar S
Romanian journal of ophthalmology 2019; 63: 249-256 (IGR: 20-4)


82350 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
Yadav M
Data in brief 2019; 25: 104361 (IGR: 20-4)


82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)


82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Franca JR
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)


82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Taskar PS
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)


82174 The Impact of R-801 Nanoparticles as a Long Acting Topical Glaucoma Therapy
Ibrahim MM
Journal of biomedical nanotechnology 2019; 15: 1968-1981 (IGR: 20-4)


82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Juliana FR
Molecules 2019; 24: (IGR: 20-4)


82430 Latanoprost uptake and release from commercial contact lenses
Horne RR
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)


82239 Leucaena leucocephala (Lam.) galactomannan nanoparticles: Optimization and characterization for ocular delivery in glaucoma treatment
Mittal N
International Journal of Biological Macromolecules 2019; 139: 1252-1262 (IGR: 20-4)


82710 Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review
Cegielska O
Polymers 2019; 11: (IGR: 20-4)


82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Ha JY
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)


82599 Applications of microneedles in delivering drugs for various ocular diseases
Gupta P
Life Sciences 2019; 237: 116907 (IGR: 20-4)


82052 Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma
Lee SM
Indian Journal of Ophthalmology 2019; 67: 1297-1302 (IGR: 20-4)


82239 Leucaena leucocephala (Lam.) galactomannan nanoparticles: Optimization and characterization for ocular delivery in glaucoma treatment
Kaur G
International Journal of Biological Macromolecules 2019; 139: 1252-1262 (IGR: 20-4)


82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Sung MS
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)


82430 Latanoprost uptake and release from commercial contact lenses
Rich JT
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)


82052 Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma
Lee JE
Indian Journal of Ophthalmology 2019; 67: 1297-1302 (IGR: 20-4)


82174 The Impact of R-801 Nanoparticles as a Long Acting Topical Glaucoma Therapy
Jablonski MM
Journal of biomedical nanotechnology 2019; 15: 1968-1981 (IGR: 20-4)


82599 Applications of microneedles in delivering drugs for various ocular diseases
Yadav KS
Life Sciences 2019; 237: 116907 (IGR: 20-4)


82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Kesse S
Molecules 2019; 24: (IGR: 20-4)


82710 Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review
Sajkiewicz P
Polymers 2019; 11: (IGR: 20-4)


82599 Applications of microneedles in delivering drugs for various ocular diseases
Yadav KS
Life Sciences 2019; 237: 116907 (IGR: 20-4)


82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Foureaux G
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)


82758 Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
Singh T
Romanian journal of ophthalmology 2019; 63: 249-256 (IGR: 20-4)


82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Patil A
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)


82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Dwivedi R
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)


82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Altamimi ASA
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)


82613 Preservative-free preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages
Ozsaygili C
Cutaneous and Ocular Toxicology 2020; 39: 21-24 (IGR: 20-4)


82350 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
Guzman-Aranguez A
Data in brief 2019; 25: 104361 (IGR: 20-4)


82430 Latanoprost uptake and release from commercial contact lenses
Bradley MW
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)


82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Carta F
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)


82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Lakhani P
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)


82052 Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma
Kim SI
Indian Journal of Ophthalmology 2019; 67: 1297-1302 (IGR: 20-4)


82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Park SW
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)


82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Saini M
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)


82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Fuscaldi LL
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)


82350 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
Perez De Lara MJ
Data in brief 2019; 25: 104361 (IGR: 20-4)


82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Boakye-Yiadom KO
Molecules 2019; 24: (IGR: 20-4)


82758 Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
Ichhpujani P
Romanian journal of ophthalmology 2019; 63: 249-256 (IGR: 20-4)


82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Veroniaina H
Molecules 2019; 24: (IGR: 20-4)


82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Ribeiro TG
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)


82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Gupta V
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)


82758 Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
Vohra S
Romanian journal of ophthalmology 2019; 63: 249-256 (IGR: 20-4)


82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Ashour E
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)


82430 Latanoprost uptake and release from commercial contact lenses
Pitt WG
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)


82052 Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma
Jung JH
Indian Journal of Ophthalmology 2019; 67: 1297-1302 (IGR: 20-4)


82350 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
Singh M
Data in brief 2019; 25: 104361 (IGR: 20-4)


82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Dada T
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)


82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Gul W
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)


82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Wang H
Molecules 2019; 24: (IGR: 20-4)


82052 Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma
Shin J
Indian Journal of Ophthalmology 2019; 67: 1297-1302 (IGR: 20-4)


82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Castilho RO
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)


82350 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
Singh J; Kaur IP
Data in brief 2019; 25: 104361 (IGR: 20-4)


82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Sun M
Molecules 2019; 24: (IGR: 20-4)


82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Yoshida MI
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)


82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Elsohly MA
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)


82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Vivekanandhan S
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)


82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Cardoso VN
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)


82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Murphy B
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)


82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Fernandes SOA
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)


82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Majumdar S
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)


82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Cronemberger S; Nogueira JC; Ferreira AJ; Faraco AAG
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)


80517 Glaucoma: Current treatment and impact of advanced drug delivery systems
Yadav KS
Life Sciences 2019; 221: 362-376 (IGR: 20-3)


80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Rossi GCM
Scientific reports 2019; 9: 4282 (IGR: 20-3)


81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Xu J
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)


81199 Designing of a pH-Triggered Carbopol®/HPMC In Situ Gel for Ocular Delivery of Dorzolamide HCl: In Vitro, In Vivo, and Ex Vivo Evaluation
Kouchak M
AAPS PharmSciTech 2019; 20: 210 (IGR: 20-3)


81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Yadav M
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)


80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Grimaudo MA
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)


80720 Causative glaucoma treatment: promising targets and delivery systems
Mietzner R
Drug Discovery Today 2019; 24: 1606-1613 (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Swann FB
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


81169 Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment
Gómez-Ballesteros M
Polymers 2019; 11: (IGR: 20-3)


81134 Development and evaluation of performance characteristics of timolol-loaded composite ocular films as potential delivery platforms for treatment of glaucoma
Tighsazzadeh M
International Journal of Pharmaceutics 2019; 566: 111-125 (IGR: 20-3)


80694 Patient-Reported Nonadherence with Glaucoma Therapy
Wolfram C
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 223-228 (IGR: 20-3)


80765 Ocular Surface Evaluation After the Substitution of Benzalkonium Chloride Preserved Prostaglandin Eye Drops by a Preservative-free Prostaglandin Analogue
Lopes NLV
Medical hypothesis, discovery and innovation in ophthalmology 2019; 8: 52-56 (IGR: 20-3)


81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Roberti G
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)


81017 Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma
Zaleska-Żmijewska A
Journal of Ophthalmology 2019; 2019: 1240537 (IGR: 20-3)


80517 Glaucoma: Current treatment and impact of advanced drug delivery systems
Yadav KS
Life Sciences 2019; 221: 362-376 (IGR: 20-3)


80907 Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients
Barwal I
Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2019; 0: 1-15 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Aptel F
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Aptel F
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80907 Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients
Kumar R
Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2019; 0: 1-15 (IGR: 20-3)


81169 Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment
López-Cano JJ
Polymers 2019; 11: (IGR: 20-3)


80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Scudeller L
Scientific reports 2019; 9: 4282 (IGR: 20-3)


81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Tanga L
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)


80694 Patient-Reported Nonadherence with Glaucoma Therapy
Stahlberg E
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 223-228 (IGR: 20-3)


80517 Glaucoma: Current treatment and impact of advanced drug delivery systems
Rajpurohit R
Life Sciences 2019; 221: 362-376 (IGR: 20-3)


80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Pescina S
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Pfeiffer N
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81017 Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma
Strzemecka E
Journal of Ophthalmology 2019; 2019: 1240537 (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Pfeiffer N
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80720 Causative glaucoma treatment: promising targets and delivery systems
Breunig M
Drug Discovery Today 2019; 24: 1606-1613 (IGR: 20-3)


81199 Designing of a pH-Triggered Carbopol®/HPMC In Situ Gel for Ocular Delivery of Dorzolamide HCl: In Vitro, In Vivo, and Ex Vivo Evaluation
Mahmoodzadeh M
AAPS PharmSciTech 2019; 20: 210 (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Singh S
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Ge Y
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)


81134 Development and evaluation of performance characteristics of timolol-loaded composite ocular films as potential delivery platforms for treatment of glaucoma
Mitchell JC
International Journal of Pharmaceutics 2019; 566: 111-125 (IGR: 20-3)


80765 Ocular Surface Evaluation After the Substitution of Benzalkonium Chloride Preserved Prostaglandin Eye Drops by a Preservative-free Prostaglandin Analogue
Gracitelli CPB
Medical hypothesis, discovery and innovation in ophthalmology 2019; 8: 52-56 (IGR: 20-3)


81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Guzman-Aranguez A
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)


81134 Development and evaluation of performance characteristics of timolol-loaded composite ocular films as potential delivery platforms for treatment of glaucoma
Boateng JS
International Journal of Pharmaceutics 2019; 566: 111-125 (IGR: 20-3)


81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Bu R
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)


80765 Ocular Surface Evaluation After the Substitution of Benzalkonium Chloride Preserved Prostaglandin Eye Drops by a Preservative-free Prostaglandin Analogue
Chalita MR
Medical hypothesis, discovery and innovation in ophthalmology 2019; 8: 52-56 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Schmickler S
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Schmickler S
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80907 Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients
Dada T
Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2019; 0: 1-15 (IGR: 20-3)


81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Manni G
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)


80517 Glaucoma: Current treatment and impact of advanced drug delivery systems
Sharma S
Life Sciences 2019; 221: 362-376 (IGR: 20-3)


81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Perez De Lara MJ
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)


80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Lumini C
Scientific reports 2019; 9: 4282 (IGR: 20-3)


80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Padula C
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Blake D
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


80694 Patient-Reported Nonadherence with Glaucoma Therapy
Pfeiffer N
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 223-228 (IGR: 20-3)


81199 Designing of a pH-Triggered Carbopol®/HPMC In Situ Gel for Ocular Delivery of Dorzolamide HCl: In Vitro, In Vivo, and Ex Vivo Evaluation
Farrahi F
AAPS PharmSciTech 2019; 20: 210 (IGR: 20-3)


81169 Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment
Bravo-Osuna I
Polymers 2019; 11: (IGR: 20-3)


81017 Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma
Wawrzyniak ZM
Journal of Ophthalmology 2019; 2019: 1240537 (IGR: 20-3)


80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Santi P
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)


81169 Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment
Herrero-Vanrell R
Polymers 2019; 11: (IGR: 20-3)


81017 Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma
Szaflik JP
Journal of Ophthalmology 2019; 2019: 1240537 (IGR: 20-3)


80765 Ocular Surface Evaluation After the Substitution of Benzalkonium Chloride Preserved Prostaglandin Eye Drops by a Preservative-free Prostaglandin Analogue
de Faria NVL
Medical hypothesis, discovery and innovation in ophthalmology 2019; 8: 52-56 (IGR: 20-3)


80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Mirabile AV
Scientific reports 2019; 9: 4282 (IGR: 20-3)


81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Zhang A
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)


81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Singh M
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)


80907 Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients
Yadav SC
Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2019; 0: 1-15 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Clarke J
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Clarke J
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
John V
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Riva I
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Le C
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Picasso E
Scientific reports 2019; 9: 4282 (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Lavín-Dapena C
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Lavín-Dapena C
Journal of Glaucoma 2019; 0: (IGR: 20-3)


80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Concheiro A
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)


81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Verticchio AC
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)


81169 Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment
Molina-Martínez IT
Polymers 2019; 11: (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Lavín-Dapena C
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Singh J
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Lavín-Dapena C
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Feng S
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)


81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Kaur IP
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)


81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Berardo F
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Fullerton M
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Moreno-Montañés J
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Moreno-Montañés J
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Alvarez-Lorenzo C
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)


81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Wang J
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)


80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Bettio F
Scientific reports 2019; 9: 4282 (IGR: 20-3)


81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Carnevale C
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Margo C
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Żarnowski T
Journal of Glaucoma 2019; 0: (IGR: 20-3)


80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Pasinetti GM
Scientific reports 2019; 9: 4282 (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Żarnowski T
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Gou J
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)


81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Carnevale C
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)


80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Nicoli S
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Csutak A
Journal of Glaucoma 2019; 0: (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Zhang Z
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Csutak A
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Yin T
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)


80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Bianchi PE
Scientific reports 2019; 9: 4282 (IGR: 20-3)


81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Oddone F
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)


81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
He H
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Jugaste T
Journal of Glaucoma 2019; 0: (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Muddasani N
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Jugaste T
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Jugaste T; Jugaste T
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Wall J
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Zhang Y
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Volksone L
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Volksone L
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Astakhov YS
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Astakhov YS
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Tang X
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Satija C; Greenberg E
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Coupier L
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Coupier L
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Coupier L
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Coupier L
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Nordmann JP
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Nordmann JP
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Mancera N
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Stalmans I
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Zurakowski D
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Stalmans I;
Journal of Glaucoma 2019; 0: (IGR: 20-3)


81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension

Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)


80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Ayyala RS
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)


79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Lazreg S
Journal Franšais d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)


79765 Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
Economou MA
Clinical Ophthalmology 2018; 12: 2399-2407 (IGR: 20-2)


80061 Effect of vitamin-E integration on delivery of prostaglandin analogs from therapeutic lenses
Sekar P
Journal of Colloid and Interface Science 2019; 539: 457-467 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Hu C
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
Mehta P
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)


79689 Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
Pasquale LR
Clinical Ophthalmology 2018; 12: 2451-2457 (IGR: 20-2)


80090 Rho kinase inhibitors for treatment of glaucoma
Mandell KJ
Expert Review of Ophthalmology 2011; 6: 611-622 (IGR: 20-2)


79583 Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment
Tiedemann D
Journal of Glaucoma 2019; 28: 325-333 (IGR: 20-2)


79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Hathout RM
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)


79766 Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
Kozobolis V
Clinical Ophthalmology 2018; 12: 2393-2398 (IGR: 20-2)


80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Maulvi FA
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)


80054 Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device
Samy KE
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 124-131 (IGR: 20-2)


79378 Brinzolamide-loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests
Mahboobian MM
Pharmaceutical Development and Technology 2019; 24: 600-606 (IGR: 20-2)


79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Arranz-Romera A
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)


79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Lee SH
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)


79383 Thermosensitive chitosan-gelatin-based hydrogel containing curcumin-loaded nanoparticles and latanoprost as a dual-drug delivery system for glaucoma treatment
Cheng YH
Experimental Eye Research 2019; 179: 179-187 (IGR: 20-2)


79689 Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
Lin S
Clinical Ophthalmology 2018; 12: 2451-2457 (IGR: 20-2)


79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
Al-Kinani AA
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)


79383 Thermosensitive chitosan-gelatin-based hydrogel containing curcumin-loaded nanoparticles and latanoprost as a dual-drug delivery system for glaucoma treatment
Ko YC
Experimental Eye Research 2019; 179: 179-187 (IGR: 20-2)


80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Patil RJ
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)


79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Kim HJ
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)


79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Gad HA
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)


80061 Effect of vitamin-E integration on delivery of prostaglandin analogs from therapeutic lenses
Chauhan A
Journal of Colloid and Interface Science 2019; 539: 457-467 (IGR: 20-2)


79378 Brinzolamide-loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests
Seyfoddin A
Pharmaceutical Development and Technology 2019; 24: 600-606 (IGR: 20-2)


80090 Rho kinase inhibitors for treatment of glaucoma
Kudelka MR
Expert Review of Ophthalmology 2011; 6: 611-622 (IGR: 20-2)


80054 Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device
Cao Y
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 124-131 (IGR: 20-2)


79583 Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment
Mouhammad ZA
Journal of Glaucoma 2019; 28: 325-333 (IGR: 20-2)


79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Merad Z
Journal Franšais d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)


79765 Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
Laukeland HK
Clinical Ophthalmology 2018; 12: 2399-2407 (IGR: 20-2)


79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Davis BM
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)


79766 Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
Konstantinidis A
Clinical Ophthalmology 2018; 12: 2393-2398 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Sun J
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Nouri MT
Journal Franšais d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)


79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Abdel-Hafez SM
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)


79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Bravo-Osuna I
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)


79378 Brinzolamide-loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests
Aboofazeli R
Pharmaceutical Development and Technology 2019; 24: 600-606 (IGR: 20-2)


79765 Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
Grabska-Liberek I
Clinical Ophthalmology 2018; 12: 2399-2407 (IGR: 20-2)


80054 Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device
Kim J
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 124-131 (IGR: 20-2)


79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Kim DH
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)


79383 Thermosensitive chitosan-gelatin-based hydrogel containing curcumin-loaded nanoparticles and latanoprost as a dual-drug delivery system for glaucoma treatment
Chang YF
Experimental Eye Research 2019; 179: 179-187 (IGR: 20-2)


79766 Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
Sideroudi H
Clinical Ophthalmology 2018; 12: 2393-2398 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Zhang Y
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79583 Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment
Utheim TP
Journal of Glaucoma 2019; 28: 325-333 (IGR: 20-2)


79689 Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
Weinreb RN
Clinical Ophthalmology 2018; 12: 2451-2457 (IGR: 20-2)


80090 Rho kinase inhibitors for treatment of glaucoma
Wirostko B
Expert Review of Ophthalmology 2011; 6: 611-622 (IGR: 20-2)


79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
Arshad MS
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)


80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Desai AR; Shukla MR
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)


79583 Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment
Dartt DA
Journal of Glaucoma 2019; 28: 325-333 (IGR: 20-2)


79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
Singh N
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)


79378 Brinzolamide-loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests
Foroutan SM
Pharmaceutical Development and Technology 2019; 24: 600-606 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Chen J
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Nasser N
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)


79766 Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
Teus M
Clinical Ophthalmology 2018; 12: 2393-2398 (IGR: 20-2)


80054 Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device
Konichi da Silva NR
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 124-131 (IGR: 20-2)


79383 Thermosensitive chitosan-gelatin-based hydrogel containing curcumin-loaded nanoparticles and latanoprost as a dual-drug delivery system for glaucoma treatment
Huang SH
Experimental Eye Research 2019; 179: 179-187 (IGR: 20-2)


79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Esteban-Pérez S
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)


79689 Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
Tsai JC
Clinical Ophthalmology 2018; 12: 2451-2457 (IGR: 20-2)


79765 Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
Rouland JF
Clinical Ophthalmology 2018; 12: 2399-2407 (IGR: 20-2)


79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Chang WS
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)


79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Garout R
Journal Franšais d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)


80054 Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device
Phone A
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 124-131 (IGR: 20-2)


79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Khalil N
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)


79583 Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment
Heegaard S
Journal of Glaucoma 2019; 28: 325-333 (IGR: 20-2)


79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Derdour A
Journal Franšais d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)


79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
van der Merwe SM
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)


79383 Thermosensitive chitosan-gelatin-based hydrogel containing curcumin-loaded nanoparticles and latanoprost as a dual-drug delivery system for glaucoma treatment
Liu CJ
Experimental Eye Research 2019; 179: 179-187 (IGR: 20-2)


79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Vales TP
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)


79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Molina-Martínez IT
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Lei Y
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79689 Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
Kramm RL
Clinical Ophthalmology 2018; 12: 2451-2457 (IGR: 20-2)


80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Vaidya RJ
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)


79378 Brinzolamide-loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests
Rupenthal ID
Pharmaceutical Development and Technology 2019; 24: 600-606 (IGR: 20-2)


79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Shamsher E
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)


80054 Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device
Bloomer MM
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 124-131 (IGR: 20-2)


79689 Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
Ianchulev T
Clinical Ophthalmology 2018; 12: 2451-2457 (IGR: 20-2)


79583 Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment
Petrovski G
Journal of Glaucoma 2019; 28: 325-333 (IGR: 20-2)


80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Ranch KM
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)


79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Kim JW
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Sun X
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Ghroud N
Journal Franšais d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)


79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
Chang MW
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)


79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Ateyya T
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)


79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Kim KH
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)


79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Kherroubi R
Journal Franšais d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)


79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Ravindran N
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Deng Y
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
Alany RG
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)


80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Vyas BA
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)


79583 Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment
Kolko M
Journal of Glaucoma 2019; 28: 325-333 (IGR: 20-2)


80054 Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device
Bhisitkul RB
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 124-131 (IGR: 20-2)


79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Amr A
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)


79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Kim JK
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)


79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Guo L
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)


80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Shah SA
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)


79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Meziane M
Journal Franšais d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)


80054 Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device
Desai TA
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 124-131 (IGR: 20-2)


79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
Ahmad Z
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)


79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Yasser N
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)


80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Shah DO
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)


79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Belkacem S
Journal Franšais d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)


79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Nasr S
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)


79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Cordeiro MF; Herrero-Vanrell R
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)


79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Ouhadj O
Journal Franšais d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)


79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Metwally AA
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)


79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Baudouin C; Tiar M
Journal Franšais d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)


78391 Chitosan-Gelatin Hydrogel Crosslinked With Oxidized Sucrose for the Ocular Delivery of Timolol Maleate
El-Feky GS
Journal of Pharmaceutical Sciences 2018; 107: 3098-3104 (IGR: 20-1)


79172 Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy
Dillinger AE
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: e1803239 (IGR: 20-1)


79236 Nanotechnology-Ocular Devices for Glaucoma Treatment: A Literature Review
Cardigos J
Current Eye Research 2019; 44: 111-117 (IGR: 20-1)


78540 Development of a biodegradable antifibrotic local drug delivery system for glaucoma microstents
Stahnke T
Bioscience reports 2018; 38: (IGR: 20-1)


79223 TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma
Jin Q
International Journal of Pharmaceutics 2018; 553: 21-28 (IGR: 20-1)


79181 Formulation and Characterization of Carvedilol Leciplex for Glaucoma Treatment: In-Vitro, Ex-Vivo and In-Vivo Study
Hassan DH
Pharmaceutics 2018; 10: (IGR: 20-1)


78445 Metal-organic frameworks, NH-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine
Kim SN
Acta biomaterialia 2018; 79: 344-353 (IGR: 20-1)


78766 Patient attitudes toward novel glaucoma drug delivery approaches
Wang BB
Digital journal of ophthalmology : DJO / sponsored by Massachusetts Eye and Ear Infirmary 2018; 24: 16-23 (IGR: 20-1)


79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Seal JR
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57 (IGR: 20-1)


78845 A review on recent drug delivery systems for posterior segment of eye
Nayak K
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 107: 1564-1582 (IGR: 20-1)


79289 The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review
Asiedu K
Journal of current ophthalmology 2019; 31: 8-15 (IGR: 20-1)


78830 Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study
Zeng Y
Life Sciences 2018; 212: 80-86 (IGR: 20-1)


78845 A review on recent drug delivery systems for posterior segment of eye
Misra M
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 107: 1564-1582 (IGR: 20-1)


79223 TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma
Li H
International Journal of Pharmaceutics 2018; 553: 21-28 (IGR: 20-1)


79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Robinson MR
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57 (IGR: 20-1)


78830 Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study
Chen J
Life Sciences 2018; 212: 80-86 (IGR: 20-1)


79236 Nanotechnology-Ocular Devices for Glaucoma Treatment: A Literature Review
Ferreira Q
Current Eye Research 2019; 44: 111-117 (IGR: 20-1)


78391 Chitosan-Gelatin Hydrogel Crosslinked With Oxidized Sucrose for the Ocular Delivery of Timolol Maleate
Zayed GM
Journal of Pharmaceutical Sciences 2018; 107: 3098-3104 (IGR: 20-1)


79172 Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy
Guter M
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: e1803239 (IGR: 20-1)


78540 Development of a biodegradable antifibrotic local drug delivery system for glaucoma microstents
Siewert S
Bioscience reports 2018; 38: (IGR: 20-1)


79289 The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review
Abu SL
Journal of current ophthalmology 2019; 31: 8-15 (IGR: 20-1)


79181 Formulation and Characterization of Carvedilol Leciplex for Glaucoma Treatment: In-Vitro, Ex-Vivo and In-Vivo Study
Abdelmonem R
Pharmaceutics 2018; 10: (IGR: 20-1)


78445 Metal-organic frameworks, NH-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine
Park CG
Acta biomaterialia 2018; 79: 344-353 (IGR: 20-1)


78766 Patient attitudes toward novel glaucoma drug delivery approaches
Lin MM
Digital journal of ophthalmology : DJO / sponsored by Massachusetts Eye and Ear Infirmary 2018; 24: 16-23 (IGR: 20-1)


78830 Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study
Li Y
Life Sciences 2018; 212: 80-86 (IGR: 20-1)


78445 Metal-organic frameworks, NH-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine
Huh BK
Acta biomaterialia 2018; 79: 344-353 (IGR: 20-1)


78766 Patient attitudes toward novel glaucoma drug delivery approaches
Nguyen T
Digital journal of ophthalmology : DJO / sponsored by Massachusetts Eye and Ear Infirmary 2018; 24: 16-23 (IGR: 20-1)


79223 TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma
Jin Z
International Journal of Pharmaceutics 2018; 553: 21-28 (IGR: 20-1)


78540 Development of a biodegradable antifibrotic local drug delivery system for glaucoma microstents
Reske T
Bioscience reports 2018; 38: (IGR: 20-1)


78391 Chitosan-Gelatin Hydrogel Crosslinked With Oxidized Sucrose for the Ocular Delivery of Timolol Maleate
Elshaier YAMM
Journal of Pharmaceutical Sciences 2018; 107: 3098-3104 (IGR: 20-1)


79172 Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy
Froemel F
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: e1803239 (IGR: 20-1)


79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Burke J
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57 (IGR: 20-1)


79181 Formulation and Characterization of Carvedilol Leciplex for Glaucoma Treatment: In-Vitro, Ex-Vivo and In-Vivo Study
Abdellatif MM
Pharmaceutics 2018; 10: (IGR: 20-1)


79236 Nanotechnology-Ocular Devices for Glaucoma Treatment: A Literature Review
Crisóstomo S; Moura-Coelho N
Current Eye Research 2019; 44: 111-117 (IGR: 20-1)


78766 Patient attitudes toward novel glaucoma drug delivery approaches
Turalba AV
Digital journal of ophthalmology : DJO / sponsored by Massachusetts Eye and Ear Infirmary 2018; 24: 16-23 (IGR: 20-1)


78830 Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study
Huang J
Life Sciences 2018; 212: 80-86 (IGR: 20-1)


79223 TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma
Huang L
International Journal of Pharmaceutics 2018; 553: 21-28 (IGR: 20-1)


79172 Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy
Weber GR
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: e1803239 (IGR: 20-1)


79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Bejanian M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57 (IGR: 20-1)


78391 Chitosan-Gelatin Hydrogel Crosslinked With Oxidized Sucrose for the Ocular Delivery of Timolol Maleate
Alsharif FM
Journal of Pharmaceutical Sciences 2018; 107: 3098-3104 (IGR: 20-1)


78540 Development of a biodegradable antifibrotic local drug delivery system for glaucoma microstents
Schmidt W
Bioscience reports 2018; 38: (IGR: 20-1)


78445 Metal-organic frameworks, NH-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine
Lee SH
Acta biomaterialia 2018; 79: 344-353 (IGR: 20-1)


78830 Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study
Huang Z
Life Sciences 2018; 212: 80-86 (IGR: 20-1)


79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Coote M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57 (IGR: 20-1)


79172 Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy
Perkumas K
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: e1803239 (IGR: 20-1)


79223 TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma
Wang F
International Journal of Pharmaceutics 2018; 553: 21-28 (IGR: 20-1)


79236 Nanotechnology-Ocular Devices for Glaucoma Treatment: A Literature Review
Cunha JP
Current Eye Research 2019; 44: 111-117 (IGR: 20-1)


78540 Development of a biodegradable antifibrotic local drug delivery system for glaucoma microstents
Schmitz KP
Bioscience reports 2018; 38: (IGR: 20-1)


78445 Metal-organic frameworks, NH-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine
Min CH
Acta biomaterialia 2018; 79: 344-353 (IGR: 20-1)


79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Attar M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57 (IGR: 20-1)


78540 Development of a biodegradable antifibrotic local drug delivery system for glaucoma microstents
Grabow N
Bioscience reports 2018; 38: (IGR: 20-1)


78445 Metal-organic frameworks, NH-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine
Lee YY
Acta biomaterialia 2018; 79: 344-353 (IGR: 20-1)


79236 Nanotechnology-Ocular Devices for Glaucoma Treatment: A Literature Review
Pinto LA
Current Eye Research 2019; 44: 111-117 (IGR: 20-1)


78830 Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study
Huang Y
Life Sciences 2018; 212: 80-86 (IGR: 20-1)


79223 TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma
Zhou Y
International Journal of Pharmaceutics 2018; 553: 21-28 (IGR: 20-1)


79172 Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy
Stamer WD; Ohlmann A
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: e1803239 (IGR: 20-1)


78445 Metal-organic frameworks, NH-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine
Kim YK
Acta biomaterialia 2018; 79: 344-353 (IGR: 20-1)


78830 Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study
Pan X
Life Sciences 2018; 212: 80-86 (IGR: 20-1)


79223 TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma
Liu Y
International Journal of Pharmaceutics 2018; 553: 21-28 (IGR: 20-1)


78540 Development of a biodegradable antifibrotic local drug delivery system for glaucoma microstents
Guthoff RF
Bioscience reports 2018; 38: (IGR: 20-1)


79236 Nanotechnology-Ocular Devices for Glaucoma Treatment: A Literature Review
Ferreira JT
Current Eye Research 2019; 44: 111-117 (IGR: 20-1)


78540 Development of a biodegradable antifibrotic local drug delivery system for glaucoma microstents
Wree A
Bioscience reports 2018; 38: (IGR: 20-1)


78445 Metal-organic frameworks, NH-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine
Park KH
Acta biomaterialia 2018; 79: 344-353 (IGR: 20-1)


78830 Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study
Wu C
Life Sciences 2018; 212: 80-86 (IGR: 20-1)


79172 Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy
Fuchshofer R
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: e1803239 (IGR: 20-1)


79223 TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma
Jiang C; Oswald J
International Journal of Pharmaceutics 2018; 553: 21-28 (IGR: 20-1)


79172 Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy
Breunig M
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: e1803239 (IGR: 20-1)


78445 Metal-organic frameworks, NH-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine
Choy YB
Acta biomaterialia 2018; 79: 344-353 (IGR: 20-1)


79223 TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma
Wu J; Song X
International Journal of Pharmaceutics 2018; 553: 21-28 (IGR: 20-1)


77935 Controlled-release nanotherapeutics: State of translation
Tan YF
Journal of Controlled Release 2018; 284: 39-48 (IGR: 19-4)


78156 Reduction in Ocular Hypotensive Eyedrops by Ab Interno Trabeculotomy Improves Not Only Ocular Surface Condition But Also Quality of Vision
Kashiwagi K
Journal of Ophthalmology 2018; 2018: 8165476 (IGR: 19-4)


78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Kim SN
Molecular pharmaceutics 2018; 15: 3143-3152 (IGR: 19-4)


78256 Old and New Drug Classes Expanding To Include Glaucoma Treatments
Kish T
P and T 2018; 43: 489-502 (IGR: 19-4)


78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Li J
International Journal of Nanomedicine 2018; 13: 3975-3987 (IGR: 19-4)


78063 Preservatives in glaucoma medication
Steven DW
British Journal of Ophthalmology 2018; 102: 1497-1503 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Davis BM
Scientific reports 2018; 8: 11066 (IGR: 19-4)


77935 Controlled-release nanotherapeutics: State of translation
Tan YF
Journal of Controlled Release 2018; 284: 39-48 (IGR: 19-4)


78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
Fahmy HM
International Journal of Pharmaceutics 2018; 548: 597-608 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Misiuk-Hojlo M
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
Saad EAES
International Journal of Pharmaceutics 2018; 548: 597-608 (IGR: 19-4)


78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Ko SA
Molecular pharmaceutics 2018; 15: 3143-3152 (IGR: 19-4)


77935 Controlled-release nanotherapeutics: State of translation
Lao LL
Journal of Controlled Release 2018; 284: 39-48 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Pahlitzsch M
Scientific reports 2018; 8: 11066 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Pomorska M
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Tian S
International Journal of Nanomedicine 2018; 13: 3975-3987 (IGR: 19-4)


78156 Reduction in Ocular Hypotensive Eyedrops by Ab Interno Trabeculotomy Improves Not Only Ocular Surface Condition But Also Quality of Vision
Matsubara M
Journal of Ophthalmology 2018; 2018: 8165476 (IGR: 19-4)


78063 Preservatives in glaucoma medication
Alaghband P
British Journal of Ophthalmology 2018; 102: 1497-1503 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Mulak M
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78063 Preservatives in glaucoma medication
Lim KS
British Journal of Ophthalmology 2018; 102: 1497-1503 (IGR: 19-4)


78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
Sabra NM
International Journal of Pharmaceutics 2018; 548: 597-608 (IGR: 19-4)


77935 Controlled-release nanotherapeutics: State of translation
Xiong GM
Journal of Controlled Release 2018; 284: 39-48 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Guo L
Scientific reports 2018; 8: 11066 (IGR: 19-4)


78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Park CG
Molecular pharmaceutics 2018; 15: 3143-3152 (IGR: 19-4)


78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Tao Q
International Journal of Nanomedicine 2018; 13: 3975-3987 (IGR: 19-4)


78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
El-Gohary AA
International Journal of Pharmaceutics 2018; 548: 597-608 (IGR: 19-4)


78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Zhao Y
International Journal of Nanomedicine 2018; 13: 3975-3987 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Rekas M
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Balendra S
Scientific reports 2018; 8: 11066 (IGR: 19-4)


77935 Controlled-release nanotherapeutics: State of translation
Venkatraman S
Journal of Controlled Release 2018; 284: 39-48 (IGR: 19-4)


78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Lee SH
Molecular pharmaceutics 2018; 15: 3143-3152 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Shah P
Scientific reports 2018; 8: 11066 (IGR: 19-4)


78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Huh BK
Molecular pharmaceutics 2018; 15: 3143-3152 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Wierzbowska J
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
Mohamed FF
International Journal of Pharmaceutics 2018; 548: 597-608 (IGR: 19-4)


78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Gui R
International Journal of Nanomedicine 2018; 13: 3975-3987 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Prost M
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
Gaber MH
International Journal of Pharmaceutics 2018; 548: 597-608 (IGR: 19-4)


78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Park YH
Molecular pharmaceutics 2018; 15: 3143-3152 (IGR: 19-4)


78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Yang F
International Journal of Nanomedicine 2018; 13: 3975-3987 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Ravindran N; Malaguarnera G
Scientific reports 2018; 8: 11066 (IGR: 19-4)


78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Zang L
International Journal of Nanomedicine 2018; 13: 3975-3987 (IGR: 19-4)


78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Kim YK
Molecular pharmaceutics 2018; 15: 3143-3152 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Wasyluk J
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Ha A
Molecular pharmaceutics 2018; 15: 3143-3152 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Sisa C
Scientific reports 2018; 8: 11066 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Lubinski W
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Chen Y; Ping Q
International Journal of Nanomedicine 2018; 13: 3975-3987 (IGR: 19-4)


78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Park KH
Molecular pharmaceutics 2018; 15: 3143-3152 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Shamsher E
Scientific reports 2018; 8: 11066 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Podboraczynska-Jodko K
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Hou D
International Journal of Nanomedicine 2018; 13: 3975-3987 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Romaniuk W
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Hamze H
Scientific reports 2018; 8: 11066 (IGR: 19-4)


78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Choy YB
Molecular pharmaceutics 2018; 15: 3143-3152 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Noor A
Scientific reports 2018; 8: 11066 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Kinasz R; Ortyl-Markiewicz R
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Sornsute A; Somavarapu S
Scientific reports 2018; 8: 11066 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Mocko L
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Cordeiro MF
Scientific reports 2018; 8: 11066 (IGR: 19-4)


78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Zaleska-Zmijewska A; Rokicki D; Baudouin C
European Journal of Ophthalmology 2018; 0: 1120672118785280 (IGR: 19-4)


77182 Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride
Wong TT
Clinical and Experimental Ophthalmology 2018; 0: (IGR: 19-3)


76239 Eyelid Changes Related to Meibomian Gland Dysfunction in Early Middle-Aged Patients Using Topical Glaucoma Medications
Kim JH
Cornea 2018; 37: 421-425 (IGR: 19-3)


76638 Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye
Wong ABC
Ocular Surface 2018; 16: 289-293 (IGR: 19-3)


76819 High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand
Ruangvaravate N
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 387-394 (IGR: 19-3)


76188 Drop instillation and glaucoma
Davis SA
Current Opinions in Ophthalmology 2018; 29: 171-177 (IGR: 19-3)


77208 Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients
Gao X
Journal of Ophthalmology 2018; 2018: 1376020 (IGR: 19-3)


76957 Delivery of therapeutics for deep-seated ocular conditions - status quo
Nguyen H
Journal of Pharmacy and Pharmacology 2018; 70: 994-1001 (IGR: 19-3)


77022 Exploring gelatin nanoparticles as novel nanocarriers for Timolol Maleate: Augmented in-vivo efficacy and safe histological profile
Shokry M
International Journal of Pharmaceutics 2018; 545: 229-239 (IGR: 19-3)


76812 Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness
Hommer A
European Journal of Ophthalmology 2018; 28: 385-392 (IGR: 19-3)


76990 Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensiv
Roberti G
Advances in Therapy 2018; 35: 686-696 (IGR: 19-3)


76857 Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma
Pitha I
Translational vision science & technology 2018; 7: 13 (IGR: 19-3)


76887 Intraocular light scatter in patients on topical intraocular pressure-lowering medication
Pérez-Bartolomé F
European Journal of Ophthalmology 2018; 0: 1120672117753667 (IGR: 19-3)


77020 Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation
Desai AR
Biomaterials science 2018; 6: 1580-1591 (IGR: 19-3)


76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Stack T
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)


77293 Efficacy of three different formulations of brimonidine for control of intraocular pressure in primary open-angle glaucoma: A 6-week randomized trial
Bhatti A
Oman journal of ophthalmology 2018; 11: 140-143 (IGR: 19-3)


76857 Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma
Kimball EC
Translational vision science & technology 2018; 7: 13 (IGR: 19-3)


76887 Intraocular light scatter in patients on topical intraocular pressure-lowering medication
Martínez de la Casa JM
European Journal of Ophthalmology 2018; 0: 1120672117753667 (IGR: 19-3)


77022 Exploring gelatin nanoparticles as novel nanocarriers for Timolol Maleate: Augmented in-vivo efficacy and safe histological profile
Hathout RM
International Journal of Pharmaceutics 2018; 545: 229-239 (IGR: 19-3)


77293 Efficacy of three different formulations of brimonidine for control of intraocular pressure in primary open-angle glaucoma: A 6-week randomized trial
Singh G
Oman journal of ophthalmology 2018; 11: 140-143 (IGR: 19-3)


76990 Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensiv
Agnifili L
Advances in Therapy 2018; 35: 686-696 (IGR: 19-3)


77182 Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride
Aung T
Clinical and Experimental Ophthalmology 2018; 0: (IGR: 19-3)


76812 Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness
Schmidl D
European Journal of Ophthalmology 2018; 28: 385-392 (IGR: 19-3)


77208 Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients
Yang Q
Journal of Ophthalmology 2018; 2018: 1376020 (IGR: 19-3)


76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Vahabikashi A
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)


76638 Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye
Wang MTM
Ocular Surface 2018; 16: 289-293 (IGR: 19-3)


76188 Drop instillation and glaucoma
Sleath B
Current Opinions in Ophthalmology 2018; 29: 171-177 (IGR: 19-3)


77020 Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation
Maulvi FA
Biomaterials science 2018; 6: 1580-1591 (IGR: 19-3)


76819 High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand
Prabhasawat P
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 387-394 (IGR: 19-3)


76957 Delivery of therapeutics for deep-seated ocular conditions - status quo
Eng S
Journal of Pharmacy and Pharmacology 2018; 70: 994-1001 (IGR: 19-3)


76239 Eyelid Changes Related to Meibomian Gland Dysfunction in Early Middle-Aged Patients Using Topical Glaucoma Medications
Shin YU
Cornea 2018; 37: 421-425 (IGR: 19-3)


76819 High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand
Vachirasakchai V
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 387-394 (IGR: 19-3)


76990 Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensiv
Berardo F
Advances in Therapy 2018; 35: 686-696 (IGR: 19-3)


77020 Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation
Pandya MM
Biomaterials science 2018; 6: 1580-1591 (IGR: 19-3)


77208 Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients
Huang W
Journal of Ophthalmology 2018; 2018: 1376020 (IGR: 19-3)


76638 Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye
Liu K
Ocular Surface 2018; 16: 289-293 (IGR: 19-3)


76812 Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness
Kromus M
European Journal of Ophthalmology 2018; 28: 385-392 (IGR: 19-3)


76188 Drop instillation and glaucoma
Carpenter DM
Current Opinions in Ophthalmology 2018; 29: 171-177 (IGR: 19-3)


76957 Delivery of therapeutics for deep-seated ocular conditions - status quo
Ngo T
Journal of Pharmacy and Pharmacology 2018; 70: 994-1001 (IGR: 19-3)


76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Johnson M
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)


77182 Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride
Ho CL
Clinical and Experimental Ophthalmology 2018; 0: (IGR: 19-3)


76239 Eyelid Changes Related to Meibomian Gland Dysfunction in Early Middle-Aged Patients Using Topical Glaucoma Medications
Seong M
Cornea 2018; 37: 421-425 (IGR: 19-3)


77022 Exploring gelatin nanoparticles as novel nanocarriers for Timolol Maleate: Augmented in-vivo efficacy and safe histological profile
Mansour S
International Journal of Pharmaceutics 2018; 545: 229-239 (IGR: 19-3)


76857 Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma
Oglesby EN
Translational vision science & technology 2018; 7: 13 (IGR: 19-3)


76887 Intraocular light scatter in patients on topical intraocular pressure-lowering medication
Arriola-Villalobos P
European Journal of Ophthalmology 2018; 0: 1120672117753667 (IGR: 19-3)


76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Scott E
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)


76957 Delivery of therapeutics for deep-seated ocular conditions - status quo
Dass CR
Journal of Pharmacy and Pharmacology 2018; 70: 994-1001 (IGR: 19-3)


76239 Eyelid Changes Related to Meibomian Gland Dysfunction in Early Middle-Aged Patients Using Topical Glaucoma Medications
Cho HY
Cornea 2018; 37: 421-425 (IGR: 19-3)


77020 Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation
Ranch KM
Biomaterials science 2018; 6: 1580-1591 (IGR: 19-3)


76812 Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness
Bata AM
European Journal of Ophthalmology 2018; 28: 385-392 (IGR: 19-3)


76990 Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensiv
Riva I
Advances in Therapy 2018; 35: 686-696 (IGR: 19-3)


76819 High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand
Tantimala R
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 387-394 (IGR: 19-3)


77208 Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients
Chen T
Journal of Ophthalmology 2018; 2018: 1376020 (IGR: 19-3)


76887 Intraocular light scatter in patients on topical intraocular pressure-lowering medication
Fernández-Pérez C
European Journal of Ophthalmology 2018; 0: 1120672117753667 (IGR: 19-3)


76638 Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye
Prime ZJ
Ocular Surface 2018; 16: 289-293 (IGR: 19-3)


76857 Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma
Pease ME
Translational vision science & technology 2018; 7: 13 (IGR: 19-3)


76188 Drop instillation and glaucoma
Blalock SJ
Current Opinions in Ophthalmology 2018; 29: 171-177 (IGR: 19-3)


76857 Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma
Fu J
Translational vision science & technology 2018; 7: 13 (IGR: 19-3)


77208 Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients
Zuo C
Journal of Ophthalmology 2018; 2018: 1376020 (IGR: 19-3)


76812 Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness
Fondi K
European Journal of Ophthalmology 2018; 28: 385-392 (IGR: 19-3)


76188 Drop instillation and glaucoma
Muir KW
Current Opinions in Ophthalmology 2018; 29: 171-177 (IGR: 19-3)


76638 Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye
Danesh-Meyer HV
Ocular Surface 2018; 16: 289-293 (IGR: 19-3)


76887 Intraocular light scatter in patients on topical intraocular pressure-lowering medication
García-Feijoó J
European Journal of Ophthalmology 2018; 0: 1120672117753667 (IGR: 19-3)


76239 Eyelid Changes Related to Meibomian Gland Dysfunction in Early Middle-Aged Patients Using Topical Glaucoma Medications
Kang MH
Cornea 2018; 37: 421-425 (IGR: 19-3)


77020 Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation
Vyas BA
Biomaterials science 2018; 6: 1580-1591 (IGR: 19-3)


76990 Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensiv
Figus M
Advances in Therapy 2018; 35: 686-696 (IGR: 19-3)


76638 Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye
Craig JP
Ocular Surface 2018; 16: 289-293 (IGR: 19-3)


76812 Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness
Werkmeister RM
European Journal of Ophthalmology 2018; 28: 385-392 (IGR: 19-3)


77020 Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation
Shah SA
Biomaterials science 2018; 6: 1580-1591 (IGR: 19-3)


76857 Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma
Schaub J; Schaub J
Translational vision science & technology 2018; 7: 13 (IGR: 19-3)


76188 Drop instillation and glaucoma
Budenz DL
Current Opinions in Ophthalmology 2018; 29: 171-177 (IGR: 19-3)


76990 Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensiv
Manni G
Advances in Therapy 2018; 35: 686-696 (IGR: 19-3)


77208 Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients
Li X
Journal of Ophthalmology 2018; 2018: 1376020 (IGR: 19-3)


77020 Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation
Shah DO
Biomaterials science 2018; 6: 1580-1591 (IGR: 19-3)


76990 Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensiv
Quaranta L
Advances in Therapy 2018; 35: 686-696 (IGR: 19-3)


76857 Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma
Kim YC
Translational vision science & technology 2018; 7: 13 (IGR: 19-3)


77208 Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients
Gao W
Journal of Ophthalmology 2018; 2018: 1376020 (IGR: 19-3)


76812 Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness
Baar C
European Journal of Ophthalmology 2018; 28: 385-392 (IGR: 19-3)


77208 Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients
Xiao H
Journal of Ophthalmology 2018; 2018: 1376020 (IGR: 19-3)


76990 Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensiv
Oddone F
Advances in Therapy 2018; 35: 686-696 (IGR: 19-3)


76857 Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma
Hu Q
Translational vision science & technology 2018; 7: 13 (IGR: 19-3)


76812 Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness
Schmetterer L
European Journal of Ophthalmology 2018; 28: 385-392 (IGR: 19-3)


76857 Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma
Hanes J
Translational vision science & technology 2018; 7: 13 (IGR: 19-3)


76812 Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness
Garhöfer G
European Journal of Ophthalmology 2018; 28: 385-392 (IGR: 19-3)


76857 Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma
Quigley HA
Translational vision science & technology 2018; 7: 13 (IGR: 19-3)


75392 Fabrication And Characterization Of Timolol Maleate And Brinzolamide Loaded Nanostructured Lipid Carrier System For Ocular Drug Delivery
Shrivastava N
Current Drug Delivery 2017; 0: (IGR: 19-2)


75326 Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma
Sánchez-López E
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: (IGR: 19-2)


75357 New pharmacotherapy for the treatment of glaucoma
Schehlein EM
Expert Opinion in Pharmacotherapy 2017; 18: 1939-1946 (IGR: 19-2)


75279 Self-Assembling Elastin-Like Hydrogels for Timolol Delivery: Development of an Ophthalmic Formulation Against Glaucoma
Fernández-Colino A
Molecular pharmaceutics 2017; 14: 4498-4508 (IGR: 19-2)


75497 Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 3 factorial design
Barse RK
Drug Development and Industrial Pharmacy 2018; 44: 800-807 (IGR: 19-2)


75519 Meibomian Gland Performance in Glaucomatous Patients With Long-term Instillation of IOP-lowering Medications
Cho WH
Journal of Glaucoma 2018; 27: 176-183 (IGR: 19-2)


75597 Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients
Kestelyn PA
International Ophthalmology 2017; 0: (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Kim J
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75322 Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model
Kopp F
Scientific reports 2017; 7: 15780 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Giannaccini M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75327 Nanogel-based natural polymers as smart carriers for the controlled delivery of Timolol Maleate through the cornea for glaucoma
Ilka R
International Journal of Biological Macromolecules 2018; 109: 955-962 (IGR: 19-2)


75322 Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model
Eickner T
Scientific reports 2017; 7: 15780 (IGR: 19-2)


75519 Meibomian Gland Performance in Glaucomatous Patients With Long-term Instillation of IOP-lowering Medications
Lai IC
Journal of Glaucoma 2018; 27: 176-183 (IGR: 19-2)


75279 Self-Assembling Elastin-Like Hydrogels for Timolol Delivery: Development of an Ophthalmic Formulation Against Glaucoma
Quinteros DA
Molecular pharmaceutics 2017; 14: 4498-4508 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Kudisch M
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75497 Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 3 factorial design
Tagalpallewar AA
Drug Development and Industrial Pharmacy 2018; 44: 800-807 (IGR: 19-2)


75597 Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients
Kestelyn PG
International Ophthalmology 2017; 0: (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Usai A
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75327 Nanogel-based natural polymers as smart carriers for the controlled delivery of Timolol Maleate through the cornea for glaucoma
Mohseni M
International Journal of Biological Macromolecules 2018; 109: 955-962 (IGR: 19-2)


75392 Fabrication And Characterization Of Timolol Maleate And Brinzolamide Loaded Nanostructured Lipid Carrier System For Ocular Drug Delivery
Khan S
Current Drug Delivery 2017; 0: (IGR: 19-2)


75326 Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma
Egea MA
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: (IGR: 19-2)


75357 New pharmacotherapy for the treatment of glaucoma
Novack G
Expert Opinion in Pharmacotherapy 2017; 18: 1939-1946 (IGR: 19-2)


75497 Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 3 factorial design
Kokare CR
Drug Development and Industrial Pharmacy 2018; 44: 800-807 (IGR: 19-2)


75597 Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients
De Bacquer D
International Ophthalmology 2017; 0: (IGR: 19-2)


75326 Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma
Davis BM
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Chiellini F
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75519 Meibomian Gland Performance in Glaucomatous Patients With Long-term Instillation of IOP-lowering Medications
Fang PC
Journal of Glaucoma 2018; 27: 176-183 (IGR: 19-2)


75279 Self-Assembling Elastin-Like Hydrogels for Timolol Delivery: Development of an Ophthalmic Formulation Against Glaucoma
Allemandi DA
Molecular pharmaceutics 2017; 14: 4498-4508 (IGR: 19-2)


75327 Nanogel-based natural polymers as smart carriers for the controlled delivery of Timolol Maleate through the cornea for glaucoma
Kianirad M
International Journal of Biological Macromolecules 2018; 109: 955-962 (IGR: 19-2)


75322 Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model
Polei S
Scientific reports 2017; 7: 15780 (IGR: 19-2)


75357 New pharmacotherapy for the treatment of glaucoma
Robin AL
Expert Opinion in Pharmacotherapy 2017; 18: 1939-1946 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
da Silva NRK
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75392 Fabrication And Characterization Of Timolol Maleate And Brinzolamide Loaded Nanostructured Lipid Carrier System For Ocular Drug Delivery
Baboota S
Current Drug Delivery 2017; 0: (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Guadagni V
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75519 Meibomian Gland Performance in Glaucomatous Patients With Long-term Instillation of IOP-lowering Medications
Chien CC
Journal of Glaucoma 2018; 27: 176-183 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Asada H
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75327 Nanogel-based natural polymers as smart carriers for the controlled delivery of Timolol Maleate through the cornea for glaucoma
Naseripour M
International Journal of Biological Macromolecules 2018; 109: 955-962 (IGR: 19-2)


75322 Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model
Falke K
Scientific reports 2017; 7: 15780 (IGR: 19-2)


75392 Fabrication And Characterization Of Timolol Maleate And Brinzolamide Loaded Nanostructured Lipid Carrier System For Ocular Drug Delivery
Ali J
Current Drug Delivery 2017; 0: (IGR: 19-2)


75497 Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 3 factorial design
Sharma JP
Drug Development and Industrial Pharmacy 2018; 44: 800-807 (IGR: 19-2)


75326 Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma
Guo L
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: (IGR: 19-2)


75597 Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients
Stevens AM
International Ophthalmology 2017; 0: (IGR: 19-2)


75279 Self-Assembling Elastin-Like Hydrogels for Timolol Delivery: Development of an Ophthalmic Formulation Against Glaucoma
Girotti A
Molecular pharmaceutics 2017; 14: 4498-4508 (IGR: 19-2)


75326 Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma
Espina M
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: (IGR: 19-2)


75279 Self-Assembling Elastin-Like Hydrogels for Timolol Delivery: Development of an Ophthalmic Formulation Against Glaucoma
Palma SD
Molecular pharmaceutics 2017; 14: 4498-4508 (IGR: 19-2)


75327 Nanogel-based natural polymers as smart carriers for the controlled delivery of Timolol Maleate through the cornea for glaucoma
Ashtari K
International Journal of Biological Macromolecules 2018; 109: 955-962 (IGR: 19-2)


75497 Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 3 factorial design
Sharma PK
Drug Development and Industrial Pharmacy 2018; 44: 800-807 (IGR: 19-2)


75322 Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model
Witt M
Scientific reports 2017; 7: 15780 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Andreazzoli M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75519 Meibomian Gland Performance in Glaucomatous Patients With Long-term Instillation of IOP-lowering Medications
Tseng SL
Journal of Glaucoma 2018; 27: 176-183 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Aya-Shibuya E; Bloomer MM
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Ori M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75326 Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma
Silva AM
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: (IGR: 19-2)


75279 Self-Assembling Elastin-Like Hydrogels for Timolol Delivery: Development of an Ophthalmic Formulation Against Glaucoma
Arias FJ
Molecular pharmaceutics 2017; 14: 4498-4508 (IGR: 19-2)


75327 Nanogel-based natural polymers as smart carriers for the controlled delivery of Timolol Maleate through the cornea for glaucoma
Mehravi B
International Journal of Biological Macromolecules 2018; 109: 955-962 (IGR: 19-2)


75322 Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model
Grabow N
Scientific reports 2017; 7: 15780 (IGR: 19-2)


75519 Meibomian Gland Performance in Glaucomatous Patients With Long-term Instillation of IOP-lowering Medications
Lai YH
Journal of Glaucoma 2018; 27: 176-183 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Pasqualetti M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75326 Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma
Calpena AC
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: (IGR: 19-2)


75322 Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model
Stachs O
Scientific reports 2017; 7: 15780 (IGR: 19-2)


75519 Meibomian Gland Performance in Glaucomatous Patients With Long-term Instillation of IOP-lowering Medications
Huang YT
Journal of Glaucoma 2018; 27: 176-183 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Mudumba S
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75326 Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma
Souto EMB
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: (IGR: 19-2)


75322 Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model
Guthoff RF
Scientific reports 2017; 7: 15780 (IGR: 19-2)


75519 Meibomian Gland Performance in Glaucomatous Patients With Long-term Instillation of IOP-lowering Medications
Kuo MT
Journal of Glaucoma 2018; 27: 176-183 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Bhisitkul RB
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Dente L
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75322 Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model
Lindner T
Scientific reports 2017; 7: 15780 (IGR: 19-2)


75326 Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma
Ravindran N
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Desai TA
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Raffa V
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75326 Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma
Ettcheto M; Camins A; García ML; Cordeiro MF
Small (Weinheim an der Bergstrasse, Germany) 2018; 14: (IGR: 19-2)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Kawaguchi I
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74105 Poly(ε-caprolactone) nanocapsule carriers with sustained drug release: single dose for long-term glaucoma treatment
Lee CH
Nanoscale 2017; 9: 11754-11764 (IGR: 19-1)


74394 Development and characterisation of electrospun timolol maleate-loaded polymeric contact lens coatings containing various permeation enhancers
Mehta P
International Journal of Pharmaceutics 2017; 532: 408-420 (IGR: 19-1)


74675 Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations
Hsu KH
Pharmaceutical Research 2017; 34: 2862-2872 (IGR: 19-1)


74115 Application of Imaging Mass Spectrometry to Assess Ocular Drug Transit
Grove KJ
SLAS discovery : advancing life sciences R & D 2017; 22: 1239-1245 (IGR: 19-1)


74544 Co-instillation of nano-solid magnesium hydroxide enhances corneal permeability of dissolved timolol
Nagai N
Experimental Eye Research 2017; 165: 118-124 (IGR: 19-1)


74789 Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery
Lancina MG
ACS biomaterials science & engineering 2017; 3: 1861-1868 (IGR: 19-1)


74581 Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
Shen J
Clinical Ophthalmology 2017; 11: 1761-1767 (IGR: 19-1)


74615 Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Di Zazzo A
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 670-677 (IGR: 19-1)


74481 Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients
Kouchak M
Drug Development and Industrial Pharmacy 2017; 0: 1-16 (IGR: 19-1)


74206 Evaluation of a photocrosslinkable hydroxyethyl chitosan hydrogel as a potential drug release system for glaucoma surgery
Qiao X
Journal of Materials Science: Materials in Medicine 2017; 28: 149 (IGR: 19-1)


74426 Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis
Nuzzi R
Frontiers in neuroscience 2017; 11: 494 (IGR: 19-1)


74692 High-precision piezo-ejection ocular microdosing: Phase II study on local and systemic effects of topical phenylephrine
Ianchulev T
Therapeutic delivery 2018; 9: 17-27 (IGR: 19-1)


74176 Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye Drop
Fedorchak MV
Scientific reports 2017; 7: 8639 (IGR: 19-1)


74203 Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
Tokuda N
Journal of Ophthalmology 2017; 2017: 3540749 (IGR: 19-1)


74193 Pure Glaucoma Drugs Are Toxic to Immortalized Human Corneal Epithelial Cells, but They Do Not Destabilize Lipid Membranes
Robciuc A
Cornea 2017; 36: 1249-1255 (IGR: 19-1)


74426 Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis
Tridico F
Frontiers in neuroscience 2017; 11: 494 (IGR: 19-1)


74176 Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye Drop
Conner IP
Scientific reports 2017; 7: 8639 (IGR: 19-1)


74206 Evaluation of a photocrosslinkable hydroxyethyl chitosan hydrogel as a potential drug release system for glaucoma surgery
Peng X
Journal of Materials Science: Materials in Medicine 2017; 28: 149 (IGR: 19-1)


74394 Development and characterisation of electrospun timolol maleate-loaded polymeric contact lens coatings containing various permeation enhancers
Al-Kinani AA
International Journal of Pharmaceutics 2017; 532: 408-420 (IGR: 19-1)


74203 Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
Kitaoka Y
Journal of Ophthalmology 2017; 2017: 3540749 (IGR: 19-1)


74789 Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery
Singh S
ACS biomaterials science & engineering 2017; 3: 1861-1868 (IGR: 19-1)


74675 Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations
Gupta K
Pharmaceutical Research 2017; 34: 2862-2872 (IGR: 19-1)


74692 High-precision piezo-ejection ocular microdosing: Phase II study on local and systemic effects of topical phenylephrine
Weinreb R
Therapeutic delivery 2018; 9: 17-27 (IGR: 19-1)


74544 Co-instillation of nano-solid magnesium hydroxide enhances corneal permeability of dissolved timolol
Ogata F
Experimental Eye Research 2017; 165: 118-124 (IGR: 19-1)


74615 Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Roberti G
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 670-677 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Kobayashi A
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74105 Poly(ε-caprolactone) nanocapsule carriers with sustained drug release: single dose for long-term glaucoma treatment
Li YJ
Nanoscale 2017; 9: 11754-11764 (IGR: 19-1)


74115 Application of Imaging Mass Spectrometry to Assess Ocular Drug Transit
Kansara V
SLAS discovery : advancing life sciences R & D 2017; 22: 1239-1245 (IGR: 19-1)


74193 Pure Glaucoma Drugs Are Toxic to Immortalized Human Corneal Epithelial Cells, but They Do Not Destabilize Lipid Membranes
Witos J
Cornea 2017; 36: 1249-1255 (IGR: 19-1)


74581 Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
Goodkin ML
Clinical Ophthalmology 2017; 11: 1761-1767 (IGR: 19-1)


74481 Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients
Malekahmadi M
Drug Development and Industrial Pharmacy 2017; 0: 1-16 (IGR: 19-1)


74105 Poly(ε-caprolactone) nanocapsule carriers with sustained drug release: single dose for long-term glaucoma treatment
Huang CC
Nanoscale 2017; 9: 11754-11764 (IGR: 19-1)


74581 Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
Tong W
Clinical Ophthalmology 2017; 11: 1761-1767 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Higashide T
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74692 High-precision piezo-ejection ocular microdosing: Phase II study on local and systemic effects of topical phenylephrine
Tsai JC
Therapeutic delivery 2018; 9: 17-27 (IGR: 19-1)


74193 Pure Glaucoma Drugs Are Toxic to Immortalized Human Corneal Epithelial Cells, but They Do Not Destabilize Lipid Membranes
Ruokonen SK
Cornea 2017; 36: 1249-1255 (IGR: 19-1)


74544 Co-instillation of nano-solid magnesium hydroxide enhances corneal permeability of dissolved timolol
Otake H
Experimental Eye Research 2017; 165: 118-124 (IGR: 19-1)


74115 Application of Imaging Mass Spectrometry to Assess Ocular Drug Transit
Prentiss M
SLAS discovery : advancing life sciences R & D 2017; 22: 1239-1245 (IGR: 19-1)


74481 Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients
Bavarsad N
Drug Development and Industrial Pharmacy 2017; 0: 1-16 (IGR: 19-1)


74203 Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
Matsuzawa A
Journal of Ophthalmology 2017; 2017: 3540749 (IGR: 19-1)


74206 Evaluation of a photocrosslinkable hydroxyethyl chitosan hydrogel as a potential drug release system for glaucoma surgery
Qiao J
Journal of Materials Science: Materials in Medicine 2017; 28: 149 (IGR: 19-1)


74789 Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery
Kompella UB
ACS biomaterials science & engineering 2017; 3: 1861-1868 (IGR: 19-1)


74615 Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Mashaghi A
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 670-677 (IGR: 19-1)


74394 Development and characterisation of electrospun timolol maleate-loaded polymeric contact lens coatings containing various permeation enhancers
Arshad MS
International Journal of Pharmaceutics 2017; 532: 408-420 (IGR: 19-1)


74675 Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations
Nayaka H
Pharmaceutical Research 2017; 34: 2862-2872 (IGR: 19-1)


74176 Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye Drop
Schuman JS
Scientific reports 2017; 7: 8639 (IGR: 19-1)


74193 Pure Glaucoma Drugs Are Toxic to Immortalized Human Corneal Epithelial Cells, but They Do Not Destabilize Lipid Membranes
Rantamäki AH
Cornea 2017; 36: 1249-1255 (IGR: 19-1)


74206 Evaluation of a photocrosslinkable hydroxyethyl chitosan hydrogel as a potential drug release system for glaucoma surgery
Jiang Z
Journal of Materials Science: Materials in Medicine 2017; 28: 149 (IGR: 19-1)


74789 Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery
Husain S
ACS biomaterials science & engineering 2017; 3: 1861-1868 (IGR: 19-1)


74544 Co-instillation of nano-solid magnesium hydroxide enhances corneal permeability of dissolved timolol
Kawasaki N
Experimental Eye Research 2017; 165: 118-124 (IGR: 19-1)


74203 Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
Tsukamoto A
Journal of Ophthalmology 2017; 2017: 3540749 (IGR: 19-1)


74615 Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Abud TB
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 670-677 (IGR: 19-1)


74105 Poly(ε-caprolactone) nanocapsule carriers with sustained drug release: single dose for long-term glaucoma treatment
Lai JY
Nanoscale 2017; 9: 11754-11764 (IGR: 19-1)


74581 Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
Attar M
Clinical Ophthalmology 2017; 11: 1761-1767 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Takeji Y
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74115 Application of Imaging Mass Spectrometry to Assess Ocular Drug Transit
Long D
SLAS discovery : advancing life sciences R & D 2017; 22: 1239-1245 (IGR: 19-1)


74394 Development and characterisation of electrospun timolol maleate-loaded polymeric contact lens coatings containing various permeation enhancers
Chang MW
International Journal of Pharmaceutics 2017; 532: 408-420 (IGR: 19-1)


74481 Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients
Saki Malehi A
Drug Development and Industrial Pharmacy 2017; 0: 1-16 (IGR: 19-1)


74675 Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations
Donthi A
Pharmaceutical Research 2017; 34: 2862-2872 (IGR: 19-1)


74692 High-precision piezo-ejection ocular microdosing: Phase II study on local and systemic effects of topical phenylephrine
Lin S
Therapeutic delivery 2018; 9: 17-27 (IGR: 19-1)


74176 Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye Drop
Cugini A
Scientific reports 2017; 7: 8639 (IGR: 19-1)


74789 Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery
Yang H
ACS biomaterials science & engineering 2017; 3: 1861-1868 (IGR: 19-1)


74544 Co-instillation of nano-solid magnesium hydroxide enhances corneal permeability of dissolved timolol
Nakazawa Y
Experimental Eye Research 2017; 165: 118-124 (IGR: 19-1)


74692 High-precision piezo-ejection ocular microdosing: Phase II study on local and systemic effects of topical phenylephrine
Pasquale LR
Therapeutic delivery 2018; 9: 17-27 (IGR: 19-1)


74675 Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations
Kaul S
Pharmaceutical Research 2017; 34: 2862-2872 (IGR: 19-1)


74115 Application of Imaging Mass Spectrometry to Assess Ocular Drug Transit
Mogi M
SLAS discovery : advancing life sciences R & D 2017; 22: 1239-1245 (IGR: 19-1)


74176 Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye Drop
Little SR
Scientific reports 2017; 7: 8639 (IGR: 19-1)


74394 Development and characterisation of electrospun timolol maleate-loaded polymeric contact lens coatings containing various permeation enhancers
Alany RG
International Journal of Pharmaceutics 2017; 532: 408-420 (IGR: 19-1)


74193 Pure Glaucoma Drugs Are Toxic to Immortalized Human Corneal Epithelial Cells, but They Do Not Destabilize Lipid Membranes
Pisella PJ
Cornea 2017; 36: 1249-1255 (IGR: 19-1)


74203 Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
Sase K
Journal of Ophthalmology 2017; 2017: 3540749 (IGR: 19-1)


74615 Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Pavese D
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 670-677 (IGR: 19-1)


74481 Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients
Andishmand L
Drug Development and Industrial Pharmacy 2017; 0: 1-16 (IGR: 19-1)


74206 Evaluation of a photocrosslinkable hydroxyethyl chitosan hydrogel as a potential drug release system for glaucoma surgery
Han B
Journal of Materials Science: Materials in Medicine 2017; 28: 149 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Sakurai K
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74615 Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Bonini S
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 670-677 (IGR: 19-1)


74193 Pure Glaucoma Drugs Are Toxic to Immortalized Human Corneal Epithelial Cells, but They Do Not Destabilize Lipid Membranes
Wiedmer SK
Cornea 2017; 36: 1249-1255 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Kawaguchi C
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74675 Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations
Chauhan A
Pharmaceutical Research 2017; 34: 2862-2872 (IGR: 19-1)


74544 Co-instillation of nano-solid magnesium hydroxide enhances corneal permeability of dissolved timolol
Kanai K
Experimental Eye Research 2017; 165: 118-124 (IGR: 19-1)


74206 Evaluation of a photocrosslinkable hydroxyethyl chitosan hydrogel as a potential drug release system for glaucoma surgery
Yang C
Journal of Materials Science: Materials in Medicine 2017; 28: 149 (IGR: 19-1)


74394 Development and characterisation of electrospun timolol maleate-loaded polymeric contact lens coatings containing various permeation enhancers
Ahmad Z
International Journal of Pharmaceutics 2017; 532: 408-420 (IGR: 19-1)


74203 Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
Sakae S
Journal of Ophthalmology 2017; 2017: 3540749 (IGR: 19-1)


74115 Application of Imaging Mass Spectrometry to Assess Ocular Drug Transit
Kim S
SLAS discovery : advancing life sciences R & D 2017; 22: 1239-1245 (IGR: 19-1)


74203 Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
Takagi H
Journal of Ophthalmology 2017; 2017: 3540749 (IGR: 19-1)


74115 Application of Imaging Mass Spectrometry to Assess Ocular Drug Transit
Rudewicz PJ
SLAS discovery : advancing life sciences R & D 2017; 22: 1239-1245 (IGR: 19-1)


74193 Pure Glaucoma Drugs Are Toxic to Immortalized Human Corneal Epithelial Cells, but They Do Not Destabilize Lipid Membranes
Holopainen JM
Cornea 2017; 36: 1249-1255 (IGR: 19-1)


74206 Evaluation of a photocrosslinkable hydroxyethyl chitosan hydrogel as a potential drug release system for glaucoma surgery
Liu W
Journal of Materials Science: Materials in Medicine 2017; 28: 149 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Sugiyama K
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74544 Co-instillation of nano-solid magnesium hydroxide enhances corneal permeability of dissolved timolol
Okamoto N; Shimomura Y
Experimental Eye Research 2017; 165: 118-124 (IGR: 19-1)


73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Battistini FD
European Journal of Pharmaceutical Sciences 2017; 105: 188-194 (IGR: 18-4)


72840 Predicted patient demand for a new delivery system for glaucoma medicine
Ozdemir S
Medicine 2017; 96: e6626 (IGR: 18-4)


72930 Ocular Surface and External Filtration Surgery: Mutual Relationships
Baudouin C
Developments in Ophthalmology 2017; 59: 67-79 (IGR: 18-4)


72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Huang J
AAPS PharmSciTech 2017; 18: 2919-2926 (IGR: 18-4)


72720 Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost
Martinez-de-la-Casa JM
Ocular Surface 2017; 15: 723-729 (IGR: 18-4)


72837 Evaluation of Ocular Surface Disease in Asian Patients with Primary Angle Closure
Ling TE
Open Ophthalmology Journal 2017; 11: 31-39 (IGR: 18-4)


71955 Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles
Sánchez-López E
European Journal of Pharmaceutics and Biopharmaceutics 2017; 110: 58-69 (IGR: 18-4)


72747 Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
Muñoz Negrete FJ
Clinical Ophthalmology 2017; 11: 557-566 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Adelli GR
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Stahl E
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Natesan S
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


72967 Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study
Lee W
BMC Ophthalmology 2017; 17: 61 (IGR: 18-4)


72633 Creation of nano eye-drops and effective drug delivery to the interior of the eye
Ikuta Y
Scientific reports 2017; 7: 44229 (IGR: 18-4)


72910 Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide
Morsi N
European Journal of Pharmaceutical Sciences 2017; 104: 302-314 (IGR: 18-4)


72940 The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells
Datta S
Investigative Ophthalmology and Visual Science 2017; 58: 2406-2412 (IGR: 18-4)


73010 RES-loaded pegylated CS NPs: for efficient ocular delivery
Pandian S
IET nanobiotechnology 2017; 11: 32-39 (IGR: 18-4)


73056 Ocular surface disease in patients under topical treatment for glaucoma
Pérez-Bartolomé F
European Journal of Ophthalmology 2017; 0: 0 (IGR: 18-4)


72910 Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide
Ibrahim M
European Journal of Pharmaceutical Sciences 2017; 104: 302-314 (IGR: 18-4)


72747 Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
Lemij HG
Clinical Ophthalmology 2017; 11: 557-566 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Bhagav P
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72837 Evaluation of Ocular Surface Disease in Asian Patients with Primary Angle Closure
Othman K
Open Ophthalmology Journal 2017; 11: 31-39 (IGR: 18-4)


72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Peng T
AAPS PharmSciTech 2017; 18: 2919-2926 (IGR: 18-4)


72967 Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study
Lee S
BMC Ophthalmology 2017; 17: 61 (IGR: 18-4)


73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Tártara LI
European Journal of Pharmaceutical Sciences 2017; 105: 188-194 (IGR: 18-4)


72633 Creation of nano eye-drops and effective drug delivery to the interior of the eye
Aoyagi S
Scientific reports 2017; 7: 44229 (IGR: 18-4)


73010 RES-loaded pegylated CS NPs: for efficient ocular delivery
Jeevanesan V
IET nanobiotechnology 2017; 11: 32-39 (IGR: 18-4)


73056 Ocular surface disease in patients under topical treatment for glaucoma
Martínez-de-la-Casa JM
European Journal of Ophthalmology 2017; 0: 0 (IGR: 18-4)


72720 Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost
Perez-Bartolome F
Ocular Surface 2017; 15: 723-729 (IGR: 18-4)


72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Bremond-Gignac D
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365 (IGR: 18-4)


72940 The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells
Baudouin C
Investigative Ophthalmology and Visual Science 2017; 58: 2406-2412 (IGR: 18-4)


71955 Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles
Espina M
European Journal of Pharmaceutics and Biopharmaceutics 2017; 110: 58-69 (IGR: 18-4)


72840 Predicted patient demand for a new delivery system for glaucoma medicine
Wong TT
Medicine 2017; 96: e6626 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Pandian S
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


73056 Ocular surface disease in patients under topical treatment for glaucoma
Arriola-Villalobos P
European Journal of Ophthalmology 2017; 0: 0 (IGR: 18-4)


71955 Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles
Doktorovova S
European Journal of Pharmaceutics and Biopharmaceutics 2017; 110: 58-69 (IGR: 18-4)


72837 Evaluation of Ocular Surface Disease in Asian Patients with Primary Angle Closure
Yan OP
Open Ophthalmology Journal 2017; 11: 31-39 (IGR: 18-4)


72720 Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost
Urcelay E
Ocular Surface 2017; 15: 723-729 (IGR: 18-4)


72967 Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study
Bae H
BMC Ophthalmology 2017; 17: 61 (IGR: 18-4)


72910 Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide
Refai H
European Journal of Pharmaceutical Sciences 2017; 104: 302-314 (IGR: 18-4)


73010 RES-loaded pegylated CS NPs: for efficient ocular delivery
Ponnusamy C
IET nanobiotechnology 2017; 11: 32-39 (IGR: 18-4)


72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Landry T
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365 (IGR: 18-4)


72940 The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells
Brignole-Baudouin F
Investigative Ophthalmology and Visual Science 2017; 58: 2406-2412 (IGR: 18-4)


72840 Predicted patient demand for a new delivery system for glaucoma medicine
Allingham RR
Medicine 2017; 96: e6626 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Ponnusamy C
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


72747 Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
Erb C
Clinical Ophthalmology 2017; 11: 557-566 (IGR: 18-4)


73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Boiero C
European Journal of Pharmaceutical Sciences 2017; 105: 188-194 (IGR: 18-4)


72633 Creation of nano eye-drops and effective drug delivery to the interior of the eye
Tanaka Y
Scientific reports 2017; 7: 44229 (IGR: 18-4)


72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Li Y
AAPS PharmSciTech 2017; 18: 2919-2926 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Taskar P
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


71955 Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles
Souto EB
European Journal of Pharmaceutics and Biopharmaceutics 2017; 110: 58-69 (IGR: 18-4)


73010 RES-loaded pegylated CS NPs: for efficient ocular delivery
Natesan S
IET nanobiotechnology 2017; 11: 32-39 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Palanichamy R
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


72910 Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide
El Sorogy H
European Journal of Pharmaceutical Sciences 2017; 104: 302-314 (IGR: 18-4)


72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Curtis M
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365 (IGR: 18-4)


72940 The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells
Denoyer A
Investigative Ophthalmology and Visual Science 2017; 58: 2406-2412 (IGR: 18-4)


72840 Predicted patient demand for a new delivery system for glaucoma medicine
Finkelstein EA
Medicine 2017; 96: e6626 (IGR: 18-4)


73056 Ocular surface disease in patients under topical treatment for glaucoma
Fernández-Pérez C
European Journal of Ophthalmology 2017; 0: 0 (IGR: 18-4)


73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Guzmán ML
European Journal of Pharmaceutical Sciences 2017; 105: 188-194 (IGR: 18-4)


72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Zhan Z
AAPS PharmSciTech 2017; 18: 2919-2926 (IGR: 18-4)


72720 Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost
Santiago JL
Ocular Surface 2017; 15: 723-729 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Hingorani T
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72837 Evaluation of Ocular Surface Disease in Asian Patients with Primary Angle Closure
Rashid RA
Open Ophthalmology Journal 2017; 11: 31-39 (IGR: 18-4)


72967 Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study
Kim CY
BMC Ophthalmology 2017; 17: 61 (IGR: 18-4)


72633 Creation of nano eye-drops and effective drug delivery to the interior of the eye
Sato K
Scientific reports 2017; 7: 44229 (IGR: 18-4)


72940 The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells
Cortopassi GA
Investigative Ophthalmology and Visual Science 2017; 58: 2406-2412 (IGR: 18-4)


72633 Creation of nano eye-drops and effective drug delivery to the interior of the eye
Inada S
Scientific reports 2017; 7: 44229 (IGR: 18-4)


72720 Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost
Moreno-Montañes J
Ocular Surface 2017; 15: 723-729 (IGR: 18-4)


73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Luciani-Giaccobbe LC
European Journal of Pharmaceutical Sciences 2017; 105: 188-194 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Pettaway S
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


73056 Ocular surface disease in patients under topical treatment for glaucoma
Polo V
European Journal of Ophthalmology 2017; 0: 0 (IGR: 18-4)


72967 Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study
Seong GJ
BMC Ophthalmology 2017; 17: 61 (IGR: 18-4)


72837 Evaluation of Ocular Surface Disease in Asian Patients with Primary Angle Closure
Tet CM
Open Ophthalmology Journal 2017; 11: 31-39 (IGR: 18-4)


71955 Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles
García ML
European Journal of Pharmaceutics and Biopharmaceutics 2017; 110: 58-69 (IGR: 18-4)


72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Gedif K
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Muthusamy S
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Zeng Y
AAPS PharmSciTech 2017; 18: 2919-2926 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Kandasamy R
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Al Shahwan S
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365 (IGR: 18-4)


73056 Ocular surface disease in patients under topical treatment for glaucoma
García-Feijoó J
European Journal of Ophthalmology 2017; 0: 0 (IGR: 18-4)


73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Palma SD
European Journal of Pharmaceutical Sciences 2017; 105: 188-194 (IGR: 18-4)


72720 Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost
Arriola-Villalobos P
Ocular Surface 2017; 15: 723-729 (IGR: 18-4)


72633 Creation of nano eye-drops and effective drug delivery to the interior of the eye
Koseki Y
Scientific reports 2017; 7: 44229 (IGR: 18-4)


72837 Evaluation of Ocular Surface Disease in Asian Patients with Primary Angle Closure
Yaakob A
Open Ophthalmology Journal 2017; 11: 31-39 (IGR: 18-4)


72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Huang Y
AAPS PharmSciTech 2017; 18: 2919-2926 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Gul W
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72916 Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Dixon ER
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 361-365 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Elsohly MA
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72633 Creation of nano eye-drops and effective drug delivery to the interior of the eye
Onodera T
Scientific reports 2017; 7: 44229 (IGR: 18-4)


73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Allemandi DA
European Journal of Pharmaceutical Sciences 2017; 105: 188-194 (IGR: 18-4)


72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Pan X
AAPS PharmSciTech 2017; 18: 2919-2926 (IGR: 18-4)


72720 Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost
Benitez-del-Castillo JM
Ocular Surface 2017; 15: 723-729 (IGR: 18-4)


72837 Evaluation of Ocular Surface Disease in Asian Patients with Primary Angle Closure
Tajudin LA
Open Ophthalmology Journal 2017; 11: 31-39 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Repka MA
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72633 Creation of nano eye-drops and effective drug delivery to the interior of the eye
Oikawa H
Scientific reports 2017; 7: 44229 (IGR: 18-4)


72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Wu CY
AAPS PharmSciTech 2017; 18: 2919-2926 (IGR: 18-4)


73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Manzo RH
European Journal of Pharmaceutical Sciences 2017; 105: 188-194 (IGR: 18-4)


72720 Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost
Garcia-Feijoo J
Ocular Surface 2017; 15: 723-729 (IGR: 18-4)


72633 Creation of nano eye-drops and effective drug delivery to the interior of the eye
Kasai H
Scientific reports 2017; 7: 44229 (IGR: 18-4)


72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Wu C
AAPS PharmSciTech 2017; 18: 2919-2926 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Majumdar S
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Olivera ME
European Journal of Pharmaceutical Sciences 2017; 105: 188-194 (IGR: 18-4)


71551 The physical properties of generic latanoprost ophthalmic solutions are not identical
Kolko M
Acta Ophthalmologica 2017; 95: 370-373 (IGR: 18-3)


71292 Chitosan-g-poly(N-isopropylacrylamide) copolymers as delivery carriers for intracameral pilocarpine administration
Lai JY
European Journal of Pharmaceutics and Biopharmaceutics 2017; 113: 140-148 (IGR: 18-3)


71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Sun J
ACS applied materials & interfaces 2017; 9: 7990-7999 (IGR: 18-3)


71521 Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma
Bouchemi M
Toxicology in Vitro 2017; 41: 21-29 (IGR: 18-3)


71312 Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma
Patil A
AAPS PharmSciTech 2017; 18: 2291-2302 (IGR: 18-3)


71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
Maria DN
Pharmaceutical Research 2017; 34: 809-824 (IGR: 18-3)


71529 Topical medication instillation techniques for glaucoma
Xu L
Cochrane Database of Systematic Reviews 2017; 2: CD010520 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Chandrawati R
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71240 An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration
Zhao L
Journal of Controlled Release 2017; 247: 153-166 (IGR: 18-3)


71499 Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma
Lorenz K
PLoS ONE 2017; 12: e0171636 (IGR: 18-3)


71633 Six month delivery of gdnf from plga/vitamin e biodegradable microspheres after intravitreal injection in rabbits
García-Caballero C
European Journal of Pharmaceutical Sciences 2017; 103: 19-26 (IGR: 18-3)


71548 PLGA Nanoparticles as Subconjunctival Injection for Management of Glaucoma
Salama HA
AAPS PharmSciTech 2017; 18: 2517-2528 (IGR: 18-3)


71478 In vivo Pharmacological Evaluations of Pilocarpine-Loaded Antioxidant-Functionalized Biodegradable Thermogels in Glaucomatous Rabbits
Chou SF
Scientific reports 2017; 7: 42344 (IGR: 18-3)


71526 Enhanced Ocular Efficacy of Topically-delivered Dorzolamide with Nanostructured Mucoadhesive Microparticles
Park CG
International Journal of Pharmaceutics 2017; 522: 66-73 (IGR: 18-3)


71287 Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies
Mandal A
Journal of Controlled Release 2017; 248: 96-116 (IGR: 18-3)


71417 Optimizing novel penetration enhancing hybridized vesicles for augmenting the in-vivo effect of an anti-glaucoma drug
Naguib SS
Drug Delivery 2017; 24: 99-108 (IGR: 18-3)


71551 The physical properties of generic latanoprost ophthalmic solutions are not identical
Koch Jensen P
Acta Ophthalmologica 2017; 95: 370-373 (IGR: 18-3)


71287 Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies
Bisht R
Journal of Controlled Release 2017; 248: 96-116 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Chang JY
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71548 PLGA Nanoparticles as Subconjunctival Injection for Management of Glaucoma
Ghorab M
AAPS PharmSciTech 2017; 18: 2517-2528 (IGR: 18-3)


71240 An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration
Chen G
Journal of Controlled Release 2017; 247: 153-166 (IGR: 18-3)


71633 Six month delivery of gdnf from plga/vitamin e biodegradable microspheres after intravitreal injection in rabbits
Prieto-Calvo E
European Journal of Pharmaceutical Sciences 2017; 103: 19-26 (IGR: 18-3)


71526 Enhanced Ocular Efficacy of Topically-delivered Dorzolamide with Nanostructured Mucoadhesive Microparticles
Kim YK
International Journal of Pharmaceutics 2017; 522: 66-73 (IGR: 18-3)


71312 Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma
Singh S
AAPS PharmSciTech 2017; 18: 2291-2302 (IGR: 18-3)


71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
Abd-Elgawad AH
Pharmaceutical Research 2017; 34: 809-824 (IGR: 18-3)


71478 In vivo Pharmacological Evaluations of Pilocarpine-Loaded Antioxidant-Functionalized Biodegradable Thermogels in Glaucomatous Rabbits
Luo LJ
Scientific reports 2017; 7: 42344 (IGR: 18-3)


71417 Optimizing novel penetration enhancing hybridized vesicles for augmenting the in-vivo effect of an anti-glaucoma drug
Hathout RM
Drug Delivery 2017; 24: 99-108 (IGR: 18-3)


71521 Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma
Roubeix C
Toxicology in Vitro 2017; 41: 21-29 (IGR: 18-3)


71529 Topical medication instillation techniques for glaucoma
Wang X
Cochrane Database of Systematic Reviews 2017; 2: CD010520 (IGR: 18-3)


71292 Chitosan-g-poly(N-isopropylacrylamide) copolymers as delivery carriers for intracameral pilocarpine administration
Luo LJ
European Journal of Pharmaceutics and Biopharmaceutics 2017; 113: 140-148 (IGR: 18-3)


71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Lei Y
ACS applied materials & interfaces 2017; 9: 7990-7999 (IGR: 18-3)


71499 Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma
Wasielica-Poslednik J
PLoS ONE 2017; 12: e0171636 (IGR: 18-3)


71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
Soliman OA
Pharmaceutical Research 2017; 34: 809-824 (IGR: 18-3)


71548 PLGA Nanoparticles as Subconjunctival Injection for Management of Glaucoma
Mahmoud AA
AAPS PharmSciTech 2017; 18: 2517-2528 (IGR: 18-3)


71478 In vivo Pharmacological Evaluations of Pilocarpine-Loaded Antioxidant-Functionalized Biodegradable Thermogels in Glaucomatous Rabbits
Lai JY
Scientific reports 2017; 7: 42344 (IGR: 18-3)


71529 Topical medication instillation techniques for glaucoma
Wu M
Cochrane Database of Systematic Reviews 2017; 2: CD010520 (IGR: 18-3)


71417 Optimizing novel penetration enhancing hybridized vesicles for augmenting the in-vivo effect of an anti-glaucoma drug
Mansour S
Drug Delivery 2017; 24: 99-108 (IGR: 18-3)


71499 Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma
Bell K
PLoS ONE 2017; 12: e0171636 (IGR: 18-3)


71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Dai Z
ACS applied materials & interfaces 2017; 9: 7990-7999 (IGR: 18-3)


71526 Enhanced Ocular Efficacy of Topically-delivered Dorzolamide with Nanostructured Mucoadhesive Microparticles
Kim SN
International Journal of Pharmaceutics 2017; 522: 66-73 (IGR: 18-3)


71287 Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies
Rupenthal ID
Journal of Controlled Release 2017; 248: 96-116 (IGR: 18-3)


71240 An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration
Li J
Journal of Controlled Release 2017; 247: 153-166 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Reina-Torres E
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71633 Six month delivery of gdnf from plga/vitamin e biodegradable microspheres after intravitreal injection in rabbits
Checa-Casalengua P
European Journal of Pharmaceutical Sciences 2017; 103: 19-26 (IGR: 18-3)


71521 Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma
Kessal K
Toxicology in Vitro 2017; 41: 21-29 (IGR: 18-3)


71312 Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma
Opere C
AAPS PharmSciTech 2017; 18: 2291-2302 (IGR: 18-3)


71521 Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma
Riancho L
Toxicology in Vitro 2017; 41: 21-29 (IGR: 18-3)


71526 Enhanced Ocular Efficacy of Topically-delivered Dorzolamide with Nanostructured Mucoadhesive Microparticles
Lee SH
International Journal of Pharmaceutics 2017; 522: 66-73 (IGR: 18-3)


71287 Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies
Mitra AK
Journal of Controlled Release 2017; 248: 96-116 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Jumeaux C
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Liu X
ACS applied materials & interfaces 2017; 9: 7990-7999 (IGR: 18-3)


71633 Six month delivery of gdnf from plga/vitamin e biodegradable microspheres after intravitreal injection in rabbits
García-Martín E
European Journal of Pharmaceutical Sciences 2017; 103: 19-26 (IGR: 18-3)


71240 An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration
Fu Y
Journal of Controlled Release 2017; 247: 153-166 (IGR: 18-3)


71499 Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma
Renieri G
PLoS ONE 2017; 12: e0171636 (IGR: 18-3)


71548 PLGA Nanoparticles as Subconjunctival Injection for Management of Glaucoma
Abdel Hady M
AAPS PharmSciTech 2017; 18: 2517-2528 (IGR: 18-3)


71312 Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma
Dash A
AAPS PharmSciTech 2017; 18: 2291-2302 (IGR: 18-3)


71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
El-Dahan MS
Pharmaceutical Research 2017; 34: 809-824 (IGR: 18-3)


71240 An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration
Mavlyutov TA
Journal of Controlled Release 2017; 247: 153-166 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Sherwood JM
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71499 Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma
Keicher A
PLoS ONE 2017; 12: e0171636 (IGR: 18-3)


71526 Enhanced Ocular Efficacy of Topically-delivered Dorzolamide with Nanostructured Mucoadhesive Microparticles
Huh BK
International Journal of Pharmaceutics 2017; 522: 66-73 (IGR: 18-3)


71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
Jablonski MM
Pharmaceutical Research 2017; 34: 809-824 (IGR: 18-3)


71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Huang T
ACS applied materials & interfaces 2017; 9: 7990-7999 (IGR: 18-3)


71521 Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma
Raveu AL
Toxicology in Vitro 2017; 41: 21-29 (IGR: 18-3)


71633 Six month delivery of gdnf from plga/vitamin e biodegradable microspheres after intravitreal injection in rabbits
Polo-Llorens V
European Journal of Pharmaceutical Sciences 2017; 103: 19-26 (IGR: 18-3)


71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Wu J
ACS applied materials & interfaces 2017; 9: 7990-7999 (IGR: 18-3)


71526 Enhanced Ocular Efficacy of Topically-delivered Dorzolamide with Nanostructured Mucoadhesive Microparticles
Park MA
International Journal of Pharmaceutics 2017; 522: 66-73 (IGR: 18-3)


71633 Six month delivery of gdnf from plga/vitamin e biodegradable microspheres after intravitreal injection in rabbits
García-Feijoo J
European Journal of Pharmaceutical Sciences 2017; 103: 19-26 (IGR: 18-3)


71521 Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma
Soualmia H
Toxicology in Vitro 2017; 41: 21-29 (IGR: 18-3)


71240 An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration
Yao A
Journal of Controlled Release 2017; 247: 153-166 (IGR: 18-3)


71499 Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma
Ruckes C
PLoS ONE 2017; 12: e0171636 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Stamer WD
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71633 Six month delivery of gdnf from plga/vitamin e biodegradable microspheres after intravitreal injection in rabbits
Molina-Martínez IT
European Journal of Pharmaceutical Sciences 2017; 103: 19-26 (IGR: 18-3)


71526 Enhanced Ocular Efficacy of Topically-delivered Dorzolamide with Nanostructured Mucoadhesive Microparticles
Won H
International Journal of Pharmaceutics 2017; 522: 66-73 (IGR: 18-3)


71240 An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration
Nickells RW
Journal of Controlled Release 2017; 247: 153-166 (IGR: 18-3)


71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Xu ZP
ACS applied materials & interfaces 2017; 9: 7990-7999 (IGR: 18-3)


71521 Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma
Baudouin C
Toxicology in Vitro 2017; 41: 21-29 (IGR: 18-3)


71499 Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma
Pfeiffer N
PLoS ONE 2017; 12: e0171636 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Zelikin AN
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71499 Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma
Thieme H
PLoS ONE 2017; 12: e0171636 (IGR: 18-3)


71633 Six month delivery of gdnf from plga/vitamin e biodegradable microspheres after intravitreal injection in rabbits
Bravo-Osuna I
European Journal of Pharmaceutical Sciences 2017; 103: 19-26 (IGR: 18-3)


71521 Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma
Brignole-Baudouin F
Toxicology in Vitro 2017; 41: 21-29 (IGR: 18-3)


71526 Enhanced Ocular Efficacy of Topically-delivered Dorzolamide with Nanostructured Mucoadhesive Microparticles
Park KH
International Journal of Pharmaceutics 2017; 522: 66-73 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Overby DR
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Sun X
ACS applied materials & interfaces 2017; 9: 7990-7999 (IGR: 18-3)


71240 An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration
Gong S
Journal of Controlled Release 2017; 247: 153-166 (IGR: 18-3)


71633 Six month delivery of gdnf from plga/vitamin e biodegradable microspheres after intravitreal injection in rabbits
Herrero-Vanrell R
European Journal of Pharmaceutical Sciences 2017; 103: 19-26 (IGR: 18-3)


71240 An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration
Guo LW
Journal of Controlled Release 2017; 247: 153-166 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Stevens MM
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71526 Enhanced Ocular Efficacy of Topically-delivered Dorzolamide with Nanostructured Mucoadhesive Microparticles
Choy YB
International Journal of Pharmaceutics 2017; 522: 66-73 (IGR: 18-3)


70135 Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys
Ciolino JB
Ophthalmology 2016; 123: 2085-2092 (IGR: 18-2)


70194 Long-Term Subconjunctival Delivery of Brimonidine Tartrate for Glaucoma Treatment Using a Microspheres/Carrier System
Pek YS
Advanced healthcare materials 2016; 5: 2823-2831 (IGR: 18-2)


70467 Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
García-Feijoo J
Clinical Ophthalmology 2016; 10: 2085-2091 (IGR: 18-2)


70011 Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
Wadhwani M
Journal of Current Glaucoma Practice 2016; 10: 49-55 (IGR: 18-2)


69937 Association Between Corneal Endothelial Cell Density and Topical Glaucoma Medication Use in an Eye Bank Donor Population
Kwon JW
Cornea 2016; 0: (IGR: 18-2)


70273 Tear Lipid Layer Thickness Change and Topical Anti-Glaucoma Medication Use
Lee SY
Optometry and Vision Science 2016; 93: 1210-1217 (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Lewis RA
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


70097 Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems
Bagli E
In vivo (Athens, Greece) 2016; 30: 535-547 (IGR: 18-2)


70355 Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper
Ianchulev T
Therapeutic delivery 2016; 7: 751-760 (IGR: 18-2)


69991 Novel Polymeric Nanoparticles Intended for Ophthalmic Administration of Acetazolamide
Quinteros DA
Journal of Pharmaceutical Sciences 2016; 105: 3183-3190 (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Al-Jumaian N
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection
Lavik E
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649 (IGR: 18-2)


70278 Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
Pillunat LE
Clinical Ophthalmology 2016; 10: 1759-1765 (IGR: 18-2)


70283 Ocular Drug Delivery through pHEMA-Hydrogel Contact Lenses Co-Loaded with Lipophilic Vitamins
Lee D
Scientific reports 2016; 6: 34194 (IGR: 18-2)


70100 Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study
Denis P
Journal Franšais d'Ophtalmologie 2016; 39: 622-630 (IGR: 18-2)


70071 Squeeze Me if You Can: Variability in Force Requirements to Extract a Drop From Common Glaucoma Bottles
Moore DB
Journal of Glaucoma 2016; 25: 780-784 (IGR: 18-2)


70532 Nanoparticle Modified Drug Loaded Biodegradable Polymeric Contact Lenses For Sustainable Ocular Drug Delivery
Dhesingh RS
Current Drug Delivery 2016; 0: (IGR: 18-2)


70581 Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent
Mlčáková E
?eska a Slovenska Oftalmologie 2016; 72: 120-127 (IGR: 18-2)


70392 Sustained drug delivery for glaucoma: current data and future trends
Aref AA
Current Opinions in Ophthalmology 2017; 28: 169-174 (IGR: 18-2)


70269 Extended wear therapeutic contact lens fabricated from timolol imprinted carboxymethyl chitosan-g-hydroxy ethyl methacrylate-g-poly acrylamide as a onetime medication for glaucoma
Anirudhan TS
European Journal of Pharmaceutics and Biopharmaceutics 2016; 109: 61-71 (IGR: 18-2)


70827 Aids for Eye Drop Administration
Davies I
Survey of Ophthalmology 2016; 0: (IGR: 18-2)


70780 A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: In vitro, in vivo and stability studies
Rathod LV
Materials science & engineering. C, Materials for biological applications 2017; 71: 529-540 (IGR: 18-2)


70243 Drug-Loaded Nanoparticles Embedded in a Biomembrane Provide a Dual-Release Mechanism for Drug Delivery to the Eye
Sharma M
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 565-573 (IGR: 18-2)


70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Konstas AG
Advances in Therapy 2017; 34: 221-235 (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Christie WC
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


70581 Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent
Mlčák P
?eska a Slovenska Oftalmologie 2016; 72: 120-127 (IGR: 18-2)


70283 Ocular Drug Delivery through pHEMA-Hydrogel Contact Lenses Co-Loaded with Lipophilic Vitamins
Cho S
Scientific reports 2016; 6: 34194 (IGR: 18-2)


70100 Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study

Journal Franšais d'Ophtalmologie 2016; 39: 622-630 (IGR: 18-2)


70780 A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: In vitro, in vivo and stability studies
Kapadia R
Materials science & engineering. C, Materials for biological applications 2017; 71: 529-540 (IGR: 18-2)


70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection
Kuehn MH
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649 (IGR: 18-2)


70532 Nanoparticle Modified Drug Loaded Biodegradable Polymeric Contact Lenses For Sustainable Ocular Drug Delivery
Prakash M
Current Drug Delivery 2016; 0: (IGR: 18-2)


70269 Extended wear therapeutic contact lens fabricated from timolol imprinted carboxymethyl chitosan-g-hydroxy ethyl methacrylate-g-poly acrylamide as a onetime medication for glaucoma
Nair AS
European Journal of Pharmaceutics and Biopharmaceutics 2016; 109: 61-71 (IGR: 18-2)


70827 Aids for Eye Drop Administration
Williams AM
Survey of Ophthalmology 2016; 0: (IGR: 18-2)


70355 Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper
Chayet A
Therapeutic delivery 2016; 7: 751-760 (IGR: 18-2)


70135 Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys
Ross AE
Ophthalmology 2016; 123: 2085-2092 (IGR: 18-2)


70243 Drug-Loaded Nanoparticles Embedded in a Biomembrane Provide a Dual-Release Mechanism for Drug Delivery to the Eye
Bhowmick R
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 565-573 (IGR: 18-2)


70273 Tear Lipid Layer Thickness Change and Topical Anti-Glaucoma Medication Use
Lee H
Optometry and Vision Science 2016; 93: 1210-1217 (IGR: 18-2)


70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Boboridis KG
Advances in Therapy 2017; 34: 221-235 (IGR: 18-2)


70194 Long-Term Subconjunctival Delivery of Brimonidine Tartrate for Glaucoma Treatment Using a Microspheres/Carrier System
Wu H
Advanced healthcare materials 2016; 5: 2823-2831 (IGR: 18-2)


69991 Novel Polymeric Nanoparticles Intended for Ophthalmic Administration of Acetazolamide
Ferreira LM
Journal of Pharmaceutical Sciences 2016; 105: 3183-3190 (IGR: 18-2)


70011 Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
Mishra SK
Journal of Current Glaucoma Practice 2016; 10: 49-55 (IGR: 18-2)


70071 Squeeze Me if You Can: Variability in Force Requirements to Extract a Drop From Common Glaucoma Bottles
Hammer JD
Journal of Glaucoma 2016; 25: 780-784 (IGR: 18-2)


70097 Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems
Goussia A
In vivo (Athens, Greece) 2016; 30: 535-547 (IGR: 18-2)


69937 Association Between Corneal Endothelial Cell Density and Topical Glaucoma Medication Use in an Eye Bank Donor Population
Rand GM
Cornea 2016; 0: (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Malik R
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70467 Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
Muñoz-Negrete FJ
Clinical Ophthalmology 2016; 10: 2085-2091 (IGR: 18-2)


70278 Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
Eschstruth P
Clinical Ophthalmology 2016; 10: 1759-1765 (IGR: 18-2)


69991 Novel Polymeric Nanoparticles Intended for Ophthalmic Administration of Acetazolamide
Schaffazick SR
Journal of Pharmaceutical Sciences 2016; 105: 3183-3190 (IGR: 18-2)


70269 Extended wear therapeutic contact lens fabricated from timolol imprinted carboxymethyl chitosan-g-hydroxy ethyl methacrylate-g-poly acrylamide as a onetime medication for glaucoma
Parvathy J
European Journal of Pharmaceutics and Biopharmaceutics 2016; 109: 61-71 (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Day DG
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


70135 Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys
Tulsan R
Ophthalmology 2016; 123: 2085-2092 (IGR: 18-2)


70243 Drug-Loaded Nanoparticles Embedded in a Biomembrane Provide a Dual-Release Mechanism for Drug Delivery to the Eye
Gappa-Fahlenkamp H
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 565-573 (IGR: 18-2)


70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Kapis P
Advances in Therapy 2017; 34: 221-235 (IGR: 18-2)


70194 Long-Term Subconjunctival Delivery of Brimonidine Tartrate for Glaucoma Treatment Using a Microspheres/Carrier System
Mohamed ST
Advanced healthcare materials 2016; 5: 2823-2831 (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Khandekar R
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70011 Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
Angmo D
Journal of Current Glaucoma Practice 2016; 10: 49-55 (IGR: 18-2)


70467 Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
Hubatsch DA
Clinical Ophthalmology 2016; 10: 2085-2091 (IGR: 18-2)


70097 Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems
Moschos MM
In vivo (Athens, Greece) 2016; 30: 535-547 (IGR: 18-2)


69937 Association Between Corneal Endothelial Cell Density and Topical Glaucoma Medication Use in an Eye Bank Donor Population
Cho KJ
Cornea 2016; 0: (IGR: 18-2)


70780 A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: In vitro, in vivo and stability studies
Sawant KK
Materials science & engineering. C, Materials for biological applications 2017; 71: 529-540 (IGR: 18-2)


70273 Tear Lipid Layer Thickness Change and Topical Anti-Glaucoma Medication Use
Bae HW
Optometry and Vision Science 2016; 93: 1210-1217 (IGR: 18-2)


70581 Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent
Karhanová M
?eska a Slovenska Oftalmologie 2016; 72: 120-127 (IGR: 18-2)


70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection
Shoffstall AJ
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649 (IGR: 18-2)


70283 Ocular Drug Delivery through pHEMA-Hydrogel Contact Lenses Co-Loaded with Lipophilic Vitamins
Park HS
Scientific reports 2016; 6: 34194 (IGR: 18-2)


70355 Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper
Kahook M
Therapeutic delivery 2016; 7: 751-760 (IGR: 18-2)


70827 Aids for Eye Drop Administration
Muir KW
Survey of Ophthalmology 2016; 0: (IGR: 18-2)


70071 Squeeze Me if You Can: Variability in Force Requirements to Extract a Drop From Common Glaucoma Bottles
Akhtari R
Journal of Glaucoma 2016; 25: 780-784 (IGR: 18-2)


70278 Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
Häsemeyer S
Clinical Ophthalmology 2016; 10: 1759-1765 (IGR: 18-2)


69937 Association Between Corneal Endothelial Cell Density and Topical Glaucoma Medication Use in an Eye Bank Donor Population
Gore PK
Cornea 2016; 0: (IGR: 18-2)


70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Marinopoulos K
Advances in Therapy 2017; 34: 221-235 (IGR: 18-2)


70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection
Atkins K
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649 (IGR: 18-2)


70278 Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
Thelen U
Clinical Ophthalmology 2016; 10: 1759-1765 (IGR: 18-2)


69991 Novel Polymeric Nanoparticles Intended for Ophthalmic Administration of Acetazolamide
Palma SD
Journal of Pharmaceutical Sciences 2016; 105: 3183-3190 (IGR: 18-2)


70071 Squeeze Me if You Can: Variability in Force Requirements to Extract a Drop From Common Glaucoma Bottles
Beck J
Journal of Glaucoma 2016; 25: 780-784 (IGR: 18-2)


70467 Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
Rossi GC
Clinical Ophthalmology 2016; 10: 2085-2091 (IGR: 18-2)


70283 Ocular Drug Delivery through pHEMA-Hydrogel Contact Lenses Co-Loaded with Lipophilic Vitamins
Kwon I
Scientific reports 2016; 6: 34194 (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Al-Humaidan A
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70355 Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper
Packer M
Therapeutic delivery 2016; 7: 751-760 (IGR: 18-2)


70194 Long-Term Subconjunctival Delivery of Brimonidine Tartrate for Glaucoma Treatment Using a Microspheres/Carrier System
Ying JY
Advanced healthcare materials 2016; 5: 2823-2831 (IGR: 18-2)


70011 Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
Velpandian T
Journal of Current Glaucoma Practice 2016; 10: 49-55 (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Craven ER
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


70581 Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent
Langová K
?eska a Slovenska Oftalmologie 2016; 72: 120-127 (IGR: 18-2)


70135 Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys
Watts AC
Ophthalmology 2016; 123: 2085-2092 (IGR: 18-2)


70273 Tear Lipid Layer Thickness Change and Topical Anti-Glaucoma Medication Use
Kim TI
Optometry and Vision Science 2016; 93: 1210-1217 (IGR: 18-2)


70097 Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems
Agnantis N
In vivo (Athens, Greece) 2016; 30: 535-547 (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Al-Madany R
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70071 Squeeze Me if You Can: Variability in Force Requirements to Extract a Drop From Common Glaucoma Bottles
Sanders S
Journal of Glaucoma 2016; 25: 780-784 (IGR: 18-2)


70355 Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper
Pasquale L
Therapeutic delivery 2016; 7: 751-760 (IGR: 18-2)


70278 Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
Foja C
Clinical Ophthalmology 2016; 10: 1759-1765 (IGR: 18-2)


70581 Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent
Marešová K
?eska a Slovenska Oftalmologie 2016; 72: 120-127 (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Walters T
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


69991 Novel Polymeric Nanoparticles Intended for Ophthalmic Administration of Acetazolamide
Allemandi DA
Journal of Pharmaceutical Sciences 2016; 105: 3183-3190 (IGR: 18-2)


70011 Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
Sihota R
Journal of Current Glaucoma Practice 2016; 10: 49-55 (IGR: 18-2)


70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection
Dumitrescu AV
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649 (IGR: 18-2)


70273 Tear Lipid Layer Thickness Change and Topical Anti-Glaucoma Medication Use
Kim CY
Optometry and Vision Science 2016; 93: 1210-1217 (IGR: 18-2)


70097 Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems
Kitsos G
In vivo (Athens, Greece) 2016; 30: 535-547 (IGR: 18-2)


69937 Association Between Corneal Endothelial Cell Density and Topical Glaucoma Medication Use in an Eye Bank Donor Population
McCartney MD
Cornea 2016; 0: (IGR: 18-2)


70135 Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys
Wang RF
Ophthalmology 2016; 123: 2085-2092 (IGR: 18-2)


70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Voudouragkaki IC
Advances in Therapy 2017; 34: 221-235 (IGR: 18-2)


70355 Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper
Weinreb RN
Therapeutic delivery 2016; 7: 751-760 (IGR: 18-2)


69937 Association Between Corneal Endothelial Cell Density and Topical Glaucoma Medication Use in an Eye Bank Donor Population
Chuck RS
Cornea 2016; 0: (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Bejanian M
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


70071 Squeeze Me if You Can: Variability in Force Requirements to Extract a Drop From Common Glaucoma Bottles
Kryscio RJ
Journal of Glaucoma 2016; 25: 780-784 (IGR: 18-2)


70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Panayiotou D
Advances in Therapy 2017; 34: 221-235 (IGR: 18-2)


70135 Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys
Zurakowski D
Ophthalmology 2016; 123: 2085-2092 (IGR: 18-2)


70278 Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
Leaback R
Clinical Ophthalmology 2016; 10: 1759-1765 (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Al-Qahtani R
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70011 Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
Kotnala A
Journal of Current Glaucoma Practice 2016; 10: 49-55 (IGR: 18-2)


69991 Novel Polymeric Nanoparticles Intended for Ophthalmic Administration of Acetazolamide
Cruz L
Journal of Pharmaceutical Sciences 2016; 105: 3183-3190 (IGR: 18-2)


70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection
Kwon YH
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649 (IGR: 18-2)


70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Mikropoulos DG
Advances in Therapy 2017; 34: 221-235 (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Altowairqi A
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70135 Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys
Serle JB
Ophthalmology 2016; 123: 2085-2092 (IGR: 18-2)


70278 Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
Pfennigsdorf S
Clinical Ophthalmology 2016; 10: 1759-1765 (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Lee SS
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


70011 Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
Bhartiya S
Journal of Current Glaucoma Practice 2016; 10: 49-55 (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Goodkin ML
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


70011 Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
Dada T
Journal of Current Glaucoma Practice 2016; 10: 49-55 (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Al-Theeb A
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70135 Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys
Kohane DS
Ophthalmology 2016; 123: 2085-2092 (IGR: 18-2)


70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Pagkalidou E
Advances in Therapy 2017; 34: 221-235 (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Zaman B
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Haidich AB
Advances in Therapy 2017; 34: 221-235 (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Zhang J
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Katsanos A
Advances in Therapy 2017; 34: 221-235 (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Al-Djasim L
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Whitcup SM
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Craven ER
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Robinson MR
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


70665 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monothe
Quaranta L
Advances in Therapy 2017; 34: 221-235 (IGR: 18-2)


70794 Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia
Edward DP
Middle East African Journal of Ophthalmology 2016; 23: 296-301 (IGR: 18-2)


70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial

American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)


69203 Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations
Angmo D
International Ophthalmology 2017; 37: 423-428 (IGR: 18-1)


69173 Ultrasound-mediated ocular delivery of therapeutic agents: a review
Lafond M
Expert Opinion on Drug Delivery 2016; 0: 1-12 (IGR: 18-1)


69304 Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)
Aguayo Bonniard A
Expert Opinion on Drug Metabolism and Toxicology 2016; 0: 1-11 (IGR: 18-1)


69172 Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension
Aptel F
Current Medical Research and Opinion 2016; 32: 1457-1463 (IGR: 18-1)


68930 Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy
Cho IS
Acta biomaterialia 2016; 39: 124-132 (IGR: 18-1)


69207 Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits
Fu J
Molecular pharmaceutics 2016; 13: 2987-2995 (IGR: 18-1)


69143 Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial
Chabi A
International Journal of Clinical Pract 2016; 70: 577-586 (IGR: 18-1)


68883 Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma
Konstas AG
Expert Opinion in Pharmacotherapy 2016; 17: 1271-1283 (IGR: 18-1)


69107 Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
Walimbe T
Clinical Ophthalmology 2016; 10: 821-827 (IGR: 18-1)


69193 Assessment of alkoxylphenacyl-based polycarbonates as a potential platform for controlled delivery of a model anti-glaucoma drug
Manickavasagam D
European Journal of Pharmaceutics and Biopharmaceutics 2016; 107: 56-66 (IGR: 18-1)


69181 Investigation of Diffusion Characteristics through Microfluidic Channels for Passive Drug Delivery Applications
Goudie MJ
Journal of Drug Delivery 2016; 2016: 7913616 (IGR: 18-1)


69485 Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma
Kim J
Investigative Ophthalmology and Visual Science 2016; 57: 4341-4346 (IGR: 18-1)


68922 Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study
Brandt JD
Ophthalmology 2016; 123: 1685-1694 (IGR: 18-1)


69273 Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells
Hakkarainen JJ
International Journal of Pharmaceutics 2016; 511: 73-78 (IGR: 18-1)


69483 An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle
Davies IJ
Clinical Ophthalmology 2016; 10: 1411-1417 (IGR: 18-1)


69141 Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa
Trzeciecka A
European Journal of Pharmacology 2016; 788: 12-20 (IGR: 18-1)


68870 Delivery of steroids into the eye for the treatment of macular edema
Hadayer A
Expert Opinion on Drug Delivery 2016; 13: 1083-1091 (IGR: 18-1)


69172 Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension
Choudhry R
Current Medical Research and Opinion 2016; 32: 1457-1463 (IGR: 18-1)


69181 Investigation of Diffusion Characteristics through Microfluidic Channels for Passive Drug Delivery Applications
Ghuman AP
Journal of Drug Delivery 2016; 2016: 7913616 (IGR: 18-1)


69207 Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits
Sun F
Molecular pharmaceutics 2016; 13: 2987-2995 (IGR: 18-1)


68883 Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma
Holló G
Expert Opinion in Pharmacotherapy 2016; 17: 1271-1283 (IGR: 18-1)


68922 Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study
Sall K
Ophthalmology 2016; 123: 1685-1694 (IGR: 18-1)


69273 Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells
Reinisalo M
International Journal of Pharmaceutics 2016; 511: 73-78 (IGR: 18-1)


69485 Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma
Kudisch M
Investigative Ophthalmology and Visual Science 2016; 57: 4341-4346 (IGR: 18-1)


69483 An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle
Brown NH
Clinical Ophthalmology 2016; 10: 1411-1417 (IGR: 18-1)


69107 Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
Chelerkar V
Clinical Ophthalmology 2016; 10: 821-827 (IGR: 18-1)


69141 Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa
Paterno JJ
European Journal of Pharmacology 2016; 788: 12-20 (IGR: 18-1)


69143 Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial
Baranak C
International Journal of Clinical Pract 2016; 70: 577-586 (IGR: 18-1)


68870 Delivery of steroids into the eye for the treatment of macular edema
Schaal S
Expert Opinion on Drug Delivery 2016; 13: 1083-1091 (IGR: 18-1)


69173 Ultrasound-mediated ocular delivery of therapeutic agents: a review
Aptel F
Expert Opinion on Drug Delivery 2016; 0: 1-12 (IGR: 18-1)


69203 Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations
Wadhwani M
International Ophthalmology 2017; 37: 423-428 (IGR: 18-1)


68930 Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy
Park CG
Acta biomaterialia 2016; 39: 124-132 (IGR: 18-1)


69304 Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)
Yeung JY
Expert Opinion on Drug Metabolism and Toxicology 2016; 0: 1-11 (IGR: 18-1)


69193 Assessment of alkoxylphenacyl-based polycarbonates as a potential platform for controlled delivery of a model anti-glaucoma drug
Wehrung D
European Journal of Pharmaceutics and Biopharmaceutics 2016; 107: 56-66 (IGR: 18-1)


69107 Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
Bhagat P
Clinical Ophthalmology 2016; 10: 821-827 (IGR: 18-1)


69483 An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle
Wen JC
Clinical Ophthalmology 2016; 10: 1411-1417 (IGR: 18-1)


69143 Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial
Lupinacci R
International Journal of Clinical Pract 2016; 70: 577-586 (IGR: 18-1)


69181 Investigation of Diffusion Characteristics through Microfluidic Channels for Passive Drug Delivery Applications
Collins SB
Journal of Drug Delivery 2016; 2016: 7913616 (IGR: 18-1)


69141 Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa
Toropainen E
European Journal of Pharmacology 2016; 788: 12-20 (IGR: 18-1)


69485 Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma
Mudumba S
Investigative Ophthalmology and Visual Science 2016; 57: 4341-4346 (IGR: 18-1)


69172 Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension
Stalmans I
Current Medical Research and Opinion 2016; 32: 1457-1463 (IGR: 18-1)


68922 Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study
DuBiner H
Ophthalmology 2016; 123: 1685-1694 (IGR: 18-1)


69273 Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells
Ragauskas S
International Journal of Pharmaceutics 2016; 511: 73-78 (IGR: 18-1)


69207 Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits
Liu W
Molecular pharmaceutics 2016; 13: 2987-2995 (IGR: 18-1)


68930 Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy
Huh BK
Acta biomaterialia 2016; 39: 124-132 (IGR: 18-1)


69304 Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)
Chan CC
Expert Opinion on Drug Metabolism and Toxicology 2016; 0: 1-11 (IGR: 18-1)


69193 Assessment of alkoxylphenacyl-based polycarbonates as a potential platform for controlled delivery of a model anti-glaucoma drug
Chamsaz EA
European Journal of Pharmaceutics and Biopharmaceutics 2016; 107: 56-66 (IGR: 18-1)


69173 Ultrasound-mediated ocular delivery of therapeutic agents: a review
Mestas JL
Expert Opinion on Drug Delivery 2016; 0: 1-12 (IGR: 18-1)


69203 Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations
Velpandian T
International Ophthalmology 2017; 37: 423-428 (IGR: 18-1)


68930 Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy
Cho MO
Acta biomaterialia 2016; 39: 124-132 (IGR: 18-1)


69273 Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells
Seppänen A
International Journal of Pharmaceutics 2016; 511: 73-78 (IGR: 18-1)


69193 Assessment of alkoxylphenacyl-based polycarbonates as a potential platform for controlled delivery of a model anti-glaucoma drug
Sanders M
European Journal of Pharmaceutics and Biopharmaceutics 2016; 107: 56-66 (IGR: 18-1)


69107 Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
Joshi A
Clinical Ophthalmology 2016; 10: 821-827 (IGR: 18-1)


69483 An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle
Stinnett SS
Clinical Ophthalmology 2016; 10: 1411-1417 (IGR: 18-1)


69173 Ultrasound-mediated ocular delivery of therapeutic agents: a review
Lafon C
Expert Opinion on Drug Delivery 2016; 0: 1-12 (IGR: 18-1)


69304 Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)
Birt CM
Expert Opinion on Drug Metabolism and Toxicology 2016; 0: 1-11 (IGR: 18-1)


69203 Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations
Kotnal A
International Ophthalmology 2017; 37: 423-428 (IGR: 18-1)


69141 Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa
Koskela A
European Journal of Pharmacology 2016; 788: 12-20 (IGR: 18-1)


69485 Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma
Asada H
Investigative Ophthalmology and Visual Science 2016; 57: 4341-4346 (IGR: 18-1)


69181 Investigation of Diffusion Characteristics through Microfluidic Channels for Passive Drug Delivery Applications
Pidaparti RM
Journal of Drug Delivery 2016; 2016: 7913616 (IGR: 18-1)


68922 Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study
Benza R
Ophthalmology 2016; 123: 1685-1694 (IGR: 18-1)


69143 Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial
Herring WJ
International Journal of Clinical Pract 2016; 70: 577-586 (IGR: 18-1)


69207 Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits
Liu Y
Molecular pharmaceutics 2016; 13: 2987-2995 (IGR: 18-1)


68922 Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study
Alster Y
Ophthalmology 2016; 123: 1685-1694 (IGR: 18-1)


69207 Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits
Gedam M
Molecular pharmaceutics 2016; 13: 2987-2995 (IGR: 18-1)


69193 Assessment of alkoxylphenacyl-based polycarbonates as a potential platform for controlled delivery of a model anti-glaucoma drug
Bouhenni R
European Journal of Pharmaceutics and Biopharmaceutics 2016; 107: 56-66 (IGR: 18-1)


69273 Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells
Kaja S
International Journal of Pharmaceutics 2016; 511: 73-78 (IGR: 18-1)


68930 Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy
Khatun Z
Acta biomaterialia 2016; 39: 124-132 (IGR: 18-1)


69141 Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa
Podracka L
European Journal of Pharmacology 2016; 788: 12-20 (IGR: 18-1)


69485 Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma
Aya-Shibuya E
Investigative Ophthalmology and Visual Science 2016; 57: 4341-4346 (IGR: 18-1)


69483 An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle
Kubelick K
Clinical Ophthalmology 2016; 10: 1411-1417 (IGR: 18-1)


69181 Investigation of Diffusion Characteristics through Microfluidic Channels for Passive Drug Delivery Applications
Handa H
Journal of Drug Delivery 2016; 2016: 7913616 (IGR: 18-1)


69203 Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations
Sihota R
International Ophthalmology 2017; 37: 423-428 (IGR: 18-1)


69107 Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
Raut A
Clinical Ophthalmology 2016; 10: 821-827 (IGR: 18-1)


69483 An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle
Patel RP
Clinical Ophthalmology 2016; 10: 1411-1417 (IGR: 18-1)


68922 Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study
Walker G
Ophthalmology 2016; 123: 1685-1694 (IGR: 18-1)


69193 Assessment of alkoxylphenacyl-based polycarbonates as a potential platform for controlled delivery of a model anti-glaucoma drug
Crish SD
European Journal of Pharmaceutics and Biopharmaceutics 2016; 107: 56-66 (IGR: 18-1)


69203 Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations
Dada T
International Ophthalmology 2017; 37: 423-428 (IGR: 18-1)


69273 Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells
Kalesnykas G
International Journal of Pharmaceutics 2016; 511: 73-78 (IGR: 18-1)


69207 Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits
Hu Q
Molecular pharmaceutics 2016; 13: 2987-2995 (IGR: 18-1)


69141 Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa
Korhonen E
European Journal of Pharmacology 2016; 788: 12-20 (IGR: 18-1)


68930 Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy
Li Z
Acta biomaterialia 2016; 39: 124-132 (IGR: 18-1)


69485 Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma
Bhisitkul RB
Investigative Ophthalmology and Visual Science 2016; 57: 4341-4346 (IGR: 18-1)


69141 Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa
Kauppinen A
European Journal of Pharmacology 2016; 788: 12-20 (IGR: 18-1)


69207 Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits
Fridley C
Molecular pharmaceutics 2016; 13: 2987-2995 (IGR: 18-1)


68922 Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study
Semba CP
Ophthalmology 2016; 123: 1685-1694 (IGR: 18-1)


69193 Assessment of alkoxylphenacyl-based polycarbonates as a potential platform for controlled delivery of a model anti-glaucoma drug
Joy A
European Journal of Pharmaceutics and Biopharmaceutics 2016; 107: 56-66 (IGR: 18-1)


68930 Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy
Kang SW
Acta biomaterialia 2016; 39: 124-132 (IGR: 18-1)


69485 Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma
Desai TA
Investigative Ophthalmology and Visual Science 2016; 57: 4341-4346 (IGR: 18-1)


69483 An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle
Benokraitis KL
Clinical Ophthalmology 2016; 10: 1411-1417 (IGR: 18-1)


69141 Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa
Kaarniranta K
European Journal of Pharmacology 2016; 788: 12-20 (IGR: 18-1)


69207 Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits
Quigley HA
Molecular pharmaceutics 2016; 13: 2987-2995 (IGR: 18-1)


69193 Assessment of alkoxylphenacyl-based polycarbonates as a potential platform for controlled delivery of a model anti-glaucoma drug
Oyewumi MO
European Journal of Pharmaceutics and Biopharmaceutics 2016; 107: 56-66 (IGR: 18-1)


68930 Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy
Choy YB
Acta biomaterialia 2016; 39: 124-132 (IGR: 18-1)


69483 An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle
Greene L; Cheek C
Clinical Ophthalmology 2016; 10: 1411-1417 (IGR: 18-1)


68930 Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy
Huh KM
Acta biomaterialia 2016; 39: 124-132 (IGR: 18-1)


69207 Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits
Hanes J
Molecular pharmaceutics 2016; 13: 2987-2995 (IGR: 18-1)


69141 Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa
Smedowski A
European Journal of Pharmacology 2016; 788: 12-20 (IGR: 18-1)


69483 An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle
Muir KW
Clinical Ophthalmology 2016; 10: 1411-1417 (IGR: 18-1)


69207 Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits
Pitha I
Molecular pharmaceutics 2016; 13: 2987-2995 (IGR: 18-1)


67477 Gallic acid grafting effect on delivery performance and antiglaucoma efficacy of antioxidant-functionalized intracameral pilocarpine carriers
Chou SF
Acta biomaterialia 2016; 38: 116-128 (IGR: 17-4)


67226 Medical management of glaucoma: focus on ophthalmologic drug delivery systems of timolol maleate
Sah AK
Artificial cells, nanomedicine, and biotechnology 2016; 0: 1-12 (IGR: 17-4)


67559 Ocular Erythropoietin Penetration after Subconjunctival Administration in Glaucomatous Rats
Resende AP
Ophthalmic Research 2016; 56: 104-110 (IGR: 17-4)


66627 Effect of preserved and preservative-free timolol eye drops on tear film stability in healthy Africans
Ilechie A
Nigerian medical journal : journal of the Nigeria Medical Association 2016; 57: 104-109 (IGR: 17-4)


67185 Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose-response phenomenon
Shen J
Clinical Ophthalmology 2016; 10: 373-383 (IGR: 17-4)


67134 Review on the Eyedrop Self-Instillation Techniques and Factors Affecting These Techniques in Glaucoma Patients
Kayikcioglu O
Scientifica 2016; 2016: 9183272 (IGR: 17-4)


67588 Meibomian Gland Dysfunction in Patients Receiving Long-Term Glaucoma Medications
Uzunosmanoglu E
Cornea 2016; 35: 1112-1116 (IGR: 17-4)


67443 Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
Perera SA
Clinical Ophthalmology 2016; 10: 757-764 (IGR: 17-4)


67463 In vitro mitomycin C absorption and delivery with different sponge materials used in filtering surgery
Urbaneja D
Clinical Ophthalmology 2016; 10: 665-669 (IGR: 17-4)


67209 Determination of phosphate concentration in glaucoma eye drops commercially available in Spain
Martínez-Soroa I
Archivos de la Sociedad Espa˝ola de Oftalmologia 2016; 91: 363-371 (IGR: 17-4)


66820 In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery
Maulvi FA
Journal of Controlled Release 2016; 226: 47-56 (IGR: 17-4)


67336 Development of a mechanism and an accurate and simple mathematical model for the description of drug release: Application to a relevant example of acetazolamide-controlled release from a bio-inspired elastin-based hydrogel
Fernández-Colino A
Materials science & engineering. C, Materials for biological applications 2016; 61: 286-292 (IGR: 17-4)


67429 Development of a novel CsA-PLGA drug delivery system based on a glaucoma drainage device for the prevention of postoperative fibrosis
Dai Z
Materials science & engineering. C, Materials for biological applications 2016; 66: 206-214 (IGR: 17-4)


67153 Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment
Cheng YH
Carbohydrate polymers 2016; 144: 390-399 (IGR: 17-4)


66718 Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma
Chiang B
Journal of Controlled Release 2016; 228: 48-57 (IGR: 17-4)


67607 Deformability properties of timolol-loaded transfersomes based on the extrusion mechanism. Statistical optimization of the process
González-Rodríguez ML
Drug Development and Industrial Pharmacy 2016; 0: 1-12 (IGR: 17-4)


66745 Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial
Stalmans I
Graefe's Archive for Clinical and Experimental Ophthalmology 2016; 254: 1151-1158 (IGR: 17-4)


67185 Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose-response phenomenon
Bejanian M
Clinical Ophthalmology 2016; 10: 373-383 (IGR: 17-4)


67429 Development of a novel CsA-PLGA drug delivery system based on a glaucoma drainage device for the prevention of postoperative fibrosis
Yu X
Materials science & engineering. C, Materials for biological applications 2016; 66: 206-214 (IGR: 17-4)


66718 Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma
Kim YC
Journal of Controlled Release 2016; 228: 48-57 (IGR: 17-4)


67607 Deformability properties of timolol-loaded transfersomes based on the extrusion mechanism. Statistical optimization of the process
Arroyo CM
Drug Development and Industrial Pharmacy 2016; 0: 1-12 (IGR: 17-4)


67588 Meibomian Gland Dysfunction in Patients Receiving Long-Term Glaucoma Medications
Mocan MC
Cornea 2016; 35: 1112-1116 (IGR: 17-4)


67443 Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
Ting DS
Clinical Ophthalmology 2016; 10: 757-764 (IGR: 17-4)


67153 Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment
Tsai TH
Carbohydrate polymers 2016; 144: 390-399 (IGR: 17-4)


66745 Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial
Oddone F
Graefe's Archive for Clinical and Experimental Ophthalmology 2016; 254: 1151-1158 (IGR: 17-4)


67209 Determination of phosphate concentration in glaucoma eye drops commercially available in Spain
de Frutos-Lezaun M
Archivos de la Sociedad Espa˝ola de Oftalmologia 2016; 91: 363-371 (IGR: 17-4)


67477 Gallic acid grafting effect on delivery performance and antiglaucoma efficacy of antioxidant-functionalized intracameral pilocarpine carriers
Luo LJ
Acta biomaterialia 2016; 38: 116-128 (IGR: 17-4)


67226 Medical management of glaucoma: focus on ophthalmologic drug delivery systems of timolol maleate
Suresh PK
Artificial cells, nanomedicine, and biotechnology 2016; 0: 1-12 (IGR: 17-4)


66627 Effect of preserved and preservative-free timolol eye drops on tear film stability in healthy Africans
Abokyi S
Nigerian medical journal : journal of the Nigeria Medical Association 2016; 57: 104-109 (IGR: 17-4)


67134 Review on the Eyedrop Self-Instillation Techniques and Factors Affecting These Techniques in Glaucoma Patients
Bilgin S
Scientifica 2016; 2016: 9183272 (IGR: 17-4)


67463 In vitro mitomycin C absorption and delivery with different sponge materials used in filtering surgery
Morilla-Grasa A
Clinical Ophthalmology 2016; 10: 665-669 (IGR: 17-4)


66820 In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery
Lakdawala DH
Journal of Controlled Release 2016; 226: 47-56 (IGR: 17-4)


67559 Ocular Erythropoietin Penetration after Subconjunctival Administration in Glaucomatous Rats
São Braz B
Ophthalmic Research 2016; 56: 104-110 (IGR: 17-4)


67336 Development of a mechanism and an accurate and simple mathematical model for the description of drug release: Application to a relevant example of acetazolamide-controlled release from a bio-inspired elastin-based hydrogel
Bermudez JM
Materials science & engineering. C, Materials for biological applications 2016; 61: 286-292 (IGR: 17-4)


67134 Review on the Eyedrop Self-Instillation Techniques and Factors Affecting These Techniques in Glaucoma Patients
Uyar M
Scientifica 2016; 2016: 9183272 (IGR: 17-4)


66745 Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial
Cordeiro MF
Graefe's Archive for Clinical and Experimental Ophthalmology 2016; 254: 1151-1158 (IGR: 17-4)


67336 Development of a mechanism and an accurate and simple mathematical model for the description of drug release: Application to a relevant example of acetazolamide-controlled release from a bio-inspired elastin-based hydrogel
Arias FJ
Materials science & engineering. C, Materials for biological applications 2016; 61: 286-292 (IGR: 17-4)


66820 In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery
Shaikh AA
Journal of Controlled Release 2016; 226: 47-56 (IGR: 17-4)


67443 Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
Nongpiur ME
Clinical Ophthalmology 2016; 10: 757-764 (IGR: 17-4)


67477 Gallic acid grafting effect on delivery performance and antiglaucoma efficacy of antioxidant-functionalized intracameral pilocarpine carriers
Lai JY
Acta biomaterialia 2016; 38: 116-128 (IGR: 17-4)


67209 Determination of phosphate concentration in glaucoma eye drops commercially available in Spain
Ostra Beldarrain M
Archivos de la Sociedad Espa˝ola de Oftalmologia 2016; 91: 363-371 (IGR: 17-4)


67559 Ocular Erythropoietin Penetration after Subconjunctival Administration in Glaucomatous Rats
Delgado E
Ophthalmic Research 2016; 56: 104-110 (IGR: 17-4)


66627 Effect of preserved and preservative-free timolol eye drops on tear film stability in healthy Africans
Boateng G
Nigerian medical journal : journal of the Nigeria Medical Association 2016; 57: 104-109 (IGR: 17-4)


66718 Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma
Doty AC
Journal of Controlled Release 2016; 228: 48-57 (IGR: 17-4)


67463 In vitro mitomycin C absorption and delivery with different sponge materials used in filtering surgery
Jimenez E
Clinical Ophthalmology 2016; 10: 665-669 (IGR: 17-4)


67588 Meibomian Gland Dysfunction in Patients Receiving Long-Term Glaucoma Medications
Kocabeyoglu S
Cornea 2016; 35: 1112-1116 (IGR: 17-4)


67153 Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment
Jhan YY
Carbohydrate polymers 2016; 144: 390-399 (IGR: 17-4)


67429 Development of a novel CsA-PLGA drug delivery system based on a glaucoma drainage device for the prevention of postoperative fibrosis
Hong J
Materials science & engineering. C, Materials for biological applications 2016; 66: 206-214 (IGR: 17-4)


67607 Deformability properties of timolol-loaded transfersomes based on the extrusion mechanism. Statistical optimization of the process
Cózar-Bernal MJ
Drug Development and Industrial Pharmacy 2016; 0: 1-12 (IGR: 17-4)


67588 Meibomian Gland Dysfunction in Patients Receiving Long-Term Glaucoma Medications
Karakaya J
Cornea 2016; 35: 1112-1116 (IGR: 17-4)


67443 Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
Chew PT
Clinical Ophthalmology 2016; 10: 757-764 (IGR: 17-4)


67607 Deformability properties of timolol-loaded transfersomes based on the extrusion mechanism. Statistical optimization of the process
González-R PL
Drug Development and Industrial Pharmacy 2016; 0: 1-12 (IGR: 17-4)


67463 In vitro mitomycin C absorption and delivery with different sponge materials used in filtering surgery
Montemayor J
Clinical Ophthalmology 2016; 10: 665-669 (IGR: 17-4)


67209 Determination of phosphate concentration in glaucoma eye drops commercially available in Spain
Egía Zurutuza A
Archivos de la Sociedad Espa˝ola de Oftalmologia 2016; 91: 363-371 (IGR: 17-4)


67153 Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment
Chiu AW
Carbohydrate polymers 2016; 144: 390-399 (IGR: 17-4)


66820 In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery
Desai AR
Journal of Controlled Release 2016; 226: 47-56 (IGR: 17-4)


67336 Development of a mechanism and an accurate and simple mathematical model for the description of drug release: Application to a relevant example of acetazolamide-controlled release from a bio-inspired elastin-based hydrogel
Quinteros D
Materials science & engineering. C, Materials for biological applications 2016; 61: 286-292 (IGR: 17-4)


66718 Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma
Grossniklaus HE
Journal of Controlled Release 2016; 228: 48-57 (IGR: 17-4)


67429 Development of a novel CsA-PLGA drug delivery system based on a glaucoma drainage device for the prevention of postoperative fibrosis
Liu X
Materials science & engineering. C, Materials for biological applications 2016; 66: 206-214 (IGR: 17-4)


66745 Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial
Hommer A
Graefe's Archive for Clinical and Experimental Ophthalmology 2016; 254: 1151-1158 (IGR: 17-4)


66627 Effect of preserved and preservative-free timolol eye drops on tear film stability in healthy Africans
Koffuor GA
Nigerian medical journal : journal of the Nigeria Medical Association 2016; 57: 104-109 (IGR: 17-4)


67429 Development of a novel CsA-PLGA drug delivery system based on a glaucoma drainage device for the prevention of postoperative fibrosis
Sun J
Materials science & engineering. C, Materials for biological applications 2016; 66: 206-214 (IGR: 17-4)


66718 Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma
Schwendeman SP
Journal of Controlled Release 2016; 228: 48-57 (IGR: 17-4)


66745 Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial
Montesano G
Graefe's Archive for Clinical and Experimental Ophthalmology 2016; 254: 1151-1158 (IGR: 17-4)


67336 Development of a mechanism and an accurate and simple mathematical model for the description of drug release: Application to a relevant example of acetazolamide-controlled release from a bio-inspired elastin-based hydrogel
Gonzo E
Materials science & engineering. C, Materials for biological applications 2016; 61: 286-292 (IGR: 17-4)


67463 In vitro mitomycin C absorption and delivery with different sponge materials used in filtering surgery
Marcobal N
Clinical Ophthalmology 2016; 10: 665-669 (IGR: 17-4)


67607 Deformability properties of timolol-loaded transfersomes based on the extrusion mechanism. Statistical optimization of the process
León JM
Drug Development and Industrial Pharmacy 2016; 0: 1-12 (IGR: 17-4)


67153 Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment
Tsai KL
Carbohydrate polymers 2016; 144: 390-399 (IGR: 17-4)


67588 Meibomian Gland Dysfunction in Patients Receiving Long-Term Glaucoma Medications
Irkec M
Cornea 2016; 35: 1112-1116 (IGR: 17-4)


66820 In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery
Choksi HH
Journal of Controlled Release 2016; 226: 47-56 (IGR: 17-4)


67443 Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
Aquino MC
Clinical Ophthalmology 2016; 10: 757-764 (IGR: 17-4)


67209 Determination of phosphate concentration in glaucoma eye drops commercially available in Spain
Irastorza Larburu MB
Archivos de la Sociedad Espa˝ola de Oftalmologia 2016; 91: 363-371 (IGR: 17-4)


66745 Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial
Ribeiro L
Graefe's Archive for Clinical and Experimental Ophthalmology 2016; 254: 1151-1158 (IGR: 17-4)


67153 Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment
Chien CS
Carbohydrate polymers 2016; 144: 390-399 (IGR: 17-4)


66718 Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma
Prausnitz MR
Journal of Controlled Release 2016; 228: 48-57 (IGR: 17-4)


67429 Development of a novel CsA-PLGA drug delivery system based on a glaucoma drainage device for the prevention of postoperative fibrosis
Sun X
Materials science & engineering. C, Materials for biological applications 2016; 66: 206-214 (IGR: 17-4)


67463 In vitro mitomycin C absorption and delivery with different sponge materials used in filtering surgery
Aragay C
Clinical Ophthalmology 2016; 10: 665-669 (IGR: 17-4)


67607 Deformability properties of timolol-loaded transfersomes based on the extrusion mechanism. Statistical optimization of the process
Calle M
Drug Development and Industrial Pharmacy 2016; 0: 1-12 (IGR: 17-4)


67443 Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
Sng CC
Clinical Ophthalmology 2016; 10: 757-764 (IGR: 17-4)


67209 Determination of phosphate concentration in glaucoma eye drops commercially available in Spain
Bachiller Cacho MP
Archivos de la Sociedad Espa˝ola de Oftalmologia 2016; 91: 363-371 (IGR: 17-4)


66820 In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery
Vaidya RJ
Journal of Controlled Release 2016; 226: 47-56 (IGR: 17-4)


67463 In vitro mitomycin C absorption and delivery with different sponge materials used in filtering surgery
Gurdiel C
Clinical Ophthalmology 2016; 10: 665-669 (IGR: 17-4)


67607 Deformability properties of timolol-loaded transfersomes based on the extrusion mechanism. Statistical optimization of the process
Canca D
Drug Development and Industrial Pharmacy 2016; 0: 1-12 (IGR: 17-4)


66745 Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial
Sunaric-Mégevand G
Graefe's Archive for Clinical and Experimental Ophthalmology 2016; 254: 1151-1158 (IGR: 17-4)


66820 In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery
Ranch KM
Journal of Controlled Release 2016; 226: 47-56 (IGR: 17-4)


67443 Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
Ho SW
Clinical Ophthalmology 2016; 10: 757-764 (IGR: 17-4)


67153 Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment
Chiou SH
Carbohydrate polymers 2016; 144: 390-399 (IGR: 17-4)


66820 In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery
Koli AR
Journal of Controlled Release 2016; 226: 47-56 (IGR: 17-4)


67607 Deformability properties of timolol-loaded transfersomes based on the extrusion mechanism. Statistical optimization of the process
Rabasco AM
Drug Development and Industrial Pharmacy 2016; 0: 1-12 (IGR: 17-4)


67463 In vitro mitomycin C absorption and delivery with different sponge materials used in filtering surgery
Armillas M
Clinical Ophthalmology 2016; 10: 665-669 (IGR: 17-4)


67443 Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
Aung T
Clinical Ophthalmology 2016; 10: 757-764 (IGR: 17-4)


67153 Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment
Liu CJ
Carbohydrate polymers 2016; 144: 390-399 (IGR: 17-4)


66745 Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial
Rossetti L
Graefe's Archive for Clinical and Experimental Ophthalmology 2016; 254: 1151-1158 (IGR: 17-4)


66820 In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery
Vyas BA
Journal of Controlled Release 2016; 226: 47-56 (IGR: 17-4)


67463 In vitro mitomycin C absorption and delivery with different sponge materials used in filtering surgery
Ortiz P; Antón A
Clinical Ophthalmology 2016; 10: 665-669 (IGR: 17-4)


66820 In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery
Shah DO
Journal of Controlled Release 2016; 226: 47-56 (IGR: 17-4)


65971 Comparison of Eye Drop Instillation Before and After Use of Drop Application Strips in Glaucoma Patients on Chronic Topical Therapy
Sharma R
Journal of Glaucoma 2016; 25: e438-e440 (IGR: 17-3)


65933 Preservative-free glaucoma treatment : Selection of the correct treatment in 1 min
Pfennigsdorf S
Ophthalmologe 2016; 113: 409-415 (IGR: 17-3)


65932 Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study
Lopes JF
BMC Ophthalmology 2015; 15: 166 (IGR: 17-3)


66345 Conjunctival fibrosis following filtering glaucoma surgery
Schlunck G
Experimental Eye Research 2016; 142: 76-82 (IGR: 17-3)


66507 Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride
Agban Y
International Journal of Pharmaceutics 2016; 501: 96-101 (IGR: 17-3)


65831 New drugs and preparations for open-angle glaucoma in adults

Drug and therapeutics bulletin 2015; 53: 141-144 (IGR: 17-3)


65932 Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study
Hubatsch DA
BMC Ophthalmology 2015; 15: 166 (IGR: 17-3)


65971 Comparison of Eye Drop Instillation Before and After Use of Drop Application Strips in Glaucoma Patients on Chronic Topical Therapy
Singhal D
Journal of Glaucoma 2016; 25: e438-e440 (IGR: 17-3)


66507 Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride
Lian J
International Journal of Pharmaceutics 2016; 501: 96-101 (IGR: 17-3)


66345 Conjunctival fibrosis following filtering glaucoma surgery
Meyer-Ter-Vehn T
Experimental Eye Research 2016; 142: 76-82 (IGR: 17-3)


65933 Preservative-free glaucoma treatment : Selection of the correct treatment in 1 min
Eschstruth P
Ophthalmologe 2016; 113: 409-415 (IGR: 17-3)


66345 Conjunctival fibrosis following filtering glaucoma surgery
Klink T
Experimental Eye Research 2016; 142: 76-82 (IGR: 17-3)


66507 Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride
Prabakar S
International Journal of Pharmaceutics 2016; 501: 96-101 (IGR: 17-3)


65932 Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study
Amaris P
BMC Ophthalmology 2015; 15: 166 (IGR: 17-3)


65971 Comparison of Eye Drop Instillation Before and After Use of Drop Application Strips in Glaucoma Patients on Chronic Topical Therapy
Shashni A
Journal of Glaucoma 2016; 25: e438-e440 (IGR: 17-3)


66507 Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride
Seyfoddin A
International Journal of Pharmaceutics 2016; 501: 96-101 (IGR: 17-3)


65971 Comparison of Eye Drop Instillation Before and After Use of Drop Application Strips in Glaucoma Patients on Chronic Topical Therapy
Agarwal E
Journal of Glaucoma 2016; 25: e438-e440 (IGR: 17-3)


66345 Conjunctival fibrosis following filtering glaucoma surgery
Grehn F
Experimental Eye Research 2016; 142: 76-82 (IGR: 17-3)


65971 Comparison of Eye Drop Instillation Before and After Use of Drop Application Strips in Glaucoma Patients on Chronic Topical Therapy
Wadhwani M
Journal of Glaucoma 2016; 25: e438-e440 (IGR: 17-3)


66507 Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride
Rupenthal ID
International Journal of Pharmaceutics 2016; 501: 96-101 (IGR: 17-3)


65971 Comparison of Eye Drop Instillation Before and After Use of Drop Application Strips in Glaucoma Patients on Chronic Topical Therapy
Dada T
Journal of Glaucoma 2016; 25: e438-e440 (IGR: 17-3)


61348 A biodegradable ocular implant for long-term suppression of intraocular pressure
Ng XW
Drug delivery and translational research 2015; 5: 469-479 (IGR: 17-1)


61068 The Degradation of Mitomycin C Under Various Storage Methods
Kinast RM
Journal of Glaucoma 2016; 25: 477-481 (IGR: 17-1)


61561 Association between Glaucoma Medication Usage and Dry Eye in Taiwan
Chen HY
Optometry and Vision Science 2015; 92: e227-e232 (IGR: 17-1)


61753 Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma
Cvenkel B
Clinical Ophthalmology 2015; 9: 625-631 (IGR: 17-1)


60982 Effect of Glaucoma Medication in Tear Film Osmolarity of Patients Without Symptoms of Ocular Discomfort
Halkiadakis I
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 330-334 (IGR: 17-1)


61590 The Impact of Glaucoma Medications on Corneal Wound Healing
Pinheiro R
Journal of Glaucoma 2016; 25: 122-127 (IGR: 17-1)


61366 Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study
Prabhasawat P
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 323-329 (IGR: 17-1)


61394 Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study
Pérez-Roca F
PLoS ONE 2015; 10: e0129419 (IGR: 17-1)


60980 Natural Bioadhesive Biodegradable Nanoparticle-Based Topical Ophthalmic Formulations for Management of Glaucoma
Ibrahim MM
Translational vision science & technology 2015; 4: 12 (IGR: 17-1)


61491 In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study
Kim JH
Korean Journal of Ophthalmology 2015; 29: 270-279 (IGR: 17-1)


61285 Effects of Long-Term Antiglaucoma Eye Drops on Conjunctival Structures: An In Vivo Confocal Microscopy Study
Zhu W
Journal of Ophthalmology 2015; 2015: 165475 (IGR: 17-1)


61137 Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost
Aihara M
Journal of Glaucoma 2016; 25: e610-e614 (IGR: 17-1)


61596 Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment
Voss K
Journal of Controlled Release 2015; 214: 1-11 (IGR: 17-1)


61390 Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy
Hsu KH
European Journal of Pharmaceutics and Biopharmaceutics 2015; 94: 312-321 (IGR: 17-1)


61143 New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance
Rodriguez-Aller M
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 203-214 (IGR: 17-1)


61728 Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension
Peace JH
American Journal of Ophthalmology 2015; 160: 266-274.e1 (IGR: 17-1)


61672 Volumetric and cost evaluation study of glaucoma medical therapy
Banga HK
International journal of applied & basic medical research 2015; 5: 96-99 (IGR: 17-1)


61681 Effect of Two Novel Sustained-Release Drug Delivery Systems on Bleb Fibrosis: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model
Schoenberg ED
Translational vision science & technology 2015; 4: 4 (IGR: 17-1)


60979 Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device
Hovakimyan M
Translational vision science & technology 2015; 4: 14 (IGR: 17-1)


61825 Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications
Saini M
Eye 2015; 29: 808-814 (IGR: 17-1)


61137 Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost
Ikeda Y
Journal of Glaucoma 2016; 25: e610-e614 (IGR: 17-1)


61394 Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study
Rodrigo-Morales E
PLoS ONE 2015; 10: e0129419 (IGR: 17-1)


61825 Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications
Dhiman R
Eye 2015; 29: 808-814 (IGR: 17-1)


61672 Volumetric and cost evaluation study of glaucoma medical therapy
Gupta AK
International journal of applied & basic medical research 2015; 5: 96-99 (IGR: 17-1)


61561 Association between Glaucoma Medication Usage and Dry Eye in Taiwan
Lin CL
Optometry and Vision Science 2015; 92: e227-e232 (IGR: 17-1)


61681 Effect of Two Novel Sustained-Release Drug Delivery Systems on Bleb Fibrosis: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model
Blake DA
Translational vision science & technology 2015; 4: 4 (IGR: 17-1)


60979 Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device
Siewert S
Translational vision science & technology 2015; 4: 14 (IGR: 17-1)


61728 Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension
Ahlberg P
American Journal of Ophthalmology 2015; 160: 266-274.e1 (IGR: 17-1)


60980 Natural Bioadhesive Biodegradable Nanoparticle-Based Topical Ophthalmic Formulations for Management of Glaucoma
Abd-Elgawad AH
Translational vision science & technology 2015; 4: 12 (IGR: 17-1)


61590 The Impact of Glaucoma Medications on Corneal Wound Healing
Panfil C
Journal of Glaucoma 2016; 25: 122-127 (IGR: 17-1)


61366 Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study
Ruangvaravate N
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 323-329 (IGR: 17-1)


61348 A biodegradable ocular implant for long-term suppression of intraocular pressure
Liu KL
Drug delivery and translational research 2015; 5: 469-479 (IGR: 17-1)


60982 Effect of Glaucoma Medication in Tear Film Osmolarity of Patients Without Symptoms of Ocular Discomfort
Kontadakis GA
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 330-334 (IGR: 17-1)


61068 The Degradation of Mitomycin C Under Various Storage Methods
Akula KK
Journal of Glaucoma 2016; 25: 477-481 (IGR: 17-1)


61596 Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment
Falke K
Journal of Controlled Release 2015; 214: 1-11 (IGR: 17-1)


61143 New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance
Guinchard S
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 203-214 (IGR: 17-1)


61491 In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study
Kim EJ
Korean Journal of Ophthalmology 2015; 29: 270-279 (IGR: 17-1)


61285 Effects of Long-Term Antiglaucoma Eye Drops on Conjunctival Structures: An In Vivo Confocal Microscopy Study
Kong X
Journal of Ophthalmology 2015; 2015: 165475 (IGR: 17-1)


61390 Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy
Carbia BE
European Journal of Pharmaceutics and Biopharmaceutics 2015; 94: 312-321 (IGR: 17-1)


61753 Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma
Štunf Š
Clinical Ophthalmology 2015; 9: 625-631 (IGR: 17-1)


61672 Volumetric and cost evaluation study of glaucoma medical therapy
Singh G
International journal of applied & basic medical research 2015; 5: 96-99 (IGR: 17-1)


61143 New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance
Guillarme D
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 203-214 (IGR: 17-1)


61590 The Impact of Glaucoma Medications on Corneal Wound Healing
Schrage N
Journal of Glaucoma 2016; 25: 122-127 (IGR: 17-1)


61825 Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications
Dada T
Eye 2015; 29: 808-814 (IGR: 17-1)


61394 Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study
Garzón I
PLoS ONE 2015; 10: e0129419 (IGR: 17-1)


61137 Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost
Mizoue S
Journal of Glaucoma 2016; 25: e610-e614 (IGR: 17-1)


61285 Effects of Long-Term Antiglaucoma Eye Drops on Conjunctival Structures: An In Vivo Confocal Microscopy Study
Xu J
Journal of Ophthalmology 2015; 2015: 165475 (IGR: 17-1)


61068 The Degradation of Mitomycin C Under Various Storage Methods
DeBarber AE
Journal of Glaucoma 2016; 25: 477-481 (IGR: 17-1)


61596 Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment
Bernsdorf A
Journal of Controlled Release 2015; 214: 1-11 (IGR: 17-1)


61390 Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy
Plummer C
European Journal of Pharmaceutics and Biopharmaceutics 2015; 94: 312-321 (IGR: 17-1)


61681 Effect of Two Novel Sustained-Release Drug Delivery Systems on Bleb Fibrosis: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model
Swann FB
Translational vision science & technology 2015; 4: 4 (IGR: 17-1)


60979 Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device
Schmidt W
Translational vision science & technology 2015; 4: 14 (IGR: 17-1)


61491 In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study
Kim YH
Korean Journal of Ophthalmology 2015; 29: 270-279 (IGR: 17-1)


61753 Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma
Srebotnik Kirbiš I
Clinical Ophthalmology 2015; 9: 625-631 (IGR: 17-1)


61728 Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension
Wagner M
American Journal of Ophthalmology 2015; 160: 266-274.e1 (IGR: 17-1)


60980 Natural Bioadhesive Biodegradable Nanoparticle-Based Topical Ophthalmic Formulations for Management of Glaucoma
Soliman OA
Translational vision science & technology 2015; 4: 12 (IGR: 17-1)


61348 A biodegradable ocular implant for long-term suppression of intraocular pressure
Veluchamy AB
Drug delivery and translational research 2015; 5: 469-479 (IGR: 17-1)


60982 Effect of Glaucoma Medication in Tear Film Osmolarity of Patients Without Symptoms of Ocular Discomfort
Tsiakou D
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 330-334 (IGR: 17-1)


61561 Association between Glaucoma Medication Usage and Dry Eye in Taiwan
Tsai YY
Optometry and Vision Science 2015; 92: e227-e232 (IGR: 17-1)


61366 Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study
Tesavibul N
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 323-329 (IGR: 17-1)


61285 Effects of Long-Term Antiglaucoma Eye Drops on Conjunctival Structures: An In Vivo Confocal Microscopy Study
Sun X
Journal of Ophthalmology 2015; 2015: 165475 (IGR: 17-1)


60980 Natural Bioadhesive Biodegradable Nanoparticle-Based Topical Ophthalmic Formulations for Management of Glaucoma
Jablonski MM
Translational vision science & technology 2015; 4: 12 (IGR: 17-1)


61390 Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy
Chauhan A
European Journal of Pharmaceutics and Biopharmaceutics 2015; 94: 312-321 (IGR: 17-1)


61137 Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost
Arakaki Y
Journal of Glaucoma 2016; 25: e610-e614 (IGR: 17-1)


61491 In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study
Kim YI
Korean Journal of Ophthalmology 2015; 29: 270-279 (IGR: 17-1)


61143 New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance
Pupier M
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 203-214 (IGR: 17-1)


61681 Effect of Two Novel Sustained-Release Drug Delivery Systems on Bleb Fibrosis: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model
Parlin AW
Translational vision science & technology 2015; 4: 4 (IGR: 17-1)


61394 Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study
Oliveira AC
PLoS ONE 2015; 10: e0129419 (IGR: 17-1)


60979 Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device
Sternberg K
Translational vision science & technology 2015; 4: 14 (IGR: 17-1)


61596 Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment
Grabow N
Journal of Controlled Release 2015; 214: 1-11 (IGR: 17-1)


61348 A biodegradable ocular implant for long-term suppression of intraocular pressure
Lwin NC
Drug delivery and translational research 2015; 5: 469-479 (IGR: 17-1)


61753 Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma
Strojan Fležar M
Clinical Ophthalmology 2015; 9: 625-631 (IGR: 17-1)


61561 Association between Glaucoma Medication Usage and Dry Eye in Taiwan
Kao CH
Optometry and Vision Science 2015; 92: e227-e232 (IGR: 17-1)


61366 Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study
Thewthong M
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 323-329 (IGR: 17-1)


61590 The Impact of Glaucoma Medications on Corneal Wound Healing
Dutescu RM
Journal of Glaucoma 2016; 25: 122-127 (IGR: 17-1)


61825 Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications
Tandon R
Eye 2015; 29: 808-814 (IGR: 17-1)


61728 Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension
Lim JM
American Journal of Ophthalmology 2015; 160: 266-274.e1 (IGR: 17-1)


60982 Effect of Glaucoma Medication in Tear Film Osmolarity of Patients Without Symptoms of Ocular Discomfort
Patsea E
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 330-334 (IGR: 17-1)


61068 The Degradation of Mitomycin C Under Various Storage Methods
Barker GT
Journal of Glaucoma 2016; 25: 477-481 (IGR: 17-1)


60982 Effect of Glaucoma Medication in Tear Film Osmolarity of Patients Without Symptoms of Ocular Discomfort
Mitropoulos P
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 330-334 (IGR: 17-1)


61348 A biodegradable ocular implant for long-term suppression of intraocular pressure
Wong TT
Drug delivery and translational research 2015; 5: 469-479 (IGR: 17-1)


61068 The Degradation of Mitomycin C Under Various Storage Methods
Gardiner SK
Journal of Glaucoma 2016; 25: 477-481 (IGR: 17-1)


61728 Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension
Wirta D
American Journal of Ophthalmology 2015; 160: 266-274.e1 (IGR: 17-1)


61143 New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance
Jeannerat D
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 203-214 (IGR: 17-1)


61825 Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications
Vanathi M
Eye 2015; 29: 808-814 (IGR: 17-1)


61681 Effect of Two Novel Sustained-Release Drug Delivery Systems on Bleb Fibrosis: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model
Zurakowski D
Translational vision science & technology 2015; 4: 4 (IGR: 17-1)


60979 Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device
Reske T
Translational vision science & technology 2015; 4: 14 (IGR: 17-1)


61596 Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment
Kastner C
Journal of Controlled Release 2015; 214: 1-11 (IGR: 17-1)


61137 Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost
Kita N
Journal of Glaucoma 2016; 25: e610-e614 (IGR: 17-1)


61394 Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study
Martín-Piedra MÁ
PLoS ONE 2015; 10: e0129419 (IGR: 17-1)


61491 In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study
Lee SH
Korean Journal of Ophthalmology 2015; 29: 270-279 (IGR: 17-1)


61728 Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension
Branch JD
American Journal of Ophthalmology 2015; 160: 266-274.e1 (IGR: 17-1)


61681 Effect of Two Novel Sustained-Release Drug Delivery Systems on Bleb Fibrosis: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model
Margo CE
Translational vision science & technology 2015; 4: 4 (IGR: 17-1)


60982 Effect of Glaucoma Medication in Tear Film Osmolarity of Patients Without Symptoms of Ocular Discomfort
Kandarakis AS
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 330-334 (IGR: 17-1)


60979 Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device
Stachs O
Translational vision science & technology 2015; 4: 14 (IGR: 17-1)


61394 Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study
Carriel V
PLoS ONE 2015; 10: e0129419 (IGR: 17-1)


61491 In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study
Jung JC
Korean Journal of Ophthalmology 2015; 29: 270-279 (IGR: 17-1)


61596 Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment
Sternberg K
Journal of Controlled Release 2015; 214: 1-11 (IGR: 17-1)


61137 Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost
Kobayashi S
Journal of Glaucoma 2016; 25: e610-e614 (IGR: 17-1)


61068 The Degradation of Mitomycin C Under Various Storage Methods
Whitson E
Journal of Glaucoma 2016; 25: 477-481 (IGR: 17-1)


61143 New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance
Rivara-Minten E
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 203-214 (IGR: 17-1)


61348 A biodegradable ocular implant for long-term suppression of intraocular pressure
Venkatraman SS
Drug delivery and translational research 2015; 5: 469-479 (IGR: 17-1)


61681 Effect of Two Novel Sustained-Release Drug Delivery Systems on Bleb Fibrosis: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model
Ponnusamy T
Translational vision science & technology 2015; 4: 4 (IGR: 17-1)


60979 Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device
Guthoff R
Translational vision science & technology 2015; 4: 14 (IGR: 17-1)


61491 In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study
Lee KW
Korean Journal of Ophthalmology 2015; 29: 270-279 (IGR: 17-1)


61137 Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost

Journal of Glaucoma 2016; 25: e610-e614 (IGR: 17-1)


61068 The Degradation of Mitomycin C Under Various Storage Methods
Mansberger SL
Journal of Glaucoma 2016; 25: 477-481 (IGR: 17-1)


61394 Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study
Ortiz-Pérez AI
PLoS ONE 2015; 10: e0129419 (IGR: 17-1)


61143 New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance
Veuthey JL
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 203-214 (IGR: 17-1)


61596 Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment
Minrath I
Journal of Controlled Release 2015; 214: 1-11 (IGR: 17-1)


61491 In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study
Park YJ
Korean Journal of Ophthalmology 2015; 29: 270-279 (IGR: 17-1)


61596 Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment
Eickner T
Journal of Controlled Release 2015; 214: 1-11 (IGR: 17-1)


60979 Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device
Wree A
Translational vision science & technology 2015; 4: 14 (IGR: 17-1)


61143 New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance
Gurny R
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 203-214 (IGR: 17-1)


61394 Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study
Sánchez-Montesinos I
PLoS ONE 2015; 10: e0129419 (IGR: 17-1)


61681 Effect of Two Novel Sustained-Release Drug Delivery Systems on Bleb Fibrosis: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model
John VT
Translational vision science & technology 2015; 4: 4 (IGR: 17-1)


60979 Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device
Witt M
Translational vision science & technology 2015; 4: 14 (IGR: 17-1)


61681 Effect of Two Novel Sustained-Release Drug Delivery Systems on Bleb Fibrosis: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model
Ayyala RS
Translational vision science & technology 2015; 4: 4 (IGR: 17-1)


61596 Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment
Wree A
Journal of Controlled Release 2015; 214: 1-11 (IGR: 17-1)


61394 Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study
Campos A; Alaminos M
PLoS ONE 2015; 10: e0129419 (IGR: 17-1)


61596 Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment
Schmitz KP
Journal of Controlled Release 2015; 214: 1-11 (IGR: 17-1)


60979 Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device
Schmitz KP; Allemann R
Translational vision science & technology 2015; 4: 14 (IGR: 17-1)


61596 Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment
Guthoff R; Witt M; Hovakimyan M
Journal of Controlled Release 2015; 214: 1-11 (IGR: 17-1)


60575 Nanotherapies for the treatment of ocular diseases
Reimondez-Troitiño S
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 279-293 (IGR: 16-4)


60330 Progression of drug delivery system for glaucoma
Xu Y
Chinese Journal of Ophthalmology 2014; 50: 946-951 (IGR: 16-4)


60505 Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency
Loma P
Experimental Eye Research 2015; 134: 141-147 (IGR: 16-4)


60578 Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives
Ramli N
Optometry and Vision Science 2015; 92: e222-e226 (IGR: 16-4)


60168 Original preparations versus generics--latanoprost: how similar is different?
Leitritz MA
Ophthalmologe 2015; 112: 127-139 (IGR: 16-4)


60589 Dry eye specific quality of life in veterans using glaucoma drops
Camp A
Contact Lens and Anterior Eye 2015; 38: 220-225 (IGR: 16-4)


60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Kanamoto T
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164 (IGR: 16-4)


60294 Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure
Lambert WS
Translational vision science & technology 2015; 4: 1 (IGR: 16-4)


60624 From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability
Rossi GC
Expert Opinion on Drug Safety 2015; 14: 619-623 (IGR: 16-4)


60097 Stability of Latanoprost in Generic Formulations Using Controlled Degradation and Patient Usage Simulation Studies
Velpandian T
Current Eye Research 2015; 40: 561-571 (IGR: 16-4)


60161 Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients - A randomized, double-blind, placebo-controlled study
Bae HW
Journal of ginseng research 2015; 39: 7-13 (IGR: 16-4)


60259 A Survey on the Preference of Sustained Glaucoma Drug Delivery Systems by Singaporean Chinese Patients: A Comparison Between Subconjunctival, Intracameral, and Punctal Plug Routes
Chan HH
Journal of Glaucoma 2015; 24: 485-492 (IGR: 16-4)


60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Pfeiffer N
Advances in Therapy 2014; 31: 1228-1246 (IGR: 16-4)


60628 Impact of supply problems of preservative-free glaucoma medications on patients and hospital staff
Shah S
Ophthalmic and Physiological Optics 2015; 35: 236-241 (IGR: 16-4)


60323 Sustained drug release by contact lenses for glaucoma treatment-a review
Carvalho IM
Journal of Controlled Release 2015; 202: 76-82 (IGR: 16-4)


60084 A National Survey of Glaucoma Specialists on the Preoperative (Trabeculectomy) Management of the Ocular Surface
Tailor R
Seminars in Ophthalmology 2014; 0: 1-7 (IGR: 16-4)


60781 Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study
Saade CE
Canadian Journal of Ophthalmology 2015; 50: 132-136 (IGR: 16-4)


60630 Usability of prostaglandin monotherapy eye droppers
Drew T
British Journal of Ophthalmology 2015; 99: 1251-1254 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Nagai N
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60150 Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells
Smedowski A
Journal of biochemical and pharmacological research 2014; 2: 175-184 (IGR: 16-4)


60477 Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues
Kocabeyoglu S
Indian Journal of Ophthalmology 2015; 63: 15-19 (IGR: 16-4)


60612 Evaluation of the efficacy and safety of a new device for eye drops instillation in patients with glaucoma
Junqueira DM
Clinical Ophthalmology 2015; 9: 367-371 (IGR: 16-4)


60542 Microbial contamination of glaucoma eyedrops used by patients compared with ocular medications used in the hospital
Teuchner B
Medicine 2015; 94: e583 (IGR: 16-4)


60084 A National Survey of Glaucoma Specialists on the Preoperative (Trabeculectomy) Management of the Ocular Surface
Batra R
Seminars in Ophthalmology 2014; 0: 1-7 (IGR: 16-4)


60781 Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study
Lari HB
Canadian Journal of Ophthalmology 2015; 50: 132-136 (IGR: 16-4)


60097 Stability of Latanoprost in Generic Formulations Using Controlled Degradation and Patient Usage Simulation Studies
Kotnala A
Current Eye Research 2015; 40: 561-571 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Yoshioka C
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60168 Original preparations versus generics--latanoprost: how similar is different?
Lipp HP
Ophthalmologe 2015; 112: 127-139 (IGR: 16-4)


60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Traverso CE
Advances in Therapy 2014; 31: 1228-1246 (IGR: 16-4)


60294 Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure
Carlson BJ
Translational vision science & technology 2015; 4: 1 (IGR: 16-4)


60630 Usability of prostaglandin monotherapy eye droppers
Wolffsohn JS
British Journal of Ophthalmology 2015; 99: 1251-1254 (IGR: 16-4)


60589 Dry eye specific quality of life in veterans using glaucoma drops
Wellik SR
Contact Lens and Anterior Eye 2015; 38: 220-225 (IGR: 16-4)


60477 Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues
Mocan MC
Indian Journal of Ophthalmology 2015; 63: 15-19 (IGR: 16-4)


60161 Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients - A randomized, double-blind, placebo-controlled study
Kim JH
Journal of ginseng research 2015; 39: 7-13 (IGR: 16-4)


60578 Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives
Supramaniam G
Optometry and Vision Science 2015; 92: e222-e226 (IGR: 16-4)


60505 Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency
Guzman-Aranguez A
Experimental Eye Research 2015; 134: 141-147 (IGR: 16-4)


60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Kiuchi Y
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164 (IGR: 16-4)


60612 Evaluation of the efficacy and safety of a new device for eye drops instillation in patients with glaucoma
Lopes FS
Clinical Ophthalmology 2015; 9: 367-371 (IGR: 16-4)


60624 From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability
Scudeller L
Expert Opinion on Drug Safety 2015; 14: 619-623 (IGR: 16-4)


60575 Nanotherapies for the treatment of ocular diseases
Csaba N
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 279-293 (IGR: 16-4)


60323 Sustained drug release by contact lenses for glaucoma treatment-a review
Marques CS
Journal of Controlled Release 2015; 202: 76-82 (IGR: 16-4)


60150 Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells
Paterno JJ
Journal of biochemical and pharmacological research 2014; 2: 175-184 (IGR: 16-4)


60542 Microbial contamination of glaucoma eyedrops used by patients compared with ocular medications used in the hospital
Wagner J
Medicine 2015; 94: e583 (IGR: 16-4)


60330 Progression of drug delivery system for glaucoma
Lyu L
Chinese Journal of Ophthalmology 2014; 50: 946-951 (IGR: 16-4)


60259 A Survey on the Preference of Sustained Glaucoma Drug Delivery Systems by Singaporean Chinese Patients: A Comparison Between Subconjunctival, Intracameral, and Punctal Plug Routes
Wong TT
Journal of Glaucoma 2015; 24: 485-492 (IGR: 16-4)


60628 Impact of supply problems of preservative-free glaucoma medications on patients and hospital staff
Theodossiades J
Ophthalmic and Physiological Optics 2015; 35: 236-241 (IGR: 16-4)


60259 A Survey on the Preference of Sustained Glaucoma Drug Delivery Systems by Singaporean Chinese Patients: A Comparison Between Subconjunctival, Intracameral, and Punctal Plug Routes
Lamoureux E
Journal of Glaucoma 2015; 24: 485-492 (IGR: 16-4)


60612 Evaluation of the efficacy and safety of a new device for eye drops instillation in patients with glaucoma
de Souza FC
Clinical Ophthalmology 2015; 9: 367-371 (IGR: 16-4)


60542 Microbial contamination of glaucoma eyedrops used by patients compared with ocular medications used in the hospital
Bechrakis NE
Medicine 2015; 94: e583 (IGR: 16-4)


60084 A National Survey of Glaucoma Specialists on the Preoperative (Trabeculectomy) Management of the Ocular Surface
Mohamed S
Seminars in Ophthalmology 2014; 0: 1-7 (IGR: 16-4)


60781 Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study
Berezina TL
Canadian Journal of Ophthalmology 2015; 50: 132-136 (IGR: 16-4)


60323 Sustained drug release by contact lenses for glaucoma treatment-a review
Oliveira RS
Journal of Controlled Release 2015; 202: 76-82 (IGR: 16-4)


60097 Stability of Latanoprost in Generic Formulations Using Controlled Degradation and Patient Usage Simulation Studies
Halder N
Current Eye Research 2015; 40: 561-571 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Mano Y
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60150 Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells
Toropainen E
Journal of biochemical and pharmacological research 2014; 2: 175-184 (IGR: 16-4)


60628 Impact of supply problems of preservative-free glaucoma medications on patients and hospital staff
Chapman K
Ophthalmic and Physiological Optics 2015; 35: 236-241 (IGR: 16-4)


60578 Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives
Samsudin A
Optometry and Vision Science 2015; 92: e222-e226 (IGR: 16-4)


60477 Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues
Irkec M
Indian Journal of Ophthalmology 2015; 63: 15-19 (IGR: 16-4)


60168 Original preparations versus generics--latanoprost: how similar is different?
Voykov B
Ophthalmologe 2015; 112: 127-139 (IGR: 16-4)


60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Tanito M
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164 (IGR: 16-4)


60624 From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability
Rolle T
Expert Opinion on Drug Safety 2015; 14: 619-623 (IGR: 16-4)


60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Lorenz K
Advances in Therapy 2014; 31: 1228-1246 (IGR: 16-4)


60505 Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency
Perez De Lara MJ
Experimental Eye Research 2015; 134: 141-147 (IGR: 16-4)


60575 Nanotherapies for the treatment of ocular diseases
Alonso MJ
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 279-293 (IGR: 16-4)


60589 Dry eye specific quality of life in veterans using glaucoma drops
Tzu JH
Contact Lens and Anterior Eye 2015; 38: 220-225 (IGR: 16-4)


60161 Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients - A randomized, double-blind, placebo-controlled study
Kim S
Journal of ginseng research 2015; 39: 7-13 (IGR: 16-4)


60294 Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure
van der Ende AE
Translational vision science & technology 2015; 4: 1 (IGR: 16-4)


60589 Dry eye specific quality of life in veterans using glaucoma drops
Feuer W
Contact Lens and Anterior Eye 2015; 38: 220-225 (IGR: 16-4)


60612 Evaluation of the efficacy and safety of a new device for eye drops instillation in patients with glaucoma
Dorairaj S
Clinical Ophthalmology 2015; 9: 367-371 (IGR: 16-4)


60542 Microbial contamination of glaucoma eyedrops used by patients compared with ocular medications used in the hospital
Orth-Höller D
Medicine 2015; 94: e583 (IGR: 16-4)


60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Mizoue S
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164 (IGR: 16-4)


60294 Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure
Shih G
Translational vision science & technology 2015; 4: 1 (IGR: 16-4)


60628 Impact of supply problems of preservative-free glaucoma medications on patients and hospital staff
Murdoch I
Ophthalmic and Physiological Optics 2015; 35: 236-241 (IGR: 16-4)


60575 Nanotherapies for the treatment of ocular diseases
de la Fuente M
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 279-293 (IGR: 16-4)


60323 Sustained drug release by contact lenses for glaucoma treatment-a review
Coelho PB
Journal of Controlled Release 2015; 202: 76-82 (IGR: 16-4)


60150 Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells
Sinha D
Journal of biochemical and pharmacological research 2014; 2: 175-184 (IGR: 16-4)


60781 Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study
Fechtner RD
Canadian Journal of Ophthalmology 2015; 50: 132-136 (IGR: 16-4)


60578 Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives
Juana A
Optometry and Vision Science 2015; 92: e222-e226 (IGR: 16-4)


60505 Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency
Pintor J
Experimental Eye Research 2015; 134: 141-147 (IGR: 16-4)


60161 Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients - A randomized, double-blind, placebo-controlled study
Kim M
Journal of ginseng research 2015; 39: 7-13 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Tnabe W
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60624 From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability
Pasinetti GM
Expert Opinion on Drug Safety 2015; 14: 619-623 (IGR: 16-4)


60097 Stability of Latanoprost in Generic Formulations Using Controlled Degradation and Patient Usage Simulation Studies
Ravi AK
Current Eye Research 2015; 40: 561-571 (IGR: 16-4)


60168 Original preparations versus generics--latanoprost: how similar is different?
Ziemssen F
Ophthalmologe 2015; 112: 127-139 (IGR: 16-4)


60259 A Survey on the Preference of Sustained Glaucoma Drug Delivery Systems by Singaporean Chinese Patients: A Comparison Between Subconjunctival, Intracameral, and Punctal Plug Routes
Perera S
Journal of Glaucoma 2015; 24: 485-492 (IGR: 16-4)


60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Saarela V
Advances in Therapy 2014; 31: 1228-1246 (IGR: 16-4)


60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Naito T
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164 (IGR: 16-4)


60624 From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability
Bianchi PE
Expert Opinion on Drug Safety 2015; 14: 619-623 (IGR: 16-4)


60323 Sustained drug release by contact lenses for glaucoma treatment-a review
Costa PC
Journal of Controlled Release 2015; 202: 76-82 (IGR: 16-4)


60161 Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients - A randomized, double-blind, placebo-controlled study
Lee N
Journal of ginseng research 2015; 39: 7-13 (IGR: 16-4)


60781 Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study
Khouri AS
Canadian Journal of Ophthalmology 2015; 50: 132-136 (IGR: 16-4)


60542 Microbial contamination of glaucoma eyedrops used by patients compared with ocular medications used in the hospital
Nagl M
Medicine 2015; 94: e583 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Ito Y
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60589 Dry eye specific quality of life in veterans using glaucoma drops
Arheart KL
Contact Lens and Anterior Eye 2015; 38: 220-225 (IGR: 16-4)


60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Liinamaa J
Advances in Therapy 2014; 31: 1228-1246 (IGR: 16-4)


60097 Stability of Latanoprost in Generic Formulations Using Controlled Degradation and Patient Usage Simulation Studies
Archunan V
Current Eye Research 2015; 40: 561-571 (IGR: 16-4)


60578 Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives
Zahari M
Optometry and Vision Science 2015; 92: e222-e226 (IGR: 16-4)


60150 Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells
Wylegala E
Journal of biochemical and pharmacological research 2014; 2: 175-184 (IGR: 16-4)


60612 Evaluation of the efficacy and safety of a new device for eye drops instillation in patients with glaucoma
Prata TS
Clinical Ophthalmology 2015; 9: 367-371 (IGR: 16-4)


60294 Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure
Dobish JN
Translational vision science & technology 2015; 4: 1 (IGR: 16-4)


60161 Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients - A randomized, double-blind, placebo-controlled study
Hong S
Journal of ginseng research 2015; 39: 7-13 (IGR: 16-4)


60097 Stability of Latanoprost in Generic Formulations Using Controlled Degradation and Patient Usage Simulation Studies
Sihota R
Current Eye Research 2015; 40: 561-571 (IGR: 16-4)


60150 Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells
Kaarniranta K
Journal of biochemical and pharmacological research 2014; 2: 175-184 (IGR: 16-4)


60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Teranishi S
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Okamoto N
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60589 Dry eye specific quality of life in veterans using glaucoma drops
Sastry A
Contact Lens and Anterior Eye 2015; 38: 220-225 (IGR: 16-4)


60294 Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure
Calkins DJ
Translational vision science & technology 2015; 4: 1 (IGR: 16-4)


60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Uusitalo H
Advances in Therapy 2014; 31: 1228-1246 (IGR: 16-4)


60323 Sustained drug release by contact lenses for glaucoma treatment-a review
Ferreira DC
Journal of Controlled Release 2015; 202: 76-82 (IGR: 16-4)


60578 Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives
Choo MM
Optometry and Vision Science 2015; 92: e222-e226 (IGR: 16-4)


60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Astakhov Y
Advances in Therapy 2014; 31: 1228-1246 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Shimomura Y
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60294 Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure
Harth E
Translational vision science & technology 2015; 4: 1 (IGR: 16-4)


60589 Dry eye specific quality of life in veterans using glaucoma drops
Galor A
Contact Lens and Anterior Eye 2015; 38: 220-225 (IGR: 16-4)


60161 Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients - A randomized, double-blind, placebo-controlled study
Seong GJ
Journal of ginseng research 2015; 39: 7-13 (IGR: 16-4)


60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Hirooka K
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164 (IGR: 16-4)


60161 Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients - A randomized, double-blind, placebo-controlled study
Kim CY
Journal of ginseng research 2015; 39: 7-13 (IGR: 16-4)


60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Rimayanti U
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164 (IGR: 16-4)


60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Boiko E; Ropo A;
Advances in Therapy 2014; 31: 1228-1246 (IGR: 16-4)


59349 Ocular surface alterations and topical antiglaucomatous therapy: a review
Actis AG; Rolle T
Open Ophthalmology Journal 2014; 8: 67-72 (IGR: 16-3)


59119 The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients
Tsumura T; Yoshikawa K; Kimura T; Suzumura H; Kawashima M; Nanno M; Ishijima K; Takeda R
Clinical Ophthalmology 2014; 8: 1681-1687 (IGR: 16-3)


59238 Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma
Holló G; Ropo A
Current Medical Research and Opinion 2014; 0: 1-4 (IGR: 16-3)


59260 Potential drug delivery approaches for XFS-associated and XFS-associated glaucoma
Kulkarni SS; Kompella UB
Journal of Glaucoma 2014; 23: S77-9 (IGR: 16-3)


59577 Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
Dubiner HB; Hubatsch DA
BMC Ophthalmology 2014; 14: 151 (IGR: 16-3)


59389 Effect of Eye Drops Containing Disulfiram and Low-Substituted Methylcellulose in Reducing Intraocular Pressure in Rabbit Models
Nagai N; Yoshioka C; Mano Y; Ito Y; Okamoto N; Shimomura Y
Current Eye Research 2014; 0: 1-11 (IGR: 16-3)


59385 Hybrid formulations of liposomes and bioadhesive polymers improve the hypotensive effect of the melatonin analogue 5-MCA-NAT in rabbit eyes
Quinteros D; Vicario-de-la-Torre M; Andrés-Guerrero V; Palma S; Allemandi D; Herrero-Vanrell R; Molina-Martínez IT
PLoS ONE 2014; 9: e110344 (IGR: 16-3)


59261 Noninvasive ocular drug delivery: potential transcorneal and other alternative delivery routes for therapeutic molecules in glaucoma
Foldvari M
Journal of Glaucoma 2014; 23: S80-2 (IGR: 16-3)


58908 Mirror-hat device as a drop delivery aid: a pilot study
Strungaru MH; Peck J; Compeau EC; Trope GE; Buys YM
Canadian Journal of Ophthalmology 2014; 49: 333-338 (IGR: 16-3)


59588 Glaucoma medications, preservatives and the ocular surface
Aptel F; Labbé A; Baudouin C; Bron A; Lachkar Y; Sellem E; Renard JP; Nordmann JP; Rouland JF; Denis P
Journal Franšais d'Ophtalmologie 2014; 37: 728-736 (IGR: 16-3)


59114 Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles
Kim YC; Edelhauser HF; Prausnitz MR
Investigative Ophthalmology and Visual Science 2014; 55: 7387-7397 (IGR: 16-3)


58788 Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative-free tafluprost
Chang C; Zhang AQ; Kagan DB; Liu H; Hutnik CM
Clinical and Experimental Ophthalmology 2015; 43: 164-172 (IGR: 16-3)


59094 Extended latanoprost release from commercial contact lenses: in vitro studies using corneal models
Mohammadi S; Jones L; Gorbet M
PLoS ONE 2014; 9: e106653 (IGR: 16-3)


59219 Comparison of the ocular surface changes following the use of two different prostaglandin F2α analogues containing benzalkonium chloride or polyquad in rabbit eyes
Lee HJ; Jun RM; Cho MS; Choi KR
Cutaneous and Ocular Toxicology 2014; 0: 1-8 (IGR: 16-3)


59269 Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives
Tu EY
Saudi Journal of Ophthalmology 2014; 28: 182-187 (IGR: 16-3)


59089 The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye
Barabino S; Antonelli S; Cimbolini N; Mauro V; Bouzin M
Investigative Ophthalmology and Visual Science 2014; 55: 6499-6504 (IGR: 16-3)


59551 Clinicians' perspectives on the use of drug-eluting contact lenses for the treatment of glaucoma
Taniguchi EV; Kalout P; Pasquale LR; Kohane DS; Ciolino JB
Therapeutic delivery 2014; 5: 1077-1083 (IGR: 16-3)


59068 Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease
Goldberg I; Graham SL; Crowston JG; d'Mellow G;
Clinical and Experimental Ophthalmology 2015; 43: 214-220 (IGR: 16-3)


59000 Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits
Warsi MH; Anwar M; Garg V; Jain GK; Talegaonkar S; Ahmad FJ; Khar RK
Colloids and surfaces. B, Biointerfaces 2014; 122: 423-431 (IGR: 16-3)


59612 Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit
Leonardi A; Bucolo C; Drago F; Salomone S; Pignatello R
International Journal of Pharmaceutics 2014; 478: 180-186 (IGR: 16-3)


58798 Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study
Wang F; Chen L; Zhang D; Jiang S; Shi K; Huang Y; Li R; Xu Q
Journal of drug targeting 2014; 22: 849-858 (IGR: 16-3)


57207 Increased Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression in the Conjunctival Epithelium Exposed to Antiglaucoma Treatments
Labbé A; Gabison E; Brignole-Baudouin F; Riancho L; Menashi S; Baudouin C
Current Eye Research 2014; 0: 1-8 (IGR: 16-2)


56875 Scleral permeability varies by mouse strain and is decreased by chronic experimental glaucoma
Pease ME; Oglesby EN; Cone-Kimball E; Steinhart MR; Kim AJ; Hanes J; Quigley HA
Investigative Ophthalmology and Visual Science 2014; 55: 2564-2573 (IGR: 16-2)


57127 Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers
Iester M; Telani S; Frezzotti P; Motolese I; Figus M; Fogagnolo P; Perdicchi A;
Journal of Ocular Pharmacology and Therapeutics 2014; 30: 476-481 (IGR: 16-2)


57343 Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension
Sanford M
Clinical Drug Investigation 2014; 34: 521-528 (IGR: 16-2)


57273 Trans-conjunctival aqueous humor outflow in glaucomatous patients treated with prostaglandin analogues: an in vivo confocal microscopy study
Mastropasqua R; Fasanella V; Pedrotti E; Lanzini M; Di Staso S; Mastropasqua L; Agnifili L
Graefe's Archive for Clinical and Experimental Ophthalmology 2014; 252: 1469-1476 (IGR: 16-2)


57348 Effects of Polyquaternium- and Benzalkonium-Chloride-Preserved Travoprost on Ocular Surfaces: An Impression Cytology Study
Sezgin Akçay BI; Güney E; Bozkurt TK; Topal CS; Akkan JC; Unlü C
Journal of Ocular Pharmacology and Therapeutics 2014; 30: 548-553 (IGR: 16-2)


57537 Formulation and evaluation of stimuli-sensitive hydrogels of timolol maleate and brimonidine tartrate for the treatment of glaucoma
Dubey A; Prabhu P
International journal of pharmaceutical investigation 2014; 4: 112-118 (IGR: 16-2)


57250 Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition
Nakano M; Lockhart CM; Kelly EJ; Rettie AE
Drug Metabolism Reviews 2014; 46: 247-260 (IGR: 16-2)


57354 Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration: Towards non-invasive glaucoma gene therapy
Alqawlaq S; Sivak JM; Huzil JT; Ivanova MV; Flanagan JG; Beazely MA; Foldvari M
Nanomedicine: Nanotechnology, Biology, and Medicine 2014; 10: 1637-1647 (IGR: 16-2)


57517 Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
Bhagat P; Sodimalla K; Paul C; Pandav SS; Raman GV; Ramakrishnan R; Joshi A; Raut A
Clinical Ophthalmology 2014; 8: 1241-1252 (IGR: 16-2)


57382 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost
Konstas AG; Voudouragkaki IC; Boboridis KG; Haidich AB; Paschalinou E; Giannopoulos T; Dragoumis ND; Makridis AK; Kahook MY
Advances in Therapy 2014; 31: 592-603 (IGR: 16-2)


57331 Controlled ocular drug delivery with nanomicelles
Vaishya RD; Khurana V; Patel S; Mitra AK
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2014; 6: 422-437 (IGR: 16-2)


57479 28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres
Fedorchak MV; Conner IP; Medina CA; Wingard JB; Schuman JS; Little SR
Experimental Eye Research 2014; 125: 210-216 (IGR: 16-2)


57435 Evaluation of an injectable thermosensitive hydrogel as drug delivery implant for ocular glaucoma surgery
Xi L; Wang T; Zhao F; Zheng Q; Li X; Luo J; Liu J; Quan D; Ge J
PLoS ONE 2014; 9: e100632 (IGR: 16-2)


57492 The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study
Aydin Kurna S; Acikgoz S; Altun A; Ozbay N; Sengor T; Olcaysu OO
Journal of Ophthalmology 2014; 2014: 460483 (IGR: 16-2)


57475 Advances in ocular drug delivery: emphasis on the posterior segment
Kang-Mieler JJ; Osswald CR; Mieler WF
Expert Opinion on Drug Delivery 2014; 0: 1-14 (IGR: 16-2)


57064 Objective evaluation of applying eye drops by elderly patients
Colomé-Campos J; Martínez-Salcedo I; Martorell-Hallado MC; Romero-Aroca P
Archivos de la Sociedad Espa˝ola de Oftalmologia 2014; 89: 177-181 (IGR: 16-2)


56364 In Vivo Laser Scanning Confocal Microscopy of the Ocular Surface in Glaucoma
Mastropasqua L; Agnifili L; Mastropasqua R; Fasanella V; Nubile M; Toto L; Carpineto P; Ciancaglini M
Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2014; 0: 1-16 (IGR: 16-1)


56656 Managing adverse effects of glaucoma medications
Inoue K
Clinical Ophthalmology 2014; 8: 903-913 (IGR: 16-1)


56427 Confocal microscopy of epithelial and langerhans cells of the cornea in patients using travoprost drops containing two different preservatives
Marsovszky L; Resch MD; Visontai Z; Németh J
Pathology oncology research : POR 2014; 20: 741-746 (IGR: 16-1)


56088 Sustained drug release in nanomedicine: a long-acting nanocarrier-based formulation for glaucoma
Natarajan JV; Darwitan A; Barathi VA; Ang M; Htoon HM; Boey F; Tam KC; Wong TT; Venkatraman SS
ACS nano 2014; 8: 419-429 (IGR: 16-1)


56517 A temperature-induced and shear-reversible assembly of latanoprost-loaded amphiphilic chitosan colloids: Characterization and in vivo glaucoma treatment
Hsiao MH; Chiou SH; Larsson M; Hung KH; Wang YL; Liu CJ; Liu DM
Acta biomaterialia 2014; 10: 3188-3196 (IGR: 16-1)


56644 Drug-induced corneal damage

Prescrire International 2014; 23: 97-100 (IGR: 16-1)


56188 Sustained drug delivery in glaucoma
Knight OJ; Lawrence SD
Current Opinions in Ophthalmology 2014; 25: 112-117 (IGR: 16-1)


56537 An update on intravitreal implants in use for eye disorders
Lambiase A; Abdolrahimzadeh S; Recupero SM
Drugs of Today 2014; 50: 239-249 (IGR: 16-1)


56493 Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
Goldberg I; Gil Pina R; Lanzagorta-Aresti A; Schiffman RM; Liu C; Bejanian M
British Journal of Ophthalmology 2014; 98: 926-931 (IGR: 16-1)


56243 Diamond nanogel-embedded contact lenses mediate lysozyme-dependent therapeutic release
Kim HJ; Zhang K; Moore L; Ho D
ACS nano 2014; 8: 2998-3005 (IGR: 16-1)


56313 Mechanism - Based Translational Pharmacokinetic - Pharmacodynamic Model to Predict Intraocular Pressure Lowering Effect of Drugs in Patients with Glaucoma or Ocular Hypertension
Durairaj C; Shen J; Cherukury M
Pharmaceutical Research 2014; 31: 2095-2106 (IGR: 16-1)


56289 Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits
Ameeduzzafar ; Ali J; Bhatnagar A; Kumar N; Ali A
International Journal of Biological Macromolecules 2014; 65: 479-491 (IGR: 16-1)


56514 Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo
Tuomela A; Liu P; Puranen J; Rönkkö S; Laaksonen T; Kalesnykas G; Oksala O; Ilkka J; Laru J; Järvinen K; Hirvonen J; Peltonen L
International Journal of Pharmaceutics 2014; 467: 34-41 (IGR: 16-1)


56624 The PEG-PCL-PEG Hydrogel as an Implanted Ophthalmic Delivery System after Glaucoma Filtration Surgery; a Pilot Study
Peng R; Qin G; Li X; Lv H; Qian Z; Yu L
Medical hypothesis, discovery and innovation in ophthalmology 2014; 3: 3-8 (IGR: 16-1)


56641 Comparison of diagnostic tests in distinct well-defined conditions related to dry eye disease
Alves M; Reinach PS; Paula JS; Vellasco E Cruz AA; Bachette L; Faustino J; Aranha FP; Vigorito A; de Souza CA; Rocha EM
PLoS ONE 2014; 9: e97921 (IGR: 16-1)


55601 Improvement in glaucoma patient quality of life by therapy switch to preservative-free timolol/dorzolamide fixed combination
Abegão Pinto L; Vandewalle E; Gerlier L; Stalmans I;
Ophthalmologica 2014; 231: 166-171 (IGR: 15-4)


55673 Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog
Niwano Y; Iwasawa A; Ayaki M
Ophthalmology and eye diseases 2014; 6: 5-12 (IGR: 15-4)


55709 The effectiveness of endonasal electrophoresis of neuroprotective agents used in the rehabilitative treatment of the patients presenting with primary open angle glaucoma
Nazarova GA; Konchugova TV; Iurova OV; Sichinava NV; Turova EA; Rassulova MA; Morozova NE
Voprosy kurortologii, fizioterapii, i lechebno? fizichesko? kultury 2013; 0: 27-30 (IGR: 15-4)


55376 Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis
Suzuki K; Teranishi S; Sagara T; Yoshino H; Nakayama M; Enoki M; Nuno Y; Hirano S; Wakuta M; Takahashi N; Tokuhisa K; Kondo Y; Shiraishi R; Ishida Y; Sonoda KH;
Journal of Glaucoma 2015; 24: e145-e150 (IGR: 15-4)


55170 In vivo performance of a drug-eluting contact lens to treat glaucoma for a month
Ciolino JB; Stefanescu CF; Ross AE; Salvador-Culla B; Cortez P; Ford EM; Wymbs KA; Sprague SL; Mascoop DR; Rudina SS; Trauger SA; Cade F; Kohane DS
Biomaterials 2014; 35: 432-439 (IGR: 15-4)


55090 Development of inclusion complex of brinzolamide with hydroxypropyl-β-cyclodextrin
Zhang Y; Ren K; He Z; Li H; Chen T; Lei Y; Xia S; He G; Xie Y; Zheng Y; Song X
Carbohydrate polymers 2013; 98: 638-643 (IGR: 15-4)


55298 Biodegradable in situ gelling delivery systems containing pilocarpine as new antiglaucoma formulations: effect of a mercaptoacetic acid/N-isopropylacrylamide molar ratio
Lai JY
Drug design, development and therapy 2013; 7: 1273-1285 (IGR: 15-4)


55757 Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation
Franca JR; Foureaux G; Fuscaldi LL; Ribeiro TG; Rodrigues LB; Bravo R; Castilho RO; Yoshida MI; Cardoso VN; Fernandes SO; Cronemberger S; Ferreira AJ; Faraco AA
PLoS ONE 2014; 9: e95461 (IGR: 15-4)


55148 Molecular dynamic simulations of ocular tablet dissolution
Ru Q; Fadda HM; Li C; Paul D; Khaw PT; Brocchini S; Zloh M
Journal of Chemical Information and Modeling 2013; 53: 3000-3008 (IGR: 15-4)


55748 Formulation and In-vitro Characterization of Sustained Release Matrix Type Ocular Timolol Maleate Mini-Tablet
Mortazavi SA; Jafariazar Z; Ghadjahani Y; Mahmoodi H; Mehtarpour F
Iranian journal of pharmaceutical research : IJPR 2014; 13: 19-27 (IGR: 15-4)


55443 Acetazolamide encapsulated dendritic nano-architectures for effective glaucoma management in rabbits
Mishra V; Jain NK
International Journal of Pharmaceutics 2014; 461: 380-390 (IGR: 15-4)


55203 Glaucoma and dry eye. Current concepts and future perspectives
Steven P; Cursiefen C
Ophthalmologe 2013; 110: 1155-1159 (IGR: 15-4)


55440 Probing influence of methodological variation on active loading of acetazolamide into nanoliposomes: biophysical, in vitro, ex vivo, in vivo and rheological investigation
Pisal PB; Joshi MA; Padamwar MN; Patil SS; Pokharkar VB
International Journal of Pharmaceutics 2014; 461: 82-88 (IGR: 15-4)


55211 Chick chorioallantoic membrane model for in ovo evaluation of timolol maleate-brimonidine tartrate ocular inserts
Ravindran VK; Repala S; Subadhra S; Appapurapu AK
Drug Delivery 2014; 21: 307-314 (IGR: 15-4)


55672 Changes in the morphological and functional patterns of the ocular surface in patients treated with prostaglandin analogues after the use of TSP 0.5%® preservative-free eyedrops: a prospective, multicenter study
Iester M; Oddone F; Fogagnolo P; Frezzotti P; Figus M;
Ophthalmic Research 2014; 51: 146-152 (IGR: 15-4)


55342 How ocular surface disease impacts the glaucoma treatment outcome
Kaštelan S; Tomić M; Metež Soldo K; Salopek-Rabatić J
BioMed research international 2013; 2013: 696328 (IGR: 15-4)


55232 Meta analysis about the efficacy and safety of anti-ocular hypertension eye drops without benzalkonium chloride
Wang YQ; Wang X; Liu P
Asian Pacific journal of tropical medicine 2013; 6: 1004-1008 (IGR: 15-4)


55321 Benzalkonium chloride and glaucoma
Rasmussen CA; Kaufman PL; Kiland JA
Journal of Ocular Pharmacology and Therapeutics 2014; 30: 163-169 (IGR: 15-4)


55729 Potential use of niosomal hydrogel as an ocular delivery system for atenolol
Abu Hashim II; El-Dahan MS; Yusif RM; Abd-Elgawad AE; Arima H
Biological & Pharmaceutical Bulletin 2014; 37: 541-551 (IGR: 15-4)


55467 In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells
Kim EJ; Kim YH; Kang SH; Lee KW; Park YJ
Korean Journal of Ophthalmology 2013; 27: 446-453 (IGR: 15-4)


55642 In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma
Katiyar S; Pandit J; Mondal RS; Mishra AK; Chuttani K; Aqil M; Ali A; Sultana Y
Carbohydrate polymers 2014; 102: 117-124 (IGR: 15-4)


55339 Development of dorzolamide loaded 6-o-carboxymethyl chitosan nanoparticles for open angle glaucoma
Shinde U; Ahmed MH; Singh K
Journal of Drug Delivery 2013; 2013: 562727 (IGR: 15-4)


55316 Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops
Rosin LM; Bell NP
Clinical Ophthalmology 2013; 7: 2131-2135 (IGR: 15-4)


55495 Development and characterization of nano-fiber patch for the treatment of glaucoma
Gagandeep ; Garg T; Malik B; Rath G; Goyal AK
European Journal of Pharmaceutical Sciences 2014; 53: 10-16 (IGR: 15-4)


55384 Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine
Kim NJ; Harris A; Gerber A; Tobe LA; Amireskandari A; Huck A; Siesky B
British Journal of Ophthalmology 2014; 98: 427-431 (IGR: 15-4)


54431 Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity
Lee SY; Wong TT; Chua J; Boo C; Soh YF; Tong L
Eye 2013; 27: 1142-1150 (IGR: 15-3)


54695 In vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma
Frezzotti P; Fogagnolo P; Haka G; Motolese I; Iester M; Bagaglia SA; Mittica P; Menicacci C; Rossetti L; Motolese E
Acta Ophthalmologica 2014; 92: e133-e140 (IGR: 15-3)


54451 Scanning electron microscopy applied to impression cytology for conjunctival damage from glaucoma therapy
Cennamo G; Forte R; Del Prete S; Cardone D
Cornea 2013; 32: 1227-1231 (IGR: 15-3)


54564 Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
Shafiee A; Bowman LM; Hou E; Hosseini K
Clinical Ophthalmology 2013; 7: 1549-1556 (IGR: 15-3)


54488 Relative Efficacy and Safety of Preservative-free Latanoprost (T2345) for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: An Adjusted Indirect Comparison Meta-Analysis of Randomized Clinical Trials
Cucherat M; Stalmans I; Rouland JF
Journal of Glaucoma 2014; 23: e69-e75 (IGR: 15-3)


54858 Ocular surface evaluation in patients treated with a fixed combination of prostaglandin analogues with 0.5% timolol maleate topical monotherapy: a randomized clinical trial
Russ HH; Nogueira-Filho PA; Barros Jde N; Faria NV; Montiani-Ferreira F; Gomes JÁ,; Mello PA
Clinics 2013; 68: 1318-1324 (IGR: 15-3)


54664 Investigation on novel chitosan nanoparticle-aptamer complexes targeting TGF-β receptor II
Chen X; Zhu X; Li L; Xian G; Wang W; Ma D; Xie L
International Journal of Pharmaceutics 2013; 456: 499-507 (IGR: 15-3)


54844 The effects of ocular hypotensive drugs on the cornea: an in vivo analysis with confocal microscopy
Ferná,ndez Jimé,nez-Ortiz H; Toledano Ferná,ndez N; Ferná,ndez Escamez CS; Perucho Martinez S; Crespo Carballé,s MJ
Archivos de la Sociedad Espa˝ola de Oftalmologia 2013; 88: 423-432 (IGR: 15-3)


54769 Critical Assessment of Implantable Drug Delivery Devices in Glaucoma Management
Manickavasagam D; Oyewumi MO
Journal of Drug Delivery 2013; 2013: 895013 (IGR: 15-3)


54528 Novel bioadhesive hyaluronan-itaconic acid crosslinked films for ocular therapy
Calles JA; Tá,rtara LI; Lopez-Garcí,a A; Diebold Y; Palma SD; Vallé,s EM
International Journal of Pharmaceutics 2013; 455: 48-56 (IGR: 15-3)


54735 Development, in vitro and in vivo characterization of Eudragit RL 100 nanoparticles for improved ocular bioavailability of acetazolamide
Verma P; Gupta RN; Jha AK; Pandey R
Drug Delivery 2013; 20: 269-276 (IGR: 15-3)


54573 Effect of preservative-free tafluprost on keratocytes, sub-Basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group
Rossi GC; Blini M; Scudeller L; Ricciardelli G; Depolo L; Amisano A; Bossolesi L; Pasinetti GM; Bianchi PE
Journal of Ocular Pharmacology and Therapeutics 2013; 29: 821-825 (IGR: 15-3)


54746 Poly-(cyclo)dextrins as ethoxzolamide carriers in ophthalmic solutions and in contact lenses
Garcí,a-Ferná,ndez MJ; Tabary N; Martel B; Cazaux F; Oliva A; Taboada P; Concheiro A; Alvarez-Lorenzo C
Carbohydrate polymers 2013; 98: 1343-1352 (IGR: 15-3)


54757 The prevalence of ocular surface complaints in Brazilian patients with glaucoma or ocular hypertension
Costa VP; Marcon IM; Galvã,o Filho RP; Malta RF
Arquivos Brasileiros de Oftalmologia 2013; 76: 221-225 (IGR: 15-3)


54861 Signs and symptoms of ocular surface disease in patients on topical intraocular pressure-lowering therapy
Gomes B; Turiel PR; Marques FP; Bernardo FP; Safady MV; Portes AL; Santhiago MR
Arquivos Brasileiros de Oftalmologia 2013; 76: 282-287 (IGR: 15-3)


54415 Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study
Singh J; Chhabra G; Pathak K
Drug Development and Industrial Pharmacy 2014; 40: 1223-1232 (IGR: 15-3)


54624 Influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucoma
Tomić M; Ka&scaron,telan S; Soldo KM; Salopek-Rabatić
BioMed research international 2013; 2013: 603782 (IGR: 15-3)


54533 A potential carrier based on liquid crystal nanoparticles for ophthalmic delivery of pilocarpine nitrate
Li J; Wu L; Wu W; Wang B; Wang Z; Xin H; Xu Q
International Journal of Pharmaceutics 2013; 455: 75-84 (IGR: 15-3)


54466 Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma
Kashiwagi K; Ito K; Haniuda H; Ohtsubo S; Takeoka S
Investigative Ophthalmology and Visual Science 2013; 54: 5629-5637 (IGR: 15-3)


54517 Iatrogenic dry eye disease: an eledoisin/carnitine and osmolyte drops study
Nebbioso M; Evangelista M; Librando A; Plateroti AM; Pescosolido N
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2013; 67: 659-663 (IGR: 15-3)


54793 In vitro characterization of a controlled-release ocular insert for delivery of brimonidine tartrate
Mealy JE; Fedorchak MV; Little SR
Acta biomaterialia 2014; 10: 87-93 (IGR: 15-3)


54348 Sustained release of matrix metalloproteinase-3 to trabecular meshwork cells using biodegradable PLGA microparticles
Turturro S; Sunoqrot S; Ying H; Hong S; Yue BY
Molecular pharmaceutics 2013; 10: 3023-3032 (IGR: 15-3)


54785 Physicochemical and Pharmacological Investigation of Topical Ocular w/o Microemulsion of Timolol Maleate for Treatment of Glaucoma
Hegde RR; Bhattacharya SS; Verma A; Ghosh A
Current Eye Research 2014; 39: 155-163 (IGR: 15-3)


54526 Long acting betaxolol ocular inserts based on polymer composite
Gevariya HB; Patel JK
Current Drug Delivery 2013; 10: 384-393 (IGR: 15-3)


53946 Apoptotic effects of topical antiglaucoma medications on conjunctival epithelium in glaucoma patients
Arici MK; Ozeç AV; Dursun A; Toker MI; Erdogan H
European Journal of Ophthalmology 2013; 0: 0 (IGR: 15-2)


54040 Tear film status in glaucoma patients
Jandroković S; Suić SP; Kordić R; Kuzman T; Petricek I
Collegium Antropologicum 2013; 37: 137-140 (IGR: 15-2)


53795 Evaluation of Ocular Surface Disease in Patients with Glaucoma
Mathews PM; Ramulu PY; Friedman DS; Utine CA; Akpek EK
Ophthalmology 2013; 120: 2241-2248 (IGR: 15-2)


53856 An Effective Prodrug Strategy to Selectively Enhance Ocular Exposure of a Cannabinoid Receptor (CB1/2) Agonist
Mainolfi N; Powers J; Amin J; Long D; Lee W; McLaughlin ME; Jaffee B; Brain CT; Elliott J; Sivak JM
Journal of Medicinal Chemistry 2013; 0: (IGR: 15-2)


53739 Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension
Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
British Journal of Ophthalmology 2013; 97: 1510-1515 (IGR: 15-2)


53875 Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
Day DG; Walters TR; Schwartz GF; Mundorf TK; Liu C; Schiffman RM; Bejanian M
British Journal of Ophthalmology 2013; 97: 989-993 (IGR: 15-2)


53925 Novel Topical Ophthalmic Formulations for Management of Glaucoma
Ibrahim MM; Abd-Elgawad AE; Soliman OA; Jablonski MM
Pharmaceutical Research 2013; 30: 2818-2831 (IGR: 15-2)


53587 Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study
Mastropasqua L; Agnifili L; Fasanella V; Curcio C; Ciabattoni C; Mastropasqua R; Toto L; Ciancaglini M
Acta Ophthalmologica 2013; 91: e397-e405 (IGR: 15-2)


54013 Ophthalmic Delivery of Brinzolamide by Liquid Crystalline Nanoparticles: In Vitro and In Vivo Evaluation
Wu W; Li J; Wu L; Wang B; Wang Z; Xu Q; Xin H
AAPS PharmSciTech 2013; 14: 1063-1071 (IGR: 15-2)


54050 Influence on ocular surface and intraocular pressure of switching from preservative-containing to preservative-free carteolol hydrochloride ophthalmic solution
Chikama T; Araie M; Nishida T
Nippon Ganka Gakkai Zasshi 2013; 117: 419-426 (IGR: 15-2)


53532 Liposomal diltiazem HCl as ocular drug delivery system for glaucoma
Mokhtar Ibrahim M; Tawfique SA; Mahdy MM
Drug Development and Industrial Pharmacy 2014; 40: 765-773 (IGR: 15-2)


53606 Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues
Ensign LM; Henning A; Schneider CS; Maisel K; Wang YY; Porosoff MD; Cone R; Hanes J
Molecular pharmaceutics 2013; 10: 2176-2182 (IGR: 15-2)


52476 Conjunctivochalasis as a Contributing Factor for the Development of Ocular Surface Disease in Medically Treated Glaucoma Patients
Kocabeyoglu S; Mocan MC; Irkec M; Orhan M; Karakaya J
Journal of Glaucoma 2014; 23: 333-336 (IGR: 15-1)


52537 The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate
Arnold JJ; Hansen MS; Gorman GS; Inoue T; Rao V; Spellen S; Hunsinger RN; Chapleau CA; Pozzo-Miller L; Stamer WD; Challa P
Investigative Ophthalmology and Visual Science 2013; 54: 1118-1126 (IGR: 15-1)


53184 Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins
Giménez-Gómez R; García-Catalán MR; Gallardo-Galera JM
Archivos de la Sociedad Espa˝ola de Oftalmologia 2013; 88: 88-91 (IGR: 15-1)


52957 Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry
Desbenoit N; Schmitz-Afonso I; Baudouin C; Laprévote O; Touboul D; Brignole-Baudouin F; Brunelle A
Analytical and bioanalytical chemistry 2013; 405: 4039-4049 (IGR: 15-1)


52484 Preservative-free treatment in glaucoma: who, when, and why
Stalmans I; Sunaric Mégevand G; Cordeiro MF; Hommer A; Rossetti L; Goñi F; Heijl A; Bron A
European Journal of Ophthalmology 2013; 23: 0 (IGR: 15-1)


52600 Nanotechnology and glaucoma: little particles for a big disease
Pita-Thomas DW; Goldberg JL
Current Opinions in Ophthalmology 2013; 24: 130-135 (IGR: 15-1)


52947 Preformulation study of methazolamide for topical ophthalmic delivery: physicochemical properties and degradation kinetics in aqueous solutions
Jiang S; Wang F; Zhu S; Zhang X; Guo Z; Li R; Xu Q
International Journal of Pharmaceutics 2013; 448: 390-393 (IGR: 15-1)


52814 Nanotechnology approaches for ocular drug delivery
Xu Q; Kambhampati SP; Kannan RM
Middle East African Journal of Ophthalmology 2013; 20: 26-37 (IGR: 15-1)


52417 Safety Assessment of Subconjunctivally Implanted Devices Containing Latanoprost in Dutch-Belted Rabbits
Jessen BA; Shiue MH; Kaur H; Miller P; Leedle R; Guo H; Evans M
Journal of Ocular Pharmacology and Therapeutics 2013; 29: 574-585 (IGR: 15-1)


52437 Preservative Exposure and Surgical Outcomes in Glaucoma Patients: The PESO Study
Boimer C; Birt CM
Journal of Glaucoma 2013; 22: 730-735 (IGR: 15-1)


52612 Glaucoma therapy and ocular surface disease: current literature and recommendations
Anwar Z; Wellik SR; Galor A
Current Opinions in Ophthalmology 2013; 24: 136-143 (IGR: 15-1)


52966 Comparative cross-sectional analysis of the effects of topical antiglaucoma drugs on the ocular surface
Lee S; Kim MK; Choi HJ; Wee WR; Kim DM
Advances in Therapy 2013; 30: 420-429 (IGR: 15-1)


52452 Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy
Jain K; Kumar RS; Sood S; Dhyanandhan G
Current Drug Delivery 2013; 10: 493-499 (IGR: 15-1)


53193 Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
Lanzl I; Hamacher T; Rosbach K; Ramez MO; Rothe R; Růžičková E; Karhanová M; Kimmich F
Clinical Ophthalmology 2013; 7: 901-910 (IGR: 15-1)


52816 Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension
Crichton AC; Vold S; Williams JM; Hollander DA
Advances in Therapy 2013; 30: 260-270 (IGR: 15-1)


53079 A comparative study of the safety and efficacy effect of 5-fluorouracil or mitomycin C mounted biological delivery membranes in a rabbit model of glaucoma filtration surgery
Wu Z; Li S; Wang N; Liu W
Clinical Ophthalmology 2013; 7: 655-662 (IGR: 15-1)


51786 Conjunctival modifications induced by medical and surgical therapies in patients with glaucoma
Mastropasqua L; Agnifili L; Mastropasqua R; Fasanella V
Current opinion in pharmacology 2013; 13: 56-64 (IGR: 14-4)


51847 Homemade lyophilized cross linking amniotic sustained-release drug membrane with anti-scarring role after filtering surgery in rabbit eyes
Li W; Chen WJ; Liu W; Liang L; Zhang MC
International Journal of Ophthalmology 2012; 5: 555-561 (IGR: 14-4)


51870 Acceptance, attitudes, and beliefs of Singaporean Chinese toward an ocular implant for glaucoma drug delivery
Foo RC; Lamoureux EL; Wong RC; Ho SW; Chiang PP; Rees G; Aung T; Wong TT
Investigative Ophthalmology and Visual Science 2012; 53: 8240-8245 (IGR: 14-4)


52049 Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients
Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
European Journal of Ophthalmology 2012; 0: 0 (IGR: 14-4)


51887 Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma
Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
British Journal of Ophthalmology 2013; 97: 196-200 (IGR: 14-4)


51718 Acute effects of glaucoma medications and benzalkonium chloride on pre-adipocyte proliferation and adipocyte cytotoxicity in vitro
Seibold LK; Ammar DA; Kahook MY
Current Eye Research 2013; 38: 70-74 (IGR: 14-4)


52005 Short-term effect of topical brinzolamide-timolol fixed combination on ocular surface of glaucoma patients
Firat PG; Samdanci E; Doganay S; Cavdar M; Sahin N; Gunduz A
International Journal of Ophthalmology 2012; 5: 714-718 (IGR: 14-4)


51781 Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses
Jung HJ; Abou-Jaoude M; Carbia BE; Plummer C; Chauhan A
Journal of Controlled Release 2013; 165: 82-89 (IGR: 14-4)


51859 Preservative-containing eye drops and adherence in ophthalmological practice
Lanzl I; Kaercher T
Ophthalmologe 2012; 109: 1087-1092 (IGR: 14-4)


51973 Hybrid Dendrimer Hydrogel/Poly(Lactic-Co-Glycolic Acid) Nanoparticle Platform: An Advanced Vehicle for Topical Delivery of Antiglaucoma Drugs and a Likely Solution to Improving Compliance and Adherence in Glaucoma Management
Yang H; Leffler CT
Journal of Ocular Pharmacology and Therapeutics 2013; 29: 166-172 (IGR: 14-4)


52099 Decrease in Corneal Damage due to Benzalkonium Chloride by the Addition of Sericin into Timolol Maleate Eye Drops
Nagai N; Ito Y; Okamoto N; Shimomura Y
Journal of oleo science 2013; 62: 159-166 (IGR: 14-4)


51808 Nanomedicine for the treatment of retinal and optic nerve diseases
Zarbin MA; Montemagno C; Leary JF; Ritch R
Current opinion in pharmacology 2013; 13: 134-148 (IGR: 14-4)


51964 Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study
Aihara M; Oshima H; Araie M;
Acta Ophthalmologica 2013; 91: e7-e14 (IGR: 14-4)


51857 Preservatives from the perspective of glaucoma surgery
Thieme H; van der Velden KK
Ophthalmologe 2012; 109: 1073-1076 (IGR: 14-4)


51858 Influence of dry eye syndrome on glaucoma diagnostic procedures
Rüfer F; Erb C
Ophthalmologe 2012; 109: 1082-1086 (IGR: 14-4)


51746 The triblock copolymers hydrogel through intracameral injection may be a new potential ophthalmic drug delivery with antiscaring drugs after glaucoma filtration surgery
Qiao Y; Qin G; Yu L
Medical Hypotheses 2013; 80: 23-25 (IGR: 14-4)


51897 A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits
Brignole-Baudouin F; Desbenoit N; Hamm G; Liang H; Both JP; Brunelle A; Fournier I; Guerineau V; Legouffe R; Stauber J; Touboul D; Wisztorski M; Salzet M; Laprevote O; Baudouin C
PLoS ONE 2012; 7: e50180 (IGR: 14-4)


51890 Extended Release of Timolol from Nanoparticle-Loaded Fornix Insert for Glaucoma Therapy
Jung HJ; Chauhan A
Journal of Ocular Pharmacology and Therapeutics 2013; 29: 229-235 (IGR: 14-4)


51734 New concepts for glaucoma implants - controlled aqueous humor drainage, encapsulation prevention and local drug delivery
Schmidt W; Kastner C; Sternberg K; Allemann R; Lobler M; Guthoff R; Schmitz KP
Current Pharmaceutical Biotechnology 2013; 14: 98-111 (IGR: 14-4)


51132 Differences in basement membrane zone components of normal conjunctiva, conjunctiva in glaucoma and normal skin
Messmer EM; Valet VM; Kampik A
Acta Ophthalmologica 2012; 90: e476-e481 (IGR: 14-3)


51341 Conjunctival inflammation in patients under topical glaucoma treatment with indication to surgery
Furtado JM; Paula JS; Soares EG; Dhegaide NH; Rocha EM; Donadi E; Rodrigues Mde L
Acta cirúrgica brasileira / Sociedade Brasileira para Desenvolvimento Pesquisa em Cirurgia 2012; 27: 732-735 (IGR: 14-3)


50883 The relationship between subbasal nerve morphology and corneal sensation in ocular surface disease
Labbé A; Alalwani H; Van Went C; Brasnu E; Georgescu D; Baudouin C
Investigative Ophthalmology and Visual Science 2012; 53: 4926-4931 (IGR: 14-3)


51253 Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
Inoue K; Iwasa M; Wakakura M; Tomita G
Clinical Ophthalmology 2012; 6: 1315-1319 (IGR: 14-3)


51391 Efficacy and Tolerability of Preservative-free Tafluprost 0.0015 % in the Treatment of Glaucoma and Ocular Hypertension
Karhanová M; Mlčák P; Fryšák Z; Marešová K
?eska a Slovenska Oftalmologie 2012; 68: 150-155 (IGR: 14-3)


50884 Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets
Nakagawa S; Usui T; Yokoo S; Omichi S; Kimakura M; Mori Y; Miyata K; Aihara M; Amano S; Araie M
Investigative Ophthalmology and Visual Science 2012; 53: 5154-5160 (IGR: 14-3)


51162 Design of an implantable device for ocular drug delivery
Lee JH; Pidaparti RM; Atkinson GM; Moorthy RS
Journal of Drug Delivery 2012; 2012: 527516 (IGR: 14-3)


51044 Investigation of surfactants suitable for stabilizing of latanoprost
Ochiai A; Ohkuma M; Danjo K
International Journal of Pharmaceutics 2012; 436: 732-737 (IGR: 14-3)


50989 Preparation and characterization of polymeric and lipid nanoparticles of pilocarpine HCl for ocular application
Lütfi G; Müzeyyen D
Pharmaceutical Development and Technology 2013; 18: 701-709 (IGR: 14-3)


51140 Characterisation of ilomastat for prolonged ocular drug release
Parkinson G; Gaisford S; Ru Q; Lockwood A; Khalili A; Sheridan R; Khaw PT; Brocchini S; Fadda HM
AAPS PharmSciTech 2012; 13: 1063-1072 (IGR: 14-3)


50556 Tear Film Osmolarity in Patients Treated for Glaucoma or Ocular Hypertension
Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C
Cornea 2012; 31: 994-999 (IGR: 14-2)


50614 Stem cell-based delivery of brain-derived neurotrophic factor gene in the rat retina
Park HY; Kim JH; Sun Kim H; Park CK
Brain Research 2012; 1469: 10-23 (IGR: 14-2)


50462 Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
Ermiş SS
Clinical Ophthalmology 2012; 6: 673-678 (IGR: 14-2)


50570 Extended drug delivery by contact lenses for glaucoma therapy
Peng CC; Burke MT; Carbia BE; Plummer C; Chauhan A
Journal of Controlled Release 2012; 162: 152-158 (IGR: 14-2)


50468 Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes
Loch C; Zakelj S; Kristl A; Nagel S; Guthoff R; Weitschies W; Seidlitz A
European Journal of Pharmaceutical Sciences 2012; 47: 131-138 (IGR: 14-2)


50376 Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy
Herná,n Pé,rez de la Ossa D; Ligresti A; Gil-Alegre ME; Aberturas MR; Molpeceres J; Di Marzo V; Torres Suá,rez AI
Journal of Controlled Release 2012; 161: 927-932 (IGR: 14-2)


50490 A Comparative Study of a Preservative-Free Latanoprost Cationic Emulsion (Catioprost(®)) and a BAK-Preserved Latanoprost Solution in Animal Models
Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
Journal of Ocular Pharmacology and Therapeutics 2012; 28: 515-523 (IGR: 14-2)


50536 A comparison of 0.1% timolol eye gel and 0.5% timolol eye drop in patients with chronic angle-closure glaucoma
Metheetrairut A; Leumsamran P; Rojananin S; Kitnarong N
Journal of the Medical Association of Thailand 2012; 95: S116-122 (IGR: 14-2)


50214 Single and mixed poloxamine micelles as nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy
Ribeiro A; Sosnik A; Chiappetta DA; Veiga F; Concheiro A; Alvarez-Lorenzo C
Journal of the Royal Society, Interface / the Royal Society 2012; 9: 2059-2069 (IGR: 14-2)


50525 Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients
Rossi GC; Pasinetti GM; Raimondi M; Ricciardelli G; Scudeller L; Blini M; Amisano A; Bianchi PE
Expert Opinion on Drug Safety 2012; 11: 519-525 (IGR: 14-2)


50583 Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension
Baudouin C; Renard JP; Nordmann JP; Denis P; Lachkar Y; Sellem E; Rouland JF; Jeanbat V; Boué,e S
European Journal of Ophthalmology 2012; 0: 0 (IGR: 14-2)


50527 Benzalkonium chloride breaks down conjunctival immunological tolerance in a murine model
Galletti JG; Gabelloni ML; Morande PE; Sabbione F; Vermeulen ME; Trevani AS; Giordano MN
Mucosal immunology 2013; 6: 24-34 (IGR: 14-2)


49184 Comparison of the Long-Term Effects of Various Topical Antiglaucoma Medications on Meibomian Glands
Arita R; Maeda S; Maeda K; Furuta A; Tomidokoro A; Aihara M; Amano S
Cornea 2012; 31: 1229-1234 (IGR: 14-1)


49353 A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma
Garcia-Feijoo J; Sampaolesi JR
Clinical Ophthalmology 2012; 6: 441-446 (IGR: 14-1)


49154 Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication
O',Hare F; Ghosh S; Lamoureux E; Vajpayee RB; Crowston JG
Clinical and Experimental Ophthalmology 2012; 40: 675-681 (IGR: 14-1)


48452 Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
Journal of Glaucoma 2012; 21: 60-64 (IGR: 14-1)


49003 Randomized Clinical Trial of the Efficacy and Safety of Preservative-free Tafluprost and Timolol in Patients With Open-Angle Glaucoma or Ocular Hypertension
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
American Journal of Ophthalmology 2012; 153: 1187-1196 (IGR: 14-1)


48963 Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma
Janulevi?ien? I; Derka? I; Paulauskait? R; Kuzmien? L
Clinical Ophthalmology 2012; 6: 103-109 (IGR: 14-1)


48735 Comparison of human ocular distribution of bimatoprost and latanoprost
Ichhpujani P; Katz LJ; Hollo G; Shields CL; Shields JA; Marr B; Eagle R; Alvim H; Wizov SS; Acheampong A; Chen J; Wheeler LA
Journal of Ocular Pharmacology and Therapeutics 2012; 28: 134-145 (IGR: 14-1)


48966 Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye
Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS
International Journal of Nanomedicine 2012; 7: 123-131 (IGR: 14-1)


49097 Overview of the BAK-free travoprost /timolol BAK-free fixed combination
Konstas AG; Quaranta L; Realini T
Expert Opinion in Pharmacotherapy 2012; 13: 757-766 (IGR: 14-1)


48854 Thermoreversible gel for delivery of activin receptor-like kinase 5 inhibitor SB-505124 for glaucoma filtration surgery
Sutariya V; Miladore N; Geldenhuys W; Bhatia D; Wehrung D; Nakamura H
Pharmaceutical Development and Technology 2013; 18: 957-962 (IGR: 14-1)


48672 Effect of prostaglandin analogues on tear proteomics and expression of cytokines and matrix metalloproteinases in the conjunctiva and cornea
Lopilly Park HY; Kim JH; Lee KM; Park CK
Experimental Eye Research 2012; 94: 13-21 (IGR: 14-1)


48602 Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation
Aburahma MH; Mahmoud AA
AAPS PharmSciTech 2011; 12: 1335-1347 (IGR: 14-1)


49051 Drug delivery by contact lens in spontaneously glaucomatous dogs
Peng CC; Ben-Shlomo A; MacKay EO; Plummer CE; Chauhan A
Current Eye Research 2012; 37: 204-211 (IGR: 14-1)


48818 A gelatin-g-poly(N-isopropylacrylamide) biodegradable in situ gelling delivery system for the intracameral administration of pilocarpine
Lai JY
Biomaterials 2012; 33: 2372-2387 (IGR: 14-1)


49144 Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury?
Lockington D; Macdonald EC; Stewart P; Young D; Caslake M; Ramaesh K
Eye 2012; 26: 734-741 (IGR: 14-1)


48791 Timogel® vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance
Rolle T; Curto D; Alovisi C; Franzone M; Brogliatti B; Grignolo FM
European Journal of Ophthalmology 0; 22: 28-33 (IGR: 14-1)


48823 Biodegradable Microfabricated Plug-Filters for Glaucoma Drainage Devices
Maleki T; Chitnis G; Park J; Cantor LB; Ziaie B
IEEE Transactions on Bio-Medical Engineering 2012; 59: 1507-1513 (IGR: 14-1)


48653 A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry
Kahook MY; Fechtner RD; Katz LJ; Noecker RJ; Ammar DA
Current Eye Research 2012; 37: 101-108 (IGR: 14-1)


49318 Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb
Lallemand F; Daull P; Benita S; Buggage R; Garrigue JS
Journal of Drug Delivery 2012; 2012: 604204 (IGR: 14-1)


49081 Effects of long-term topical anti-glaucoma medications on meibomian glands
Arita R; Maeda S; Maeda K; Furuta A; Tomidokoro A; Aihara M; Amano S
Graefe's Archive for Clinical and Experimental Ophthalmology 2012; 250: 1181-1185 (IGR: 14-1)


49016 New Mucoadhesive Chitosan Film for Ophthalmic Drug Delivery of Timolol Maleate: In Vivo Evaluation
Fulgê,ncio GD; Viana FA; Ribeiro RR; Yoshida MI; Faraco AG; Cunha-Jú,nior AD
Journal of Ocular Pharmacology and Therapeutics 2012; 28: 350-358 (IGR: 14-1)


49041 Generic versus brand-name North American topical glaucoma drops
Mammo ZN; Flanagan JG; Trope GE
Canadian Journal of Ophthalmology 2012; 47: 55-61 (IGR: 14-1)


48948 Topical drug delivery to the eye: dorzolamide
Loftsson T; Jansook P; Stefá,nsson E
Acta Ophthalmologica 2012; 90: 603-608 (IGR: 14-1)


48921 First experience with BAK-free travoprost 0.004% in topical glaucoma medication
Gado AS; MacKy TA
Clinical Ophthalmology 2012; 6: 1-4 (IGR: 14-1)


49331 Ocular surface and external filtration surgery: mutual relationships
Baudouin C
Developments in Ophthalmology 2012; 50: 64-78 (IGR: 14-1)


47862 Challenges in the clinical measurement of ocular surface disease in glaucoma patients
Pflugfelder SC; Baudouin C
Clinical Ophthalmology 2011; 5: 1575-1583 (IGR: 13-4)


48266 Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension
Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; LabbÚ A
Journal Franšais d'Ophtalmologie 2011; 34: 684-690 (IGR: 13-4)


47931 Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases
Schwartz GF; Kotak S; Mardekian J; Fain JM
BMC Ophthalmology 2011; 11: 14 (IGR: 13-4)


47832 Economic outcomes of glaucoma treatment with prostaglandin eye drops preserved with polyquad(registered trademark) instead of benzalkonium chloride in Germany
Gerlier L; Lamotte M; Lorenz K; Berdeaux G; Verboven Y; Pfeiffer N
Value in Health 2011; 14: A503 (IGR: 13-4)


48030 In vivo and ocular safety study of dorsolamide HCL ocular insert
Ghelani TK; Seth AK; Saini V; Kumar S; Yadav YC; Singhal S
Pharmacologyonline 2011; 2: 1179-1187 (IGR: 13-4)


48398 Periocular injection of in situ hydrogels containing Leu-Ile, an inducer for neurotrophic factors, promotes retinal ganglion cell survival after optic nerve injury
Nakatani M; Shinohara Y; Takii M; Mori H; Asai N; Nishimura S; Furukawa-Hibi Y; Miyamoto Y; Nitta A
Experimental Eye Research 2011; 93: 873-879 (IGR: 13-4)


47824 Pharmacokinetics of pirfenidone after topical administration in rabbit eye
Sun G; Lin X; Zhong H; Yang Y; Qiu X; Ye C; Wu K; Yu M
Molecular Vision 2011; 17: 2191-2196 (IGR: 13-4)


47608 The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits
Shafaa MW; Sabra NM; Fouad RA
Biopharmaceutics and Drug Disposition 2011; 32: 507-517 (IGR: 13-4)


48336 Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells
Brignole-Baudouin F; Riancho L; Liang H; Baudouin C
Current Eye Research 2011; 36: 979-988 (IGR: 13-4)


48037 Sustained release of an Anti-Glaucoma drug: Demonstration of efficacy of a liposomal formulation in the rabbit eye
Natarajan JV; Chattopadhyay S; Ang M; Darwitan A; Foo S; Zhen M; Koo M; Wong TT; Venkatraman SS
PLoS ONE 2011; 6:9 Article Number: e24513 (IGR: 13-4)


47881 Advances in preservative-free glaucoma drops
Stefan C; Pop A; Cojocaru I
Oftalmologia 2011; 55: 3-6 (IGR: 13-4)


47683 Challenge and treatment strategy for ocular surface damage in patients with long term use of antiglaucoma drugs
He XG
Chinese Journal of Ophthalmology 2011; 47: 101-104 (IGR: 13-4)


47580 Effect of ion pairing on in vitro transcorneal permeability of a (Delta)(9)-tetrahydrocannabinol prodrug: Potential in glaucoma therapy
Hingorani T; Gul W; Elsohly M; Repka MA; Majumdar S
Journal of Pharmaceutical Sciences 2011; (IGR: 13-4)


48004 Ophthalmic preservatives: Focus on polyquaternium-1
Rolando M; Crider JY; Kahook MY
Expert Opinion on Drug Delivery 2011; 8: 1425-1438 (IGR: 13-4)


48070 Effects of antiglaucoma drugs on the ocular surface in rabbits: a fixed-combination drug versus two concomitant drugs
Cho HK; Park MH; Moon JI
Japanese Journal of Ophthalmology 2011; 55: 670-675 (IGR: 13-4)


47599 Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane
Singh KH; Shinde UA
Pharmazie 2011; 66: 594-599 (IGR: 13-4)


47779 Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma
Chong RS; Su D; Tsai A; Jiang Y; Htoon HM; Lamoureux EL; Aung T; Wong TT
Journal of Glaucoma 2011; (IGR: 13-4)


47753 Pharmacokinetics of antiglaucoma medications
Sachdev M; Yadava U; Bamrolia N
Journal of Current Glaucoma Practice 2011; 5: 21-26 (IGR: 13-4)


48002 Nanotechnology in ocular delivery: Current and future directions
Sultana Y; Maurya DP; Iqbal Z; Aqil M
Drugs of Today 2011; 47: 441-455 (IGR: 13-4)


47887 Antiglaucoma drugs: The role of preservative-free formulations
Bagnis A; Papadia M; Scotto R; Traverso CE
Saudi Journal of Ophthalmology 2011; 25: 389-394 (IGR: 13-4)


47852 Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma
Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P
European Journal of Ophthalmology 2011; 22: 34-44 (IGR: 13-4)


47835 A systematic review of observational studies of patients with ocular hypertension or glaucoma receiving long term topical eye therapies
Christova L; Cottrell S; Mudge M; Tilden D; Harvey C
Value in Health 2011; 14: A510 (IGR: 13-4)


47833 Longer term patient benefits of polyquad(registered trademark) preservative instead of benzalkonium chloride in prostaglandin eye drops: A microsimulation model in ocular hypertension and open-angle glaucoma
Gerlier L; Lamotte M; Berdeaux G; Verboven Y; Pfeiffer N
Value in Health 2011; 14: A502 (IGR: 13-4)


47812 Detection of raman spectra in ocular drugs for potential in vivo application of raman spectroscopy
Elshout M; Erckens RJ; Webers CA; Beckers HJ; Berendschot TT; de Brabander J; Hendrikse F; Schouten JS
Journal of Ocular Pharmacology and Therapeutics 2011; 27: 445-451 (IGR: 13-4)


47996 Prodrugs - An efficient way to breach delivery and targeting barriers
Huttunen KM; Rautio J
Current Topics in Medicinal Chemistry 2011; 11: 2265-2287 (IGR: 13-4)


47809 Novel ophthalmic timolol meleate liposomal-hydrogel and its improved local glaucomatous therapeutic effect in vivo
Hui-Hui Z; Qiu-Hua L; Zhi-Jun Y; Wei-San P; Shu-Fang N
Drug Delivery 2011; 18: 502-510 (IGR: 13-4)


47947 Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs
Holden CA; Tyagi P; Thakur A; Kadam R; Jadhav G; Kompella UB; Yang H
Nanomedicine: Nanotechnology, Biology, and Medicine 2011; (IGR: 13-4)


47853 Timogel((registered trademark)) vs timolol 0.5% ophthalmic solution: Efficacy, safety, and acceptance
Rolle T; Curto D; Alovisi C; Franzone M; Brogliatti B; Grignolo FM
European Journal of Ophthalmology 2011; 22: 28-33 (IGR: 13-4)


48334 Evaluation of Sustained Release of PLC-Loaded Prednisolone Acetate Microfilm on Postoperative Inflammation in an Experimental Model of Glaucoma Filtration Surgery
Ang M; Yan P; Zhen M; Foo S; Venkatraman SS; Wong TT
Current Eye Research 2011; 36: 1123-1128 (IGR: 13-4)


46458 Ocular Surface Disease and Quality of Life in Patients With Glaucoma
Skalicky SE; Goldberg I; McCluskey P
American Journal of Ophthalmology 2011; (IGR: 13-3)


46941 About ocular surface damage
Stefan C; Pop A; Cojocaru I
Oftalmologia 2011; 55: 38-40 (IGR: 13-3)


46956 Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea
Okamoto N; Ito Y; Nagai N; Murao T; Takiguchi Y; Kurimoto T; Mimura O
Journal of oleo science 2010; 59: 423-430 (IGR: 13-3)


46746 Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension
Erb C; Lanzl I; Seidova S-F; Kimmich F
Advances in Therapy 2011; 1-11 (IGR: 13-3)


46375 Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy
Kitazawa Y; Smith P; Sasaki N; Kotake S; Bae K; Iwamoto Y
Eye 2011; 25: 1161-1169 (IGR: 13-3)


47012 Benzalkonium chloride in glaucoma medications
Noecker R; Miller KV
Ocular Surface 2011; 9: 159-162 (IGR: 13-3)


46668 Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure
Checa-Casalengua P; Jiang C; Bravo-Osuna I; Tucker BA; Molina-Martinez IT; Young MJ; Herrero-Vanrell R
Journal of Controlled Release 2011; (IGR: 13-3)


47008 Nanovesicular Formulation of Brimonidine Tartrate for the Management of Glaucoma: In Vitro and In Vivo Evaluation
Maiti S; Paul S; Mondol R; Ray S; Sa B
AAPS PharmSciTech 2011; (IGR: 13-3)


46997 Evaluation of the ocular penetration of topical alpha-luminol (Galavit((registered trademark))/GVT((registered trademark)))
da Silva EG; Gionfriddo JR; Hudachek SF; Gustafson DL; Olea-Popelka FJ; Scofield VL; Powell CC; Hill AE
Veterinary Ophthalmology 2011; 14: 180-185 (IGR: 13-3)


46781 Thermosensitive in situ gel of Timolol Maleate for the treatment of open angle glaucoma
Yeole PG; Iyer D
Research Journal of Pharmaceutical, Biological and Chemical Sciences 2011; 2: 1048-1064 (IGR: 13-3)


46778 Formulation and evaluation of dorzolamide hydrochloride polymeric film
Tandale YN; Wagh VD
International Journal of PharmTech Research 2011; 3: 1817-1824 (IGR: 13-3)


47009 Brimonidine Tartrate-Eudragit Long-Acting Nanoparticles: Formulation, Optimization, In Vitro and In Vivo Evaluation
Bhagav P; Upadhyay H; Chandran S
AAPS PharmSciTech 2011; (IGR: 13-3)


46330 Managing treatment side effects: the respective roles of the active ingredient and the preservative
Aptel F; Denis P; Baudouin C
Journal Franšais d'Ophtalmologie 2011; 34: 409-412 (IGR: 13-3)


47011 Preservative use in topical glaucoma medications
Tressler CS; Beatty R; Lemp MA
Ocular Surface 2011; 9: 140-158 (IGR: 13-3)


46555 Prescribing for older adults
Boparai MK; Korc-Grodzicki B
Mount Sinai Journal of Medicine 2011; 78: 613-626 (IGR: 13-3)


46441 Sclera-choroid-RPE transport of eight ?-blockers in human, bovine, porcine, rabbit, and rat models
Kadam RS; Cheruvu NP; Edelhauser HF; Kompella UB
Investigative Ophthalmology and Visual Science 2011; 52: 5387-5399 (IGR: 13-3)


46863 Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells
Ammar DA; Kahook MY
Molecular Vision 2011; 17: 1806-1813 (IGR: 13-3)


46889 Drug delivery to the posterior segment of the eye
Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
European Journal of Ophthalmology 2011; 21: 20-26 (IGR: 13-3)


46720 In vitro and in vivo evaluation of an intraocular implant for glaucoma treatment
Natu MV; Gaspar MN; Fontes Ribeiro CA; Cabrita AM; De Sousa HC; Gil MH
International Journal of Pharmaceutics 2011; 415: 73-82 (IGR: 13-3)


46926 Benzalkonium chloride daily dose - An important criterion in glaucoma treatment
Vyborny P; Sicakova S
?eska a Slovenska Oftalmologie 2011; 67: 63-66 (IGR: 13-3)


46570 An in vitro evaluation for corneal damages by anti-glaucoma combination eye drops using human corneal epithelial cell (HCE-T)
Nagai N; Murao T; Oe K; Ito Y; Okamoto N; Shimomura Y
Yakugaku Zasshi 2011; 131: 985-991 (IGR: 13-3)


46844 Symptoms and signs of tear film dysfunction in glaucomatous patients
Valente C; Iester M; Corsi E; Rolando M
Journal of Ocular Pharmacology and Therapeutics 2011; 27: 281-285 (IGR: 13-3)


46451 A Video Study of Drop Instillation in Both Glaucoma and Retina Patients with Visual Impairment
Hennessy AL; Katz J; Covert D; Kelly CA; Suan EP; Speicher MA; Sund NJ; Robin AL
American Journal of Ophthalmology 2011; (IGR: 13-3)


45442 The influence of ocular surface diseases in the management of glaucoma
Van Went C; Brasnu E; Hamard P; Baudouin C; LabbÚ A
Journal Franšais d'Ophtalmologie 2011; 34: 230-237 (IGR: 13-2)


45879 Current dilemmas and controversies in allergic contact dermatitis to ophthalmic medications
Novitskaya ES; Dean SJ; Craig JP; Alexandroff AB
Clinics in Dermatology 2011; 29: 295-299 (IGR: 13-2)


45881 Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells
Ammar DA; Noecker RJ; Kahook MY
Advances in Therapy 2011; 28: 501-510 (IGR: 13-2)


45454 Comparison of the In Vitro Tolerance and In Vivo Efficacy of Traditional Timolol Maleate Eye Drops versus New Formulations with Bioadhesive Polymers
AndrÚs-Guerrero V; Vicario-de-la-Torre M; Molina-MartÝnez IT; BenÝtez-Del-Castillo JM; GarcÝa-Feijoo J; Herrero-Vanrell R
Investigative Ophthalmology and Visual Science 2011; 52: 3548-3556 (IGR: 13-2)


46315 Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: Powerful eye health application technique and therapeutic platform
Babizhayev MA
Drug Testing and Analysis 2011; (IGR: 13-2)


45911 Force requirements in topical medicine usethe squeezability factor
Connor AJ; Severn PS
Eye 2011; 25: 466-469 (IGR: 13-2)


46259 Corneal cell culture models: A tool to study corneal drug absorption
Dey S
Expert Opinion on Drug Metabolism and Toxicology 2011; 7: 529-532 (IGR: 13-2)


45937 Enhancement of anti-glaucoma potential by novel ocular drug delivery system
Gupta S; Gilhotra RM
International Journal of Pharmacy and Pharmaceutical Sciences 2011; 3: 55-58 (IGR: 13-2)


46186 Enhanced Solubility, Stability, and Transcorneal Permeability of Delta-8-Tetrahydrocannabinol in the Presence of Cyclodextrins
Hippalgaonkar K; Gul W; Elsohly MA; Repka MA; Majumdar S
AAPS PharmSciTech 2011; (IGR: 13-2)


45645 Efficacy and safety of topical travoprost with sofzia(registered trademark) preservative for Japanese glaucoma patients
Kanamoto T; Kiuchi Y; Suehiro T; Nakano T; Nakano Y; Hirota A; Miyata A
Hiroshima Journal of Medical Sciences 2010; 59: 71-75 (IGR: 13-2)


45938 Effect of a single drop of Latanoprost ophthalmic gel on intra ocular pressure in the treatment of glaucoma
Kulkarni SV; Sandeep HN; Shankar MS; Ranjit Kumar P; Someshwara Rao B; Ramesh B; Ashok Kumar PA
International Journal of Pharmaceutical Sciences 2010; 2: 429-435 (IGR: 13-2)


45917 Novel drug delivery systems for glaucoma
Lavik E; Kuehn MH; Kwon YH
Eye 2011; 25: 578-586 (IGR: 13-2)


46095 Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy
Monaco G; Cacioppo V; Consonni D; Troiano P
European Journal of Ophthalmology 2011; 21: 243-250 (IGR: 13-2)


46266 A poly((epsilon)-caprolactone) device for sustained release of an anti-glaucoma drug
Natu MV; Gaspar MN; Ribeiro CAF; Correia IJ; Silva D; De Sousa HC; Gil MH
Biomedical Materials 2011; 6: 025003 (IGR: 13-2)


45940 Formulation and evaluation of Latanoprost ophthalmic gels
Sandeep HN; Kulkarni SV; Vinod R; Shankar MS; Someshwara Rao B; Ashok Kumar P
Journal of Global Pharma Technology 2010; 2: 35-39 (IGR: 13-2)


46101 Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue
Servat JJ; Bernardino CR
Drugs and Aging 2011; 28: 267-282 (IGR: 13-2)


46292 A timely review of state-of-the-art chronopharmaceuticals synchronized with biological rhythms
Sewlall S; Pillay V; Danckwerts MP; Choonara YE; Ndesendo VM; Du Toit LC
Current Drug Delivery 2010; 7: 370-388 (IGR: 13-2)


46288 An updated patent review on ocular drug delivery systems with potential for commercial viability
Srivastava R; Pathak K
Recent Patents on Drug Delivery and Formulation 2011; 5: 146-162 (IGR: 13-2)


46122 Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects
Terai N; Muller-Holz M; Spoerl E; Pillunat LE
Clinical Ophthalmology 2011; 5: 517-525 (IGR: 13-2)


46211 Polymers and drugs suitable for the development of a drug delivery drainage system in glaucoma surgery
Lobler M; Sternberg K; Stachs O; Allemann R; Grabow N; Roock A; Kreiner CF; Streufert D; Neffe AT; Hanh BD
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2011; 97: 388-395 (IGR: 13-2)


28163 The effects of topical antiglaucoma on conjunctival impression cytology in malay glaucoma patients
Hoi TS; Nor MM; Hitam WHW; Jaafar H; Shatriah I
International Medical Journal 2010; 17: 271-274 (IGR: 13-1)


28151 Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
Katz G; Springs CL; Craven ER; Montecchi-Palmer M
Clinical Ophthalmology 2010; 4: 1253-1261 (IGR: 13-1)


28155 Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
Miyashiro MJ; Lo SC; Stewart JA; Stewart WC
Clinical Ophthalmology 2010; 4: 1355-1359 (IGR: 13-1)


27915 Rare case of allergic blepharoconjuctivitis due to dorsolamide eyedrops
Urbancek S; Hazuchova H
Contact Dermatitis 2010; 63 SUPPL. 1 (65-66 (IGR: 13-1)


28110 Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients
Renieri G; Fuhrer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 597-603 (IGR: 13-1)


28045 Timolol maleate a gold standard drug in glaucoma used as ocular films and inserts: An overview
Rathore KS; Nema RK; Sisodia SS
International Journal of Pharmaceutical Sciences Review and Research 2010; 3: 23-29 (IGR: 13-1)


28043 Preparation and evaluation of niosomes of brimonidine tartrate as ocular drug delivery system
Prabhu P; Koland M; Vijaynarayan K; Harish NM; Ganesh D; Charyulu RN; Satynarayana D
Journal of Pharmaceutical Research and Health Care 2010; 2: 293-301 (IGR: 13-1)


28042 Preparation and evaluation of nano-vesicles of brimonidine tartrate as an ocular drug delivery system
Prabhu P; Kumar NR; Koland M; Harish NM; Vijayanarayan K; Dhondge G; Charyulu RN
Journal of Young Pharmacists 2010; 2: 356-361 (IGR: 13-1)


28105 The role of benzalkonium chloride in the occurrence of punctate keratitis: A meta-analysis of randomized, controlled clinical trials
Trocme S; Hwang L-J; Bean GW; Sultan MB
Annals of Pharmacotherapy 2010; 44: 1914-1921 (IGR: 13-1)


27813 Handiness and acceptability of the new Abak((registered trademark)) bottle in chronically treated patients. A cross-sectional, retrospective and multicentre study
Gabisson P; Briat B; Le Foll J; Conan S; Bale-Le Bescond F; Talmud M; Chibret H
Annales Pharmaceutiques Francaises 2011; 69: 22-29 (IGR: 13-1)


27812 Ocular toxicity of benzalkonium
Chibret H
Annales Pharmaceutiques Francaises 2011; 69:108-115 (IGR: 13-1)


27900 Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate
Gupta S; Vyas SP
Scientia Pharmaceutica 2010; 78: 959-976 (IGR: 13-1)


28206 Newer approaches for optimal bioavailability of ocularly delivered drugs: Review
Kesavan K; Balasubramaniam J; Kant S; Singh PN; Pandit JK
Current Drug Delivery 2011; 8: 172-193 (IGR: 13-1)


27912 Ocular intolerance to antiglaucoma medications is underestimated
Bresson-Dumont H
Bulletin de la SociÚtÚ Belge d'Ophtalmologie 2010; 315: 47-53 (IGR: 13-1)


28090 Evaluating eye drop instillation technique in glaucoma patients
Gupta R; Patil B; Shah BM; Bali SJ; Mishra SK; Dada T
Journal of Glaucoma 2011; Epub ahead of print (IGR: 13-1)


28211 Ocular drug delivery - A look towards nanobioadhesives
Du Toit LC; Pillay V; Choonara YE; Govender T; Carmichael T
Expert Opinion on Drug Delivery 2011; 8: 71-94 (IGR: 13-1)


27954 Drug delivery to the posterior segment of the eye
Kuppermann BD; Loewenstein A
Developments in Ophthalmology 2010; 47: 59-72 (IGR: 13-1)


27957 A potential new therapeutic system for glaucoma: Solid lipid nanoparticles containing methazolamide
Li R; Jiang S; Liu D; Bi X; Wang F; Zhang Q; Xu Q
Journal of Microencapsulation 2011; 28: 134-141 (IGR: 13-1)


27494 Efficacy and patient tolerability of travoprost bak-free solution in patients with open-angle glaucoma and ocular hypertension
Mirza SK; Johnson SM
Clinical Ophthalmology 2010; 4: 877-888 (IGR: 12-4)


27488 Tolerability and effectiveness of preservativefree dorzolamide-timolol (preservative-free COSOPT((registered trademark))) in patients with open-angle glaucoma or ocular hypertension
Hutnik C; Neima D; Ibrahim F; Scott R; Vaillancourt J; Haine D; Sampalis JS; Bastien N; Foucart S
Clinical Ophthalmology 2010; 4: 581-590 (IGR: 12-4)


27287 Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT(trademark)) in patients with elevated intraocular pressure in a randomized clinical trial
Shedden A; Adamsons IA; Getson AJ; Laurence JK; Lines CR; Hewitt DJ; Ho TW
Graefe's Archive for Clinical and Experimental Ophthalmology 2010; 248: 1757-1764 (IGR: 12-4)


27319 Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-(beta)-cyclodextrin in rabbit
Ito Y; Nagai N; Shimomura Y
Biological & Pharmaceutical Bulletin 2010; 33: 1574-1578 (IGR: 12-4)


27543 Changing the composition of buffered eye-drops prevents undesired side effects
Schrage NF; Frentz M; Reim M
The British journal of ophthalmology 2010; 94: 1519-1522 (IGR: 12-4)


27647 Ocular drug delivery from molecularly-imprinted contact lenses
Alvarez-Lorenzo C; Yanez F; Concheiro A
Journal of Drug Delivery Science and Technology 2010; 20: 237-248 (IGR: 12-4)


27123 Nanotechnology in ophthalmology
Zarbin MA; Montemagno C; Leary JF; Ritch R
Canadian Journal of Ophthalmology 2010; 45: 457-476 (IGR: 12-4)


27136 Optical fiber-coupled ocular spectrometer for measurement of drug concentration in the anterior eye-applications in pharmaceuticals research
Miller J; Wilson WS; Blue R; Wilson CG; Uttamchandani D
IEEE Transactions on Bio-Medical Engineering 2010; 57: 2903-2909 (IGR: 12-4)


27138 In vitro and in vivo evaluation of stimuli sensitive hydrogel for ophthalmic drug delivery
Singh V; Busheetti SS; Raju SA; Ahmad R; Singh M
Indian Journal of Pharmaceutical Education and Research 2010; 44: 380-385 (IGR: 12-4)


27355 Ocular pharmacokinetics of methazolamide ophthalmic suspension in rabbit aqueous humor
Liu W; Gan Y; Gan L; Ping Q-N; Cao F; Xiao Y-Y
Journal of China Pharmaceutical University 2010; 41: 337-341 (IGR: 12-4)


27307 Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells
Ammar DA; Noecker RJ; Kahook MY
Advances in Therapy 2010; 27: 837-845 (IGR: 12-4)


27323 Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: Formulation of dorzolamide eye drop microparticle suspension
Jansook P; Stefansson E; Thorsteinsdottir M; Sigurdsson BB; Kristjansdottir SS; Bas JF; Sigurdsson HH; Loftsson T
European Journal of Pharmaceutics and Biopharmaceutics 2010; 76: 208-214 (IGR: 12-4)


27523 Applications of nanoparticles in ophthalmology
Diebold Y; Calonge M
Progress in Retinal and Eye Research 2010; 29: 596-609 (IGR: 12-4)


27005 Preservatives in eye drops: toward awareness of their toxicity.
Vaede D; Baudouin C; Warnet JM; Brignole-Baudouin F
Journal Franšais d'Ophtalmologie 2010; 33: 505-524 (IGR: 12-4)


27556 Trends in ophthalmic preservatives: A review
Barot M; Gokulgandhi MR; Parikh JR
Drug Delivery Technology 2010; 10: 46-49 (IGR: 12-4)


27555 New devices for dispensing ophthalmic treatments may be the key to managing the life cycles of established products
Birkhoff M; Marx D
Drug Delivery Technology 2010; 10: 16-21 (IGR: 12-4)


27354 Preparation and characterization of timolol maleate ocular films
Rathore KS; Nema RK; Sisodia SS
International Journal of PharmTech Research 2010; 2: 1995-2000 (IGR: 12-4)


27502 Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines
Ayaki M; Iwasawa A
Clinical Ophthalmology 2010; 4: 919-924 (IGR: 12-4)


27305 Biodegradable implants for sustained drug release in the eye
Lee SS; Hughes P; Ross AD; Robinson MR
Pharmaceutical Research 2010; 27: 2043-2053 (IGR: 12-4)


27264 Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide
Qian Y; Wang F; Li R; Zhang Q; Xu Q
Drug Development and Industrial Pharmacy 2010; 36: 1340-1347 (IGR: 12-4)


27118 Changing the composition of buffered eye-drops prevents undesired side effects
Schrage NF; Frentz M; Reim M
British Journal of Ophthalmology 2010; 94: 1519-1522 (IGR: 12-4)


27296 Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system
Kaur IP; Aggarwal D; Singh H; Kakkar S
Graefe's Archive for Clinical and Experimental Ophthalmology 2010; 248: 1467-1472 (IGR: 12-4)


26671 Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations
Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 355-360 (IGR: 12-3)


26672 Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 287-292 (IGR: 12-3)


26875 A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension
Hommer A
Drugs of Today 2010; 46: 409-416 (IGR: 12-3)


26547 IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Current Medical Research and Opinion 2010; 26: 1905-1913 (IGR: 12-3)


26669 Ion-and pH-activated novel in-situ gel system for sustained ocular drug delivery
Gupta H; Velpandian T; Jain S
Journal of Drug Targeting 2010; 18: 499-505 (IGR: 12-3)


26775 Numerical simulations of ethacrynic acid transport from precorneal region to trabecular meshwork
Lin CW; Yuan F
Annals of Biomedical Engineering 2010; 38: 935-944 (IGR: 12-3)


26743 Enhancement of miotic potential of pilocarpine by tamarind gum based in-situ gelling ocular dosage form
Mehra GR; Manish M; Rashi S; Neeraj G; Mishra DN
Acta Pharmaceutica Sciencia 2010; 52: 145-154 (IGR: 12-3)


26885 Impact of glaucoma medication on ocular tissue
Valente C; Iester M
Expert Review of Ophthalmology 2010; 5: 405-412 (IGR: 12-3)


26675 Design and evaluation of thermoreversible in situ gelling system of forskolin for the treatment of glaucoma
Gupta S; Samanta MK
Pharmaceutical Development and Technology 2010; 15: 386-393 (IGR: 12-3)


26695 A case study: Safety evaluation of ophthalmic drug-device combination products
Brown AP
International Journal of Toxicology 2010; 29: 118 (IGR: 12-3)


26629 Anti-glaucomatic niosomal system: Recent trend in ocular drug delivery research
Paul S; Mondol R; Ranjit S; Maiti S
International Journal of Pharmacy and Pharmaceutical Sciences 2010; 2: 15-18 (IGR: 12-3)


26747 Preservatives in eyedrops: The good, the bad and the ugly
Baudouin C; Labbe A; Liang H; Pauly A; Brignole-Baudouin F
Progress in Retinal and Eye Research 2010; 29: 312-334 (IGR: 12-3)


26344 Study of alpha-lipoic acid penetration in the human aqueous after topical administration
Cagini C; Leontiadis A; Ricci MA; Bartolini A; Dragoni A; Pellegrino RM
Clinical and Experimental Ophthalmology 2010; 38: 572-576 (IGR: 12-3)


26904 Microchips and controlled-release drug reservoirs
Staples M
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2010; 2: 400-417 (IGR: 12-3)


26481 Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy
Asada H; Takaoka-Shichijo Y; Nakamura M; Kimura A
Yakugaku Zasshi 2010; 130: 867-871 (IGR: 12-3)


26473 Microbial contamination of nipradiol with and without benzalkonium chloride
Inoue K; Wakakura M; Miyanaga Y; Tomita G
Nippon Ganka Gakkai Zasshi 2010; 114: 604-611 (IGR: 12-3)


26876 Promising complexes of acetazolamide for topical ocular administration
Granero GE; Longhi MR
Expert Opinion on Drug Delivery 2010; 7: 943-953 (IGR: 12-3)


26123 Treatment of glaucoma in patients with dry eye syndrome
LabbÚ A; Baudouin C
Journal Franšais d'Ophtalmologie 2010; 33: 285-290 (IGR: 12-2)


25896 Incidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications
Fukuchi T; Wakai K; Suda K; Nakatsue T; Sawada H; Hara H; Ueda J; Tanaka T; Yamada A; Abe H
Clinical Ophthalmology 2010; 4: 203-209 (IGR: 12-2)


25992 Cytometric assessment of cytostatic and cytotoxic effects of topical glaucoma medications on human epithelial corneal line cells
Pozarowska D; Pozarowski P; Darzynkiewicz Z
Cytometry Part B - Clinical Cytometry 2010; 78: 130-137 (IGR: 12-2)


25888 Considerations in glaucoma therapy: Fixed combinations versus their component medications
Higginbotham EJ
Clinical Ophthalmology 2010; 4: 1-9 (IGR: 12-2)


25717 The ocular surface in glaucoma
Baudouin C
Cornea 2009; 28: S14-S19 (IGR: 12-2)


25674 Methazolamide calcium phosphate nanoparticles in an ocular delivery system
Chen R; Qian Y; Li R; Zhang Q; Liu D; Wang M; Xu Q
Yakugaku Zasshi 2010; 130: 419-424 (IGR: 12-2)


25718 Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications
Fechtner RD; Godfrey DG; Budenz D; Stewart JA; Stewart WC; Jasek MC
Cornea 2010; 29: 618-621 (IGR: 12-2)


26218 Time course of changes in ocular wavefront aberration after instillation of 0.5% timolol gel-forming solution
Hiraoka T; Daito M; Okamoto F; Kiuchi T; Hirohara Y; Mihashi T; Oshika T
British Journal of Ophthalmology 2010; 94: 433-439 (IGR: 12-2)


25993 Evaluation of the biocompatibility of novel peptide hydrogel in rabbit eye
Liang L; Xu X-D; Chen C-S; Fang J-H; Jiang F-G; Zhang X-Z; Zhuo R-X
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2010; 93: 324-332 (IGR: 12-2)


26276 Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino K; Puska P; Palmgren E; Hamacher T; Hofmann G
Acta Ophthalmologica 2010; 88: 329-336 (IGR: 12-2)


25825 Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: Development, characterization, and evaluation
Wadhwa S; Paliwal R; Paliwal SR; Vyas SP
Journal of Drug Targeting 2010; 18: 292-302 (IGR: 12-2)


26051 Molecularly imprinted therapeutic contact lenses
White CJ; Byrne ME
Expert Opinion on Drug Delivery 2010; 7: 765-780 (IGR: 12-2)


25761 Preparation and evaluation of a contact lens vehicle for puerarin delivery
Xu J; Li X; Sun F
Journal of Biomaterials Science, Polymer Edition 2010; 21: 271-288 (IGR: 12-2)


26064 Chitosan and its derivatives as intraocular penetration enhancers
Zambito Y; Di Colo G
Journal of Drug Delivery Science and Technology 2010; 20: 45-52 (IGR: 12-2)


25462 Characteristics of respondents with glaucoma and dry eye in a national panel survey
Schmier J K; Covert D W
Clinical Ophthalmology 2009; 3: 645-650 (IGR: 12-1)


25393 The effect of forskolin ophthalmic inserts on intraocular pressure in rabbit eyes
Wagh V D; Wagh K V; Inamdar B; Samanta M K
International Journal of Pharmacy and Pharmaceutical Sciences 2009; 146-155 (IGR: 12-1)


25305 Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: A prospective, randomized, double-masked, active-controlled, thr
Sonty S; Mundorf T K; Stewart J A; Stewart W C
Clinical Therapeutics 2009; 31: 2063-2071 (IGR: 12-1)


25328 Designing dendrimers for ocular drug delivery
Spataro G; Malecaze F; Turrin C -O; Soler V; Duhayon C; Elena P -P; Majoral J -P; Caminade A -M
European Journal of Medicinal Chemistry 2010; 45: 326-334 (IGR: 12-1)


25239 The effect of lubricating eye drop containing hydroxypropyl guar on perimetry results of patients with glaucoma and trachomatous dry eye
Guzey M; Satici A; Karaman SK; Sezer S; Bozkurt O
Ophthalmologica 2010; 24: 109-115 (IGR: 12-1)


25276 Influence of various concentrations of terpene-4-ol enhancer and carbopol-934 mucoadhesive upon the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide ophthalmic formulations using albino rabbits
Afouna M I; Khedr A; Abdel-Naim A B; Al-Marzoqi A
Journal of Pharmaceutical Sciences 2010; 99: 119-127 (IGR: 12-1)


25511 Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride
Ammar H O; Salama H A; Ghorab M; Mahmoud A A
AAPS PharmSciTech 2009; 10: 808-819 (IGR: 12-1)


25512 Dual-Drug Delivery System Based on In Situ Gel-Forming Nanosuspension of Forskolin to Enhance Antiglaucoma Efficacy
Gupta S; Samanta M K; Raichur A M
AAPS PharmSciTech 2010; 1-14 (IGR: 12-1)


25498 Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination
Rossi G C M; Pasinetti G M; Scudeller L; Tinelli C; Milano G; Bianchi P E
Expert Opinion in Pharmacotherapy 2010; 11: 499-504 (IGR: 12-1)


25014 The precautionary principle: what is the risk of reusing disposable drops in routine ophthalmology consultations and what are the costs of reducing this risk to zero?
Somner JE; Cavanagh DJ; Wong KK; Whitelaw M; Thomson T; Mansfield D
Eye 2010; 24: 361-363 (IGR: 12-1)


24763 Brimonidine purite solution for open-angle glaucoma or ocular hypertension
Batiste CG; Myers J; Katz LJ
Expert Review of Ophthalmology 2008; 3: 513-515 (IGR: 11-4)


24645 Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: A randomized clinical trial
Plager DA; Whitson JT; Netland PA; Vijaya L; Sathyan P; Sood D; Krishnadas SR; Robin AL; Gross RD; Scheib SA
Journal of AAPOS 2009; 13: 384-390 (IGR: 11-4)


24670 Different concepts of drug delivery in disease entities
Serafin A; Stanczak A
Mini Reviews in Medicinal Chemistry 2009; 9: 481-497 (IGR: 11-4)


24757 Drug delivery systems for the eye
Kearns VR; Williams RL
Expert Review of Medical Devices 2009; 6: 277-290 (IGR: 11-4)


24663 Antiglaucoma drops--with or without preservatives
Zemba M
Oftalmologia 2009; 1990 (IGR: 11-4)


24861 Xal-Ease(R): impact of an ocular hypotensive delivery device on ease of eyedrop administration, patient compliance, and satisfaction
Nordmann JP; Baudouin C; Bron A; Denis P; Rouland JF; Sellem E; Renard JP
European Journal of Ophthalmology 2009; 19: 949-956 (IGR: 11-4)


24597 A medical device/drug delivery system for treatment of glaucoma
Schultz CL; Poling TR; Mint JO
Clinical and Experimental Optometry 2009; 92: 343-348 (IGR: 11-4)


24764 Preservatives in topical ophthalmic medications: Historical and clinical perspectives
Freeman PD; Kahook MY
Expert Review of Ophthalmology 2009; 4: 59-64 (IGR: 11-4)


24664 Effects of preservatives in anti-glaucoma agents on the ocular surface
Potop V
Oftalmologia 2009; 1990 (IGR: 11-4)


24244 Effects of (-)-carveol and HPMC on the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide formulations in normotensive New Zealand rabbits
Afouna MI; Khedr A; Al-Marzoqi A
Drug Development Research 2009; 70: 191-198 (IGR: 11-3)


24514 Sustained Release and Permeation of Timolol from Surface-Modified Solid Lipid Nanoparticles through Bioengineered Human Cornea
Attama AA; Reichl S; Mller-Goymann CC
Current Eye Research 2009; 34: 698-705 (IGR: 11-3)


24212 Cytotoxicity of antiglaucoma ophthalmic solutions for human corneal endothelial cells
Ayaki M; Noda Y; Yaguchi S; Koide R; Iwasawa A; Inoue T; Inoue Y
Nippon Ganka Gakkai Zasshi 2009; 113: 576-582 (IGR: 11-3)


24069 A drug-eluting contact lens
Ciolino JB; Hoare TR; Iwata NG; Behlau I; Dohlman CH; Langer R; Kohane DS
Investigative Ophthalmology and Visual Science 2009; 50: 3346-3352 (IGR: 11-3)


23547 Ocular surface disfunction in glaucoma
Stefan C; Dumitrica DM
Oftalmologia 2008; 52: 114-119 (IGR: 11-2)


23462 Polymeric nanoparticulate system: A potential approach for ocular drug delivery
Nagarwal RC; Kant S; Singh PN; Maiti P; Pandit JK
Journal of Controlled Release 2009; 136: 2-13 (IGR: 11-2)


23594 The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies
Flach AJ
Transactions of the American Ophthalmological Society 2008; 106:- 138-145; discussion 145-148 (IGR: 11-2)


23953 Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage
Pauly A; Meloni M; Brignole-Baudouin F; Warnet JM; Baudouin C
Investigative Ophthalmology and Visual Science 2009; 50: 1644-1652 (IGR: 11-2)


23933 The effects of 5-fluorouracil on ocular tissues in vitro and in vivo after controlled release from a multifunctional implant
Huhtala A; R÷nkk÷ S; Terńsvirta M; Puustjńrvi T; Sihvola R; Vehanen K; Laukkanen A; Anttila J; Urtti A; Pohjonen T
Investigative Ophthalmology and Visual Science 2009; 50: 2216-2223 (IGR: 11-2)


23840 Route of penetration of topically instilled nipradilol into the ipsilateral posterior retina
Mizuno K; Koide T; Shimada S; Mori J; Sawanobori K; Araie M
Investigative Ophthalmology and Visual Science 2009; 50: 2839-2847 (IGR: 11-2)


23773 An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I
American Journal of Ophthalmology 2009; 147: 725-735 (IGR: 11-2)


22873 Quantitative analysis of conjunctival goblet cells after chronic application of topical drops
Kahook MY; Noecker R
Advances in Therapy 2008; 25: 743-751 (IGR: 11-1)


22842 Poly (ε-caprolactone) microparticles containing Levobunolol HCl prepared by a multiple emulsion (W/O/W) solvent evaporation technique: Effects of some formulation parameters on microparticle characteristics
Karatas A; Sonakin OOzlem; KiliCarslan M; Baykara T
Journal of Microencapsulation 2009; 26: 63-74 (IGR: 11-1)


22885 Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor
Volotinen M; Maenpaa J; Kautiainen H; Tolonen A; Uusitalo J; Ropo A; Vapaatalo H; Aine E
European Journal of Pharmaceutical Sciences 2009; 36:-3 292-296 (IGR: 11-1)


22764 Tear film and ocular surface alterations in chronic users of antiglaucoma medications
Baffa LP; Ricardo JR; Dias AC; Modulo CM; Braz AM; Paula JS; Rodrigues ML; Rocha EM
Arquivos Brasileiros de Oftalmologia 2008; 71: 18-21 (IGR: 11-1)


22827 Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery
Jiao J
Advanced Drug Delivery Reviews 2008; 60: 1663-1673 (IGR: 11-1)


22642 Dosage variability of topical ocular hypotensive products: a densitometric assessment
Gaynes BI; Singa RM; Cao Y
Journal of Glaucoma 2009; 18: 149-152 (IGR: 11-1)


22965 Poly (epsilon-caprolactone) microparticles containing Levobunolol HCl prepared by a multiple emulsion (W/O/W) solvent evaporation technique: effects of some formulation parameters on microparticle characteristics
Karatas A; Sonakin O; KiliCarslan M; Baykara T
Journal of Microencapsulation 2009; 26: 63-74 (IGR: 11-1)


22755 Development of ocular drug delivery systems
Saska Z; Hajdu M; Laki M; Klebovich I; Antal I
Acta Pharmaceutica Hungarica 2008; 78: 156-164 (IGR: 11-1)


23365 Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT
AndrÚs-Guerrero V; Alarma-Estrany P; Molina-MartÝnez IT; Peral A; Herrero-Vanrell R; Pintor J
Experimental Eye Research 2009; 88: 504-511 (IGR: 11-1)


22843 Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/ poly(lactic acid) microspheres for over 3 months
Bertram JP; Saluja SS; McKain J; Lavik EB
Journal of Microencapsulation 2009; 26: 18-26 (IGR: 11-1)


22676 Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost
Pellinen P; Lokkila J
Ophthalmic Research 2009; 1: 118-122 (IGR: 11-1)


21504 Tafluprost, a new potent prostanoid receptor agonist: A dose-response study on pharmacodynamics and tolerability in healthy volunteers
Sutton A; Gouws P; Ropo A
International Journal of Clinical Pharmacology and Therapeutics 2008; 46: 400-406 (IGR: 10-3)


21655 Ocular novel drug delivery: Impacts of membranes and barriers
Barar J; Javadzadeh AR; Omidi Y
Expert Opinion on Drug Delivery 2008; 5: 567-581 (IGR: 10-3)


21571 Scope and limitations of the co-drug approach to topical drug delivery
Lau WM; White AW; Gallagher SJ; Donaldson M; McNaughton G; Heard CM
Current Pharmaceutical Design 2008; 14: 794-802 (IGR: 10-3)


21883 Prevalence of ocular surface disease in glaucoma patients
Leung EW; Medeiros FA; Weinreb RN
Journal of Glaucoma 2008; 17: 350-355 (IGR: 10-3)


21596 A refillable microfabricated drug delivery device for treatment of ocular diseases
Lo R; Li P-Y; Saati S; Agrawal R; Humayun MS; Meng E
Lab on a Chip - Miniaturisation for Chemistry and Biology 2008; 8: 1027-1030 (IGR: 10-3)


21498 Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs
Sakanaka K; Kawazu K; Tomonari M; Kitahara T; Nakashima M; Nishida K; Nakamura J; Sasaki H; Higuchi S
Biological & Pharmaceutical Bulletin 2008; 31: 1590-1595 (IGR: 10-3)


21104 Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears
Kahook MY; Noecker RJ
Cornea 2008; 27: 339-343 (IGR: 10-2)


21395 Comparison of ocular surface side effects of topical travoprost and bimatoprost
Alag÷z G; Bayer A; Boran C; Serin D; KŘkner A; Elšio?lu M
Ophthalmologica 2008; 22: 161-167 (IGR: 10-2)


20974 Duration of IOP reduction with travoprost BAK-free solution
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
Journal of Glaucoma 2008; 17: 217-222 (IGR: 10-2)


20902 An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes
Ciancaglini M; Carpineto P; Agnifili L; Nubile M; Fasanella V; Lanzini M; Calienno R; Mastropasqua L
European Journal of Ophthalmology 2008; 18: 400-407 (IGR: 10-2)


20944 Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle
Cheng L; Anglin E; Cunin F; Kim D; Sailor MJ; Falkenstein I; Tammewar A; Freeman WR
British Journal of Ophthalmology 2008; 92: 705-711 (IGR: 10-2)


21304 Recent patents on ocular drug delivery systems
Conway BR
Recent Patents on Drug Delivery and Formulation 2008; 2: 1-8 (IGR: 10-2)


21361 Penetration of topically applied levofloxacin into eyes with thin-wall filtering bleb after trabeculectomy
Qiao LY; Wang NL; Liang YB; Zhu SQ; Wan XH; Lee PY
Eye 2008; 22: 666-670 (IGR: 10-2)


20879 In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line
Brasnu E; Brignole-Baudouin F; Riancho L; Guenoun JM; Warnet JM; Baudouin C
Current Eye Research 2008; 33: 303-312 (IGR: 10-2)


21383 Orbital drainage of different sizes of colloids in rabbits: A dynamic scintigraphic study
Beden U; Yapici O; Sullu Y; Sonmez B; Erkan D
Investigative Ophthalmology and Visual Science 2008; 49: 2563-2567 (IGR: 10-2)


21394 Very-high-frequency ultrasound corneal imaging as a new tool for early diagnosis of ocular surface toxicity in rabbits treated with a preserved glaucoma drug
Denoyer A; Ossant F; Arbeille B; Fetissof F; Patat F; Pourcelot L; Pisella PJ
Ophthalmic Research 2008; 40: 298-308 (IGR: 10-2)


20503 Drug-induced ocular disorders
Li J; Tripathi RC; Tripathi BJ
Drug Safety 2008; 31: 127-141 (IGR: 10-1)


20374 Modeling of corneal and retinal pharmacokinetics after periocular drug administration
Amrite AC; Edelhauser HF; Kompella UB
Investigative Ophthalmology and Visual Science 2008; 49: 320-332 (IGR: 10-1)


20610 Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system
Gupta H; Jain S; Mathur R; Mishra P; Mishra AK; Velpandian T
Drug Delivery 2007; 14: 507-515 (IGR: 10-1)


20731 Challenges and solutions in topical ocular drug-delivery systems
Ali M; Byrne ME
Expert Review of Clinical Pharmacology 2008; 1: 145-161 (IGR: 10-1)


20845 Barriers to Glaucoma Drug Delivery
Ghate D; Edelhauser HF
Journal of Glaucoma 2008; 17: 147-156 (IGR: 10-1)


20409 Effect of eye pigmentation on transscleral drug delivery
Cheruvu NP; Amrite AC; Kompella UB
Investigative Ophthalmology and Visual Science 2008; 49: 333-341 (IGR: 10-1)


20730 Controlled release gelatin hydrogels and lyophilisates with potential application as ocular inserts
Natu MV; Sardinha JP; Correia IJ; Gil MH
Biomedical Materials 2007; 2: 241-249 (IGR: 10-1)


20529 A history of the development of eye drops used to treat glaucoma
Komatsu Y
Yakushigaku Zasshi 2007; 42: 7-16 (IGR: 10-1)


20490 Clinical significance of topical instillation technique in Japanese glaucoma patients
Ikeda H; Tsukamoto H; Sugimoto A; Sawa A; Crabtree BL; Byrd HJ; Murakami T; Mishima HK; Kihira K
Pharmazie 2008; 63: 81-85 (IGR: 10-1)


20545 Ocular surface changes in primary open angle glaucoma with long term topical anti glaucoma medication
Kamath AP; Satyanarayana S; Rodrigues FEA
Medical Journal Armed Forces India 2007; 63: 341-345 (IGR: 10-1)


20536 On the correct use of eye drops
Steiner M
Australian Prescriber 2008; 31: 16-17 (IGR: 10-1)


19834 Effect of anti-glaucoma topical medications on expression of TGF-β and MMP of human Tenons fibroblast
Zhang J-Y; Leng F; Peng S-M
International Journal of Ophthalmology 2007; 7: 1294-1297 (IGR: 9-4)


19691 Ocular side effects of glaucoma treatment agents
Ehongo A; Bremer F
Bulletin de la SociÚtÚ Belge d'Ophtalmologie 2007; 304: 103-110 (IGR: 9-4)


19775 Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma
Jiang C; Moore MJ; Zhang X; Klassen H; Langer R; Young M
Molecular Vision 2007; 13: 1783-1792 (IGR: 9-4)


19757 Immobilization of drugs for glaucoma treatment
Almeida JF; Fonseca A; Baptista CMSG; Leite E; Gil MH
Journal of Materials Science: Materials in Medicine 2007; 18: 2309-2317 (IGR: 9-4)


19677 Timolol transport from microemulsions trapped in HEMA gels
Li C-C; Abrahamson M; Kapoor Y; Chauhan A
Journal of Colloid and Interface Science 2007; 315: 297-306 (IGR: 9-4)


19710 Effects of topical antiglaucoma medications on corneal epithelium as evaluated by gene expression patterns
Okada Y
Cornea 2007; 26: S46-S54 (IGR: 9-4)


19693 Medical applications of poly(styrene-block-isobutylene-block-styrene) ('SIBS')
Pinchuk L; Wilson GJ; Barry JJ; Schoephoerster RT; Parel J-M; Kennedy JP
Biomaterials 2008; 29: 448-460 (IGR: 9-4)


19816 Development of the conceptual framework for the Eye-Drop Satisfaction Questionnaire (EDSQ) in glaucoma using a qualitative study
Nordmann JP; Denis P; Vigneux M; Trudeau E; Guillemin I; Berdeaux G
BMC Health Services Research 2007; 7: Article Number: 124 (IGR: 9-4)


19258 Ocular hypotensive effect of 1% carteolol long-acting eye drops - a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product
Yamamoto T
Nippon Ganka Gakkai Zasshi 2007; 111: 463-472 (IGR: 9-3)


19308 Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor
Aggarwal D; Pal D; Mitra AK; Kaur IP
International Journal of Pharmaceutics 2007; 338: 21-26 (IGR: 9-3)


19601 In Vitro Studies of Antiglaucomatous Prostaglandin Analogues: Travoprost with and without Benzalkonium Chloride and Preserved Latanoprost
Baudouin C; Riancho L; Warnet JM; Brignole F
Investigative Ophthalmology and Visual Science 2007; 48: 4123-4128 (IGR: 9-3)


19275 Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery
Cao Y; Zhang C; Shen W; Cheng Z; Yu LL; Ping Q
Journal of Controlled Release 2007; 120: 186-194 (IGR: 9-3)


19607 Coated microneedles for drug delivery to the eye
Jiang J; Gill HS; Ghate D; McCarey BE; Patel SR; Edelhauser HF; Prausnitz MR
Investigative Ophthalmology and Visual Science 2007; 48: 4038-4043 (IGR: 9-3)


19534 A model for quantifying difficulty in squeezing eyedrops from their containers
Nesher R; Ezra-Nimni O; Shumla E; Gur J; Hamisha S; Nesher G
Archives of Ophthalmology 2007; 125: 1114-1117 (IGR: 9-3)


19513 Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye
Sigurdsson HH; Konrß­sdˇttir F; Loftsson T; Stefßnsson E
Acta Ophthalmologica Scandinavica 2007; 85: 598-602 (IGR: 9-3)


17562 Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres
Ward MS; Khoobehi A; Lavik EB; Langer R; Young MJ
Journal of Pharmaceutical Sciences 2007; 96: 558-568 (IGR: 9-2)


18103 Phosphate concentrations in antiglaucoma medication
Bernauer W; Thiel MA; Rentsch KM
Klinische Monatsblńtter fŘr Augenheilkunde 2007; 224: 249-251 (IGR: 9-2)


17609 Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs
Bu H-Z; Gukasyan HJ; Goulet L; Lou X-J; Xiang C; Koudriakova T
Current drug metabolism 2007; 8: 91-107 (IGR: 9-2)


18087 Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract
Cantor LB; Hoop J; WuDunn D; Yung CW; Catoira Y; Valluri S; Cortes A; Acheampong A; Woodward DF; Wheeler LA
British Journal of Ophthalmology 2007; 91: 629-632 (IGR: 9-2)


17606 Liposome-encapsulated mitomycin C for the reduction of corneal healing rate and ocular toxicity
Chetoni P; Burgalassi S; Monti D; Najarro M; Boldrini E
Journal of Drug Delivery Science and Technology 2007; 17: 43-48 (IGR: 9-2)


17518 Accuracy and performance of a commercially available dosing aid
Cronin TH; Kahook MY; Lathrop KL; Noecker RJ
British Journal of Ophthalmology 2007; 91: 497-499 (IGR: 9-2)


18037 The TRAVATAN Dosing Aid accurately records when drops are taken
Friedman DS; Jampel HD; Congdon NG; Miller R; Quigley HA
American Journal of Ophthalmology 2007; 143: 699-701 (IGR: 9-2)


18019 Ocular symptoms and signs with preserved and preservative-free glaucoma medications
Jaenen N; Baudouin C; Pouliquen P; Manni G; Figueiredo A; Zeyen T
European Journal of Ophthalmology 2007; 17: 341-349 (IGR: 9-2)


17534 Developments in dosing aids and adherence devices for glaucoma therapy: Current and future perspectives
Kahook MY
Expert Review of Medical Devices 2007; 4: 261-266 (IGR: 9-2)


17607 Development of a vesicular system for effective ocular delivery of acetazolamide A comprehensive approach and successful venture
Kaur IP; Mitra AK; Aggarwal D
Journal of Drug Delivery Science and Technology 2007; 17: 33-41 (IGR: 9-2)


17605 Ocular transport model for ophthalmic delivery of timolol through p-HEMA contact lenses
Li CC; Chauhan A
Journal of Drug Delivery Science and Technology 2007; 17: 69-79 (IGR: 9-2)


17610 Transscleral diffusion of ethacrynic acid and sodium fluorescein
Lin C-W; Wang Y; Challa P; Epstein DL; Yuan F
Molecular Vision 2007; 13: 243-251 (IGR: 9-2)


18073 Ocular drug delivery: molecules, cells, and genes
Liu X; Brandt CR; Rasmussen CA; Kaufman PL
Canadian Journal of Ophthalmology 2007; 42: 447-454 (IGR: 9-2)


18015 Penetration of betaxolol HCL ionic suspension 0.25% and betaxolol HCL solution 0.50% into the aqueous humor
Sagdic Yalvac I; Basci NE; Dulger B; Duman S
European Journal of Ophthalmology 2007; 17: 368-371 (IGR: 9-2)


17155 Brimonidine in the treatment of glaucoma and ocular hypertension
Cantor LB
Therapeutics and Clinical Risk Management 2006; 2: 337-346 (IGR: 9-1)


17051 Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation
Gonzalez JR; Baiza-Duran L; Quintana-Hau J; Tornero-Montano R; Castaneda-Hernandez G; Ortiz M; Alarcon-Oceguera F; Beltran-Loustaunau M; Cortez-Gastelum M; Garciduenas-Mejia J
Journal of Clinical Pharmacology 2007; 47: 121-126 (IGR: 9-1)


17092 Preparation and testing of buffered eye d